Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
 
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 1 of 71 
 REVISION HISTORY 
Revisions to Version 1.0 (Original Protocol) 
Current Version and Date:  v2.0_18 Feb 2018 (Amendment 01)  
Change Rationale Affected Protocol Sections 
Revised lesion count wording during the 
Recurrence Follow-up Period to indicate 
that lesions ‚Äòwithin the treatment area‚Äô should be counted.  Previously it was 
stated that lesions counted must be 
completely in the treatment area. To address concern 
regarding possible 
underestimation of 
recurrence. x Section 7.5.1 
Deleted reference to analysis of 
treatment/location interaction to show concordance. To provide clarification; 
the face and scalp will be analyzed as a whole; the 
face and scalp will also be 
analyzed separately to 
show consistency as to 
treatment location. x Synopsis/Efficacy Analyses 
x Section [IP_ADDRESS] 
Provided language about pooling sites and 
additional analysis for site-to-site 
variability. To address potential 
variability among sites. x Synopsis/Efficacy Analyses 
x Section [IP_ADDRESS] 
Provided additional language about how 
recurrence rates will be analyzed. Clarification of analysis for 
recurrence rate. x Synopsis/Efficacy Analyses 
x Section [IP_ADDRESS] 
Added language for partial response rate 
analysis. To address multiplicity 
issues for the secondary 
efficacy endpoint. x Synopsis/Efficacy Analyses 
x Section [IP_ADDRESS] 
Revised subsection numbering for 
additional AK lesion count analysis. Editorial. x Section [IP_ADDRESS] 
Revised language regarding missing data 
handling/sensitivity and subgroup analyses. Clarification for these 
efficacy analyses. x Section [IP_ADDRESS] 
x Section [IP_ADDRESS] 
Deleted reduction in AK lesion count 
during Days 1-57 as a secondary objective/endpoint. To limit the number of 
secondary 
objectives/endpoints being 
measured in the study. x Synopsis 
- Secondary Objectives - Secondary Endpoints 
x Section 3.2 
x Section [IP_ADDRESS].[ADDRESS_938166], will be conducted at Day 57/early termination visit, at the 
clinical site; pregnancy testing will be for 
women of childbearing potential. 
    Modification and 
clarification of pregnancy testing procedures. x Table [ADDRESS_938167] 
unresolved LSRs, hypo- or hyper-
pi[INVESTIGATOR_371], or scarring in the treatment 
area. Clarification. x Synopsis 
- Study Design - LSR assessments 
x Table 1/footnote b 
x Section 4.1 
x Section 4.4 
x Section [IP_ADDRESS] 
x Section 7.4 
The complete physical examination at 
Screening will not include an assessment 
of the integumentary system, as that will be part of the expanded dermatological 
examination. Clarification. x Table 1/footnote g 
x Section 7.1.9 
Information on study drug, label 
information, study kit dispensing, drug 
accountability, documentation, and 
instructions for requesting unblinding for 
medical emergencies or serious adverse 
events will be provided in a Pharmacy Manual, not a Clinical Operation Manual. Clarification. x Section 6.1.1 
x Section 6.3 
x Section 6.5.1 
x Section 8.2.5 
Medical history pertaining to actinic 
keratosis will include:  
x The initial diagnosis date of AK on 
the face or scalp, depending on the 
selection of the treatment area for the study 
x An AK treatment history of the face 
or scalp including all commercial and 
investigational products and surgical 
modalities dating back to the initial diagnosis.  Clarification. x Section 6.4.1 
x Section 7.1.4 
Revised/reorganized the description of 
study endpoints. Clarification. x Synopsis/Statistical 
Methods/Endpoints 
x Section 3.2 
x Section 9.1.1 
Clinical Study Protocol_Amendment 01 KX01-AK-004
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 3 of 71TITLE PAGE 
 
Clinical Study Protocol 
Study Protocol 
Number: KX01-AK-004 
Study Protocol 
Title: A Phase 3, Double-Blind, Vehicl e-Controlled, Rando mized, Parallel 
Group, Multicenter, Efficacy and Sa fety Study of KX2-391 Ointment 
1% in Adult Subjects with Actinic  Keratosis on the Face or Scalp  
Sponsor : Athenex, Inc.  
[ADDRESS_938168] NJ [ZIP_CODE], [LOCATION_003] Tel:  [PHONE_14374]  
Investigational 
Product Name: [CONTACT_548047]2-391 Ointment 1% 
Indication: Actinic keratosis on face or scalp 
Phase: 3  
Approval Date:   v1.0 
v2.0 29 Jun 2017 (original protocol) 
18 Feb 2018 (Amendment 01) 
IND Number: 122464 
UTN Number: U1111-1191-8287  
GCP Statement: This study is to be performed in full compliance with International 
Council for Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) and all applicable local Good Clinical Pr actice (GCP) and regulations.  All 
required study documentation will be archived as required by [CONTACT_12721]. 
Confidentiality 
Statement: This document is confidential.  It contains proprietary information of 
Athenex, Inc. (the Sponsor).  An y viewing or disclosure of such 
information that is not authorized in  writing by [CONTACT_55360].  Such information may be used solely for the purpose of reviewing or performing this study. 

Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
 
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 4 of 71 
 CLINICAL PROTOCOL SYNOPSIS 
Compound No.:  KX2-391  
Name [CONTACT_3261]:  N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl) acetamide  
Study Protocol Title 
A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy 
and Safety Study of KX2-391 Ointment 1% in Adult Subjects with Actinic Keratosis on the Face or 
Scalp  
Sites 
Approximately [ADDRESS_938169] out, approximately 20 months 
Phase 3  
Study Hypothesis 
Treatment with KX2-391 Ointment 1% topi[INVESTIGATOR_691728] 5 consecutive days will demonstrate a 
greater complete clearance (defined as 100% clearance of clinically typi[INVESTIGATOR_691729] [AK] lesions at Day 57) than vehicle ointment once daily for 5 consecutive days in adults 
with AK on the face or scalp. 
Objectives  
Primary Objective 
x To evaluate the efficacy of topi[INVESTIGATOR_691730]2-391 Ointment 1% once daily for 5 consecutive days 
compared to vehicle control in terms of 100% clearance at Day 57 in the treatment of adults 
with AK, when applied to a contiguous area of 25 cm2 on the face or scalp 
Secondary Objectives 
x To evaluate the safety of topi[INVESTIGATOR_691730]2-391 Ointment 1% once daily for 5 consecutive days in 
terms of local skin reactions (LSRs) and other safety evaluations such as adverse events 
(AEs) and laboratory assessments 
x To compare the rates of p DUWLDOUHVSRQGHUVGHILQHGDV¬ï 75% clearance of AK lesions in the 
treatment area on the face or scalp at Day 57 between the KX2-391 Ointment 1%-treated 
group and vehicle-treated group  
x To determine the recurrence of AK in the treatment area up to [ADDRESS_938170]-Day 57 in 
subjects who had complete clearance at Day 57 after 5 consecutive days of treatment with 
KX2-391 Ointment 1%  
x To evaluate the safety of topi[INVESTIGATOR_691730]2-391 Ointment 1% within the treatment area during the 
Recurrence Follow-up Period  
Study Design 
This is a double-blind, vehicle-controlled, randomized, parallel group, multicenter study to evaluate 
the efficacy and safety of KX2-391 Ointment 1% admi nistered topi[INVESTIGATOR_691731]. 
Enrollment will be controlled so that approximately two thirds of subjects enrolled will be treated on 
the face and approximately one third of subjects enrolled will be treated on the scalp. 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
 
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 5 of 71 
 The study consists of Screening, Treatment, Response Assessment Period, and a Recurrence Follow-
up Period.  After a Screening Period of up to 28 days, subjects will return to the site for confirmation 
of eligibility.  Eligible subjects will be randomized on Day 1 to treatment in a 1:1 (KX2-391 
Ointment 1% or vehicle) ratio in each treatment area subgroup. 
The treatment area will be marked with indelible marker at Baseline (Day 1 predose) at the 
investigational site.  Subjects will be given verbal and written instructions on self-administration of 
study drug/vehicle and a study kit containing [ADDRESS_938171] unresolved LSRs, hypo- or hy per- pi[INVESTIGATOR_371], scarring in the treatment area, 
or treatment-related AEs at Day 57 will return for additional follow-up, which includes standardized 
photography of the treatment area, every 7 to 28 days until resolution, returned to baseline, or deemed stabilized by [CONTACT_32366]. 
Subjects who achieve 100% clearance of AK lesions in the treatment area at Day 57 will continue in 
the Recurrence Follow-up Period to determine recurrence rate and safety for up to 12 months 
following the Day 57 Visit.  Visits du ring the Recurrence Follow-up Period will occur every 
3 months.  Subjects who develop AK lesions in the treatment area during the Recurrence Follow-up 
Period will be discontinued at the time of recurrence.  
Number of Subjects 
A sufficient number of subjects will be screened to randomize approximately 300 subjects.  At each 
site, a minimum of 10 subjects and a maximum of 20 subjects are projected to be enrolled.  
Inclusion Criteria 
1. 0DOHVDQGIHPDOHV¬ï\HDUVROG  
2. A treatment area on the face or scalp that: 
x is a contiguous area measuring 25 cm2 
x contains 4 to 8 clinically typi[INVESTIGATOR_2855], visible, and discrete AK lesions  
3. Subjects who in the judgment of the Investigator, are in good general health based on: 
x medical history 
x physical examination (PE) findings 
x vital signs  
x electrocardiogram (ECG), clinical chemistry, hematology, and urinalysis results  
4. Females must be postmenopausal (>[ADDRESS_938172] 12 months of amenorrhea), 
surgically sterile (by [CONTACT_31658], bilateral oophorectomy, or tubal ligation); or, if of 
childbearing potential, must be using highly effective contraception for at least [ADDRESS_938173] on Day 1 prior to randomization. 
8. Willing to avoid excessive sunlight or ultraviolet (UV) light exposure, including the use of 
tanning beds, to the face or scalp  
9. Able to comprehend and are willing to sign the informed consent form (ICF). 
Exclusion Criteria 
1. Clinically atypi[INVESTIGATOR_199]/or rapi[INVESTIGATOR_547924], eg, hypertrophic, 
hyperkeratotic, recalcitrant disease (had cryosurg ery on two previous occasions) and/or cutaneous 
horn 
2. Location of the treatment area is: 
x On any location other than the face or scalp 
x Within 5 cm of an incompletely healed wound 
x Within 5 cm of a suspected basal cell carci noma (BCC) or squamous cell carcinoma (SCC) 
3. Been previously treated with KX2-391 Ointment 
4. Anticipated need for in-patient hospi[INVESTIGATOR_565808]-patient surgery from Day 1 to Day 57 
5. Treatment with 5-fluorouracil (5-FU), imiquim od, ingenol mebutate, diclofenac, photodynamic 
therapy, or other treatments for AK within the treatment area or  within 2 cm of the treatment 
area, within 8 weeks prior to the Screening visit 
6. Use of the following therapi[INVESTIGATOR_13265]/or medications  within 2 weeks prior to the Screening visit: 
x Cosmetic or therapeutic procedures (eg, use of liquid nitrogen, surgical excision, curettage, 
dermabrasion, medium or greater depth chemical peel, laser resurfacing) within the treatment 
area or  within 2 cm of the selected treatment area 
x Acid-containing therapeutic products (eg, salicylic acid or fruit acids, such as alpha- and 
beta-hydroxyl acids and glycolic acids), topi[INVESTIGATOR_22775], or light chemical peels within the 
treatment area or  within 2 cm of the selected treatment area  
x Topi[INVESTIGATOR_142742] (non-medicated/non-irritant lotion and cream are acceptable) or topi[INVESTIGATOR_691732] 2 cm of the selected treatment area; artificial 
tanners within the treatment area or  within 5 cm of the selected treatment area 
7. Use of the following therapi[INVESTIGATOR_13265]/or medications within 4 weeks prior to the Screening visit:  
x Treatment with immunomodulators (eg, azathioprine), cytotoxic drugs (eg, 
cyclophosphamide, vinblastine, chlorambucil, methotrexate) or interferons/interferon 
inducers 
x Treatment with systemic medications that suppress the immune system (eg, cyclosporine, 
prednisone, methotrexate, alefacept, infliximab) 
8. Use of systemic retinoids (eg, isotretinoin, acitretin, bexarotene) within 6 months prior to the 
Screening visit 
9. A history of sensitivity and/or allergy to any of the ingredients in the study medication  
10. A skin disease (eg, atopic dermatitis, psoriasis, eczema) or condition (eg, scarring, open wounds) 
that, in the opi[INVESTIGATOR_689], might interfere with the study conduct or evaluations, or 
which exposes the subject to unacceptable risk by [CONTACT_691783]_Amendment [ADDRESS_938174], whichever is longer, 
before dosing 
Study Treatments 
KX2-391 Ointment 1% or vehicle ointment will be applied topi[INVESTIGATOR_231704] [ADDRESS_938175] will participate for up 
to 85 days: screening up to [ADDRESS_938176] is approximately 15 months.  
Concomitant Drug/Therapy 
Use of any treatment for AK lesions other than study drug on the treatment area is prohibited during 
the study.  
Assessments during the Treatment and Response Assessment Periods (Day 1 through Day 57) 
Efficacy Assessments  
A dermatologist (Investigator or Subinvestigator) will perform a count of clinically visible AK lesions 
(lesion count) for all subjects at Screening, Baseline (Day 1 predose), and at the Response Assessment Visits on Days 8, 15, 29, and 57. 
Safety Assessments 
Safety will be assessed periodically through Day 57 by [CONTACT_88668], serious adverse events 
(SAEs), LSRs, and events of special interest. 
Safety assessments will also include vital signs, the performance of PEs, ECGs, laboratory evaluation 
of hematology, biochemistry, and urinalyses, and evaluation of pi[INVESTIGATOR_691733] ( Table 1 , Schedule of Procedures and Assessments). 
At each study visit, subjects will be asked a general question ‚ÄúHow have you been since the last 
visit?‚Äù.  Adverse events will be recorded at each study visit, before assessment of LSRs, 
pi[INVESTIGATOR_371], and scarring in the treatment area.  AEs will be reported separately from LSRs. 
LSR Assessments The LSR assessment is the Investigator‚Äôs (or Subinvestigator‚Äôs) assessment of the following signs on the 
treatment area:  erythema, flaking/scaling, crusting, swelling, ves iculation/pustulation, and 
erosion/ulceration.  These signs will be assessed using a grading scale ranging from 0=absent, 1=mild 
(slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense).  In addition to LSRs, hypo- and hyper- pi[INVESTIGATOR_691734].  Application site reactions not classified as LSRs (eg, itching, 
burning, stinging, tenderness, pain) will be reported as AEs.  Standardized photography will be 
performed on Day [ADDRESS_938177] 
x Overdose of study medication 
x Pregnancy  
x Ocular exposures to study medication 
x Skin cancers (including BCC, SCC, and melanoma); the location and treatment will be 
reported. 
Assessments during the Recurrence Follow-up Period (up to [ADDRESS_938178]-Day 57) 
Efficacy Assessments  
A dermatologist (Investigator or Subinvestigator) will perform a count of clinically visible AK 
lesions (lesion count) for subjects who achieve 100% clearance of AK lesions in the treatment area at 
Day [ADDRESS_938179] 
x Skin cancers (including BCC, SCC, and melanoma) within the treatment area 
x Pregnancy 
Statistical Methods 
Efficacy: 
Primary Endpoint 
x Complete (100%) clearance rate of AK lesions, defined as the proportion of subjects at 
Day 57 with no clinically visible AK lesions in the treatment area  
Secondary Endpoints Key Secondary Endpoint: 
x Partial clearance rate of AK lesions, defined as the proportion of subjects at Day 57 with a 
¬ï75% reduction in the number of AK lesions identified at Baseline (Day 1 predose) in the 
treatment area  
Additional Endpoint: 
x Recurrence rate of AK lesions in subjects who achieved complete clearance at Day 57 
Safety: 
x Evaluation of LSRs, pi[INVESTIGATOR_691735], AEs, SAEs, events of 
special interest, clinical laboratory data, and other safety assessments (vital signs, PEs, 
ECGs) 
x AEs within the treatment area after Day [ADDRESS_938180]-Day 57  
Analysis Populations 
Intent-To-Treat (ITT) Population:  all randomized subjects. This is the primary efficacy population.  
Per-Protocol (PP)/Evaluable Population:   all randomized subjects who have received at least [ADDRESS_938181] efficacy, and returned for the final visit on Day 57.  
Safety Population :  all randomized subjects who have received at least one dose of study treatment. 
 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
 
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 9 of 71 
 Recurrence Follow-up Population:   all subjects who achieved complete clearance at Day 57, 
regardless of which treatment they received. 
Efficacy Analyses 
To achieve statistical significance in the study, the Day 57 complete clearance rate will be analyzed 
using a Cochran-Mantel-Haenszel (CMH) model cont rolling for treatment location and treatment 
group.  Before applying the CMH method, a Breslow-Da y test with a significance level of 10% will 
be used to explore heterogeneity of the odds ratios across treatment location subgroups. 
Further, the Pearson Chi Square (used to power the study) will be applied to demonstrate basic 
agreement with the CMH. 
The primary efficacy analysis will be performed with the ITT population, and will be repeated with 
the PP/Evaluable population to support the primary efficacy analysis results. 
Low enrollment sites will be pooled to analysis si tes with approximately 20 subjects in each pool. For 
example, the number of subjects enrolled will be graphically displayed by [CONTACT_691784] (face or scalp) from the smallest number to the largest, with bars depi[INVESTIGATOR_691736]. Then, analysis sites will be defined for approximately every [ADDRESS_938182] at a 
significance level of 10% will be applied. A finding of statistical significance in this test will be 
followed by [CONTACT_691785]. The outlier sites will be discussed and 
an exploratory analysis excluding the outlier sites may be carried out to estimate the impact of site-
by-treatment interactions. This process will be documented as an appendix to the final version of the 
SAP, prior to the first database lock. 
Partial clearance rate will be analyzed in the same way as the primary efficacy endpoint (complete 
clearance rate).  However, to control for multiplic ity, partial clearance rate as the key secondary 
efficacy endpoint will be examined using a step- down gatekeepi[INVESTIGATOR_691737] I error rate. In other words, the primary endpoint will serve as a gatekeeper for the key 
secondary endpoint. The complete clearance rate will be tested initially; if, and only if it is 
statistically significant at the 0.[ADDRESS_938183]-Day 57 
visit.  Subjects with missing AK assessments in the Recurrence Follow-up Period will be considered 
as censored.  
Safety Analyses 
For AEs, verbatim terms on the electronic case report form (eCRF) will be mapped to preferred terms 
(PTs) and system organ classes (SOCs) using the Medical Dictionary for Regulatory Activities 
(MedDRA; v 16.0 or higher).   
Treatment-emergent adverse events (TEAEs) are defined as either those AEs with an onset after the 
first dose or those pre-existing AEs that worsen after the first dose.  The incidence of TEAEs will be 
summarized by [CONTACT_1570].  TEAEs will also be summarized by [CONTACT_78621].  By-subject listings of all SAEs and events of special interest will be provided.  
Laboratory parameters will be summarized using descriptive statistics at baseline and at each 
subsequent timepoint by [CONTACT_1570].  Changes from baseline will also be summarized by [CONTACT_1570].  In addition, shift tables (ie, low-normal-high at baseline versus low-normal-high at 
follow-up in a 3-by-3 contingency table) will be pr ovided to assess changes in laboratory values from 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
 
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 10 of 71 
 baseline to Day 8 and baseline to Day 15 in each treatment group. 
LSR, hyper- or hypo-pi[INVESTIGATOR_691738] 57 will be 
displayed and summarized by [CONTACT_3232].   
Safety data collected through Day 57 and during the Recurrence Follow-up Period will be analyzed 
separately.  
Interim Analyses 
No interim analysis is planned for this study.  
Sample Size Rationale 
The sample size was estimated based on the primary efficacy endpoint for the comparison of 
KX2-391 Ointment 1% and vehicle control.  By [CONTACT_57971] g a Pearson Chi-square method, a sample size of 
100 scalp-treated subjects and 200 face- treated subjects, both of which are with a 1:1 treatment 
allocation ratio, will give a greater than 90% power to detect a 20% difference (30% for active 
treatment and 10% for vehicle control) with a two-tailed significant level 0.05.  
FINAL: v2.0_18 Feb 2018 
 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
 
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 11 of 71 
 SCHEDULE OF PROCEDURES AND ASSESSMENTS 
Table 1 Schedule of Procedures and Assessments in KX01-AK-004  
Period Screening  Treatment Response Assessment  Recurrence Follow-upa 
Clinic Visit 1 2 At home once-
daily self-
administration 
of treatment  3 4 5 6 7 / 
Early 
Termb  8, 9, 10, 11a 
Day -[ADDRESS_938184]-Day 57c 
Visit time window (days) None None  None ¬±2 ¬±2 ¬±3 ¬±5 ¬±14 
Informed consent X         
Inclusion & exclusion criteria X Xd        
Demographics X         
Medical/surgical history X         
AK history/AK treatment history X         
Prior and concomitant medications/therapi[INVESTIGATOR_014] X Xd  X X X X X X 
Fitzpatrick skin-type scale X         
Expanded dermatological exame X         
Treatment area identification X Xd,f         
AK lesion count in treatment area X Xd   X X X X X 
Physical examination, including weight and 
heightg X       X   
Vital signsh X Xd  X    X  
ECGi X Xd  X  X    
Clinical chemistry, hematology, and UA Xj    X X    
Serum pregnancy test for WOCBP X    X     
Urine pregnancy test for WOCBP  Xk      X   
AEsl X Xd  X X X X X Xm 
Focused dermatological exam of treatment 
area  Xd  X X X X X  
 LSRs  Xd  X X X X X  
 Pi [INVESTIGATOR_691739] g  Xd  X X X  X X  
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
 
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 12 of 71 
 Table 1 Schedule of Procedures and Assessments in KX01-AK-004  
Period Screening  Treatment Response Assessment  Recurrence Follow-upa 
Clinic Visit 1 2 At home once-
daily self-
administration 
of treatment  3 4 5 6 7 / 
Early 
Termb  8, 9, 10, 11a 
Day -[ADDRESS_938185]-Day 57c 
Standardized photography  Xd  X X X X X  
Randomization  X        
Instructions for self-administration; 
dispense stud y medication   Xd        
Study medication application  X X        
Study drug / dosin g log return    Xn      
AE = adverse event; AK = actinic keratosis; ECG = electrocardiogram; HEENT = head, eyes, ears, nose, and throat; LSR = local sk in reaction; Term = Termination; UA = 
urinalysis; WOCBP = women of child-bearing potential. 
a. For Day [ADDRESS_938186] their final assessments at the visit when the AK recurrence is identified.  
d. These are baseline procedures/assessments and will be performed before randomization. 
e. An expanded dermatological examination to cover the sun-exposed areas where photo-damage is likely will be conducted at Screeni ng only. 
f. The location and shape of the treatment area will be marked on an  acetate transparency sheet for recording purposes and on the subject‚Äôs skin for identification of the 
treatment area for daily self-administration of study ointment. 
g. A complete PE will include weight and an assessment of HEENT, integumentary (Day 57 only), gast rointestinal, ca rdiovascular, re spi[INVESTIGATOR_696], musculoskeletal, and 
neurological systems.  Height will be measured at Screen ing only.  This will be considered the baseline assessment. 
h. Vital signs measurements will be taken after the subject has been seated for at least [ADDRESS_938187] be in the recumbent position for a period of 5 minutes prior to the ECG.  Baseline ECG is performed predose.  
j. This will be considered the baseline assessment. 
k. For females of childbearing potential: urine pregnancy test on Day 1 before randomization. 
l. At each study visit, subjects will be aske d a general question ‚ÄúHow have you been since the last visit?‚Äù.  AEs will be recorded  before assessment of LSRs, pi[INVESTIGATOR_371], and 
scarring in the treatment area.  AEs will be reported separately from LSRs.   
m. Only AEs in the treatment area will be collected. 
n. On Day 5 (Visit 3), subjects are to come into the clinic after study treatment is self-administered.  Subjects are to bring all  5 study drug packets (used and unused) in the study 
kit and the dosing log back to the site. 
Clinical Study Protocol_Amendment [ADDRESS_938188] OF ABBREVIATIONS AND DEFINITIONS OF TERMS ..........................................18  
1 INVESTIGATORS AND STUDY PERSONNEL ..........................................................19  
2 INTRODUCTION ...........................................................................................................19  
2.1 Background ............................................................................................................19  
2.1.1  Indication .....................................................................................................19  
2.1.2  Mechanism of Action ...................................................................................19  
2.1.3  Nonclinical Studies ......................................................................................19  
2.1.4  Clinical Experience with KX2-391 ..............................................................21  
[IP_ADDRESS]  KX2-391 in Cancer (Oral) ...................................................................21  
[IP_ADDRESS]  KX2-[ADDRESS_938189] Withdrawal / Di scontinuation Criteria ......................................................29  
6 STUDY TREATMENTS .................................................................................................30  
6.1 Identity of Study Drugs ..........................................................................................30  
6.1.1  Formulation, Packaging, and Labeling ........................................................30  
6.1.2  Storage Conditions .......................................................................................31  
6.2 Dosage and Administration of Study Drugs ..........................................................31  
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 14 of 71 
 
 6.2.1  Administration of Study Drugs ....................................................................31  
[IP_ADDRESS]  Instructions in the Event of Ocular Exposure ......................................31  
6.2.2  Criteria for Interruption of Treatment/Dose Adjustments ...........................32  
6.3 Randomization/Method of Assigning Subjects to Treatment Groups ...................32  
6.3.1  Blinding........................................................................................................32  
6.4 Prior and Concomitant Me dications / Therapy ......................................................33  
6.4.1  Prior Medications / Therapy ........................................................................33  
6.4.2  Concomitant Medica tions/Therapy ..............................................................33  
6.4.3  Prohibited Medication/Therapy ...................................................................[ADDRESS_938190] rictions during Study .......................................34  
6.5 Drug Accountability and Treatment Compliance ..................................................34  
6.5.1  Drug Supplies and Accountability ...............................................................34  
6.5.2  Treatment Compliance .................................................................................35  
7 STUDY PROCEDURES AND ASSESSMENTS ...........................................................35  
7.1 Screening Assessments ..........................................................................................35  
7.1.1  Informed Consent.........................................................................................35  
7.1.2  Inclusion/Exclusion Criteria ........................................................................35  
7.1.3  Demography .................................................................................................36  
7.1.4  Medical/Surgical and Actin ic Keratosis History .........................................36  
7.1.5  Prior Medications .........................................................................................36  
7.1.6  Fitzpatrick Skin-Type Classification ...........................................................36  
7.1.7  Expanded Dermatologic al Examination ......................................................36  
7.1.8  Treatment Area Identification a nd AK Lesion Count Examination ............36  
7.1.9  Physical Examinations .................................................................................37  
7.1.10  Vital Signs ....................................................................................................37  
7.1.11  Electrocardiograms ......................................................................................37  
7.1.12  Laboratory Measurements ...........................................................................37  
7.1.13  Pregnancy Testing ........................................................................................37  
7.2 Baseline Assessments ............................................................................................37  
7.2.1  Inclusion/Exclusion Criteria ........................................................................37  
7.2.2  Prior Medications .........................................................................................38  
7.2.3  Treatment Area Identification ......................................................................38  
7.2.4  Actinic Keratosis Lesion Count ...................................................................38  
7.2.5  Focused Dermatological Ex am of Treatment Area .....................................38  
[IP_ADDRESS]  Local Skin Reactions ...........................................................................39  
[IP_ADDRESS]  Pi[INVESTIGATOR_691740] ...................................................................39  
7.2.6  Standardized Photography ...........................................................................39  
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 15 of 71 
 
 7.2.7  Vital Signs ....................................................................................................39  
7.2.8  Electrocardiograms ......................................................................................39  
7.2.9  Pregnancy Testing ........................................................................................40  
7.2.10  Randomization .............................................................................................40  
7.2.11  Instructions for Self-administrati on of Study Treatment, Dispensing, 
and Return of Study Treatment ....................................................................40  
7.3 Treatment Period and Res ponse Assessment Period .............................................40  
7.3.1  Treatment Administration ‚Äì Days 1-5 .........................................................40  
7.3.2  Efficacy Assessments...................................................................................40  
[IP_ADDRESS]  Actinic Keratosis Lesion Count ...........................................................40  
7.3.3  Pharmacokinetic, Pharmacodynamic , Pharmacogenomic, and Other 
Biomarker Assessments ...............................................................................41  
7.3.4  Safety Assessments ......................................................................................41  
[IP_ADDRESS]  Adverse Events ....................................................................................41  
[IP_ADDRESS].1  Assessing Severity of Adverse Events ...........................................43  
[IP_ADDRESS].2  Assessing Relationship to Study Treatment ..................................43  
[IP_ADDRESS]  Serious Adverse Events .......................................................................44  
[IP_ADDRESS]  Events of Special Interest.....................................................................44  
[IP_ADDRESS]  Concomitant Medications ....................................................................45  
[IP_ADDRESS]  Focused Dermatological Exam of  Treatment Area and Standard 
Photography .........................................................................................45  
[IP_ADDRESS].1  Local Skin Reactions .....................................................................45  
[IP_ADDRESS].2  Pi[INVESTIGATOR_691740] .............................................................46  
[IP_ADDRESS]  Physical Examinations .........................................................................46  
[IP_ADDRESS]  Vital Signs ............................................................................................46  
[IP_ADDRESS]  Electrocardiograms ..............................................................................46  
[IP_ADDRESS]  Laboratory Measurements ...................................................................[ADDRESS_938191] .................................................................50  
8.2.1  Pregnancy .....................................................................................................50  
8.2.2  Study Drug Overdose ...................................................................................51  
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 16 of 71 
 
 8.2.3  Ocular Exposure...........................................................................................51  
8.2.4  Skin Cancer ..................................................................................................51  
8.2.5  Breaking the Blind .......................................................................................52  
9 STATISTICAL METHODS ............................................................................................52  
9.1 Statistical and Analytical Plans ..............................................................................52  
9.1.1  Study Endpoints ...........................................................................................53  
[IP_ADDRESS]  Efficacy ................................................................................................53  
[IP_ADDRESS].1  Primary Endpoint ...........................................................................53  
[IP_ADDRESS].2  Secondary Endpoints .....................................................................53  
[IP_ADDRESS]  Safety ...................................................................................................[ADDRESS_938192] Disposition ......................................................................................54  
9.1.4  Demographic and Other Base line Characteristics .......................................54  
9.1.5  Prior and Concomitant Therapy ...................................................................54  
9.1.6  Efficacy An alyses ........................................................................................54  
[IP_ADDRESS]  Primary Efficacy Endpoint Analysis ...................................................54  
[IP_ADDRESS]  Secondary Efficacy Endpoint Analyses ...............................................55  
[IP_ADDRESS]  Additional AK Lesion Count Analysis ................................................55  
[IP_ADDRESS]  Missing Data Handling and Sensitivity Analysis ................................56  
[IP_ADDRESS]  Subgroup Analysis ...............................................................................56  
9.1.7  Safety Analyses ............................................................................................56  
[IP_ADDRESS]  Extent of Exposure ...............................................................................56  
[IP_ADDRESS]  Adverse Events ....................................................................................57  
[IP_ADDRESS]  Laboratory Values ................................................................................57  
[IP_ADDRESS]  Pregnancy Tests ...................................................................................58  
[IP_ADDRESS]  Vital Signs ............................................................................................58  
[IP_ADDRESS]  Electrocardiograms ..............................................................................58  
[IP_ADDRESS]  Physical Examinations .........................................................................58  
[IP_ADDRESS]  Local Skin Reactions and Pi[INVESTIGATOR_691740] .........................58  
9.1.8  Determination of Sample Size .....................................................................58  
9.1.9  Interim Analysis ...........................................................................................58  
9.1.10  Other Statistical/Analytical Issues ...............................................................58  
9.1.11  Procedure for Revising the Planned Analysis ..............................................59  
10 PROCEDURES AND INSTRUCTIONS ........................................................................60  
10.1 Access to Source Data / Documents ......................................................................[ADDRESS_938193] .........................................................................................................66  
12 APPENDICES .................................................................................................................67  
APPENDIX 1  INSTRUCTIONS FOR SUBJECTS‚Äô SELF-ADMINISTRATION OF 
STUDY TREATMENT ...................................................................................................[ADDRESS_938194] OF APPENDICES 
Appendix 1  Instructions for Subjects‚Äô Self-ad ministration of Study Treatment ...........[ADDRESS_938195] operating procedure 
TEAE treatment-emergent adverse event 
US [LOCATION_002] UV ultraviolet (light) 
 
 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 19 of 71 
 
 1 INVESTIGATORS AND STUDY PERSONNEL 
This study will be conducted by  [CONTACT_691786], 
Inc. (the Sponsor) at approximately 25 to 40 i nvestigational sites in the [LOCATION_002] (US). 
The name, telephone number, and email address of the Medical Monitor and other contact 
[CONTACT_691787]. 
2 INTRODUCTION 
2.1 Background 
2.1.1 Indication 
In this study, the efficacy and safety of KX2-391 Ointment 1% will be evaluated in adult 
subjects with a diagnosis of clinically typi[INVESTIGATOR_547922] (AK) on the face or scalp. 
2.1.2 Mechanism of Action 
KX2-391 (referred to as KX01 in study protocol numbers) is a synthetic and highly selective 
inhibitor of Src tyrosine kinase signaling an d tubulin polymerization.  KX2-391 Ointment is 
being developed as a topi[INVESTIGATOR_565829].  KX2-391 is also being developed as an oral 
agent for oncology indications. 
KX2-391 promotes the induction of p53, G2/M arre st of proliferating cell populations and 
subsequent apoptosis via the s timulation of Caspase-3 and PARP cleavage.  Potent inhibition 
of the growth of primary human keratinocytes and several melanoma cell lines in vitro (50% 
growth inhibition [GI 50 YDOXHV@¬îQ0VXJJHVWVWKDW.; -391 has the potential to inhibit 
the proliferative expansion and promote apoptos is of abnormally prolif erating cells in the 
epi[INVESTIGATOR_691741].  KX2-391 has also been observed to 
inhibit T cell migration and endothelial tubule formation in vitro, suggesting additional 
potential therapeutic benefits for conditions where pathology is supported by [CONTACT_691788], inflammation, and/or angiogenesis. 
2.1.3 Nonclinical Studies 
Details regarding KX2-391 nonclinical studies  are provided in the KX2-391 Ointment 
Investigator‚Äôs Brochure. 
The bioavailability of KX2-391 after dermal administration to rats (1.59%) and rabbits 
(2.49% to 6.47%, depending on conc entration) was low.  Plasma  concentrations of KX2-[ADDRESS_938196] level (NOAEL) dose (1.2 5 mg/kg/dose) in a 28-day twice-daily oral 
toxicity study. Following 28 days of KX2- 391 topi[INVESTIGATOR_691742]_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 20 of 71 
 
 (0.1%, 1%, and 2%) in rats and minipi[INVESTIGATOR_14107], an increase in KX2-391 plasma exposure was 
observed from Day 1 to Day 28, suggesting slight drug accumulation. 
In 28-day repeat-dose toxicology studies, KX2 -391 ointment was administered to rats and 
minipi[INVESTIGATOR_691743] 0.1%, 1%, and 2%. Ointment volumes of 2 mL/kg body weight 
were applied to approximately 10% of the body surface area of the skin. The administration 
sites were occluded with gauze a nd the applications left for 8 h/day in rats. The application 
site was semi-occluded for 20-22 hours in mi nipi[INVESTIGATOR_14107]. These doses contained 2, 20, or 
40 mg/kg KX2-391, respectively, e quivalent to 12, 120, or 240 mg/m2 in rats and 70, 700, or 
1400 mg/m2 in minipi[INVESTIGATOR_14107]. Systemic exposures on Day 28 to KX2-391 following daily 
application of 0.1% ointment were C max 22.9 ng/mL (male)/33.7 ng/mL (female) and 
AUC 0-24h 205 h*ng/mL (male)/216 h*ng/mL (female) in rats, and C max 2.03 ng/mL 
(male)/7.25 ng/mL (female), AUC 0-24h 37.4 h*ng/mL (male)/65.5 h*ng/mL (female) in 
minipi[INVESTIGATOR_14107]. Exposure (AUC) in humans was not calculated due to the lack of quantifiable 
plasma concentrations following topi[INVESTIGATOR_691730]2-391 administration. However, the maximum 
Cmax value at the NOAEL in rats and minipi[INVESTIGATOR_691744] 24 and 5 times greater than 
the maximum plasma KX2-391 concentration of 1.42 ng/mL achieved in the clinic 
(Study KX01-AK-002). 
Other dermal toxicity studies with KX2- 391 showed that KX2-391 ointment may be 
sensitizing to the skin (Buehler assay and mu rine local lymph node assay), that KX2-391 
ointment was negative for phototoxicity, and that  KX2-391 ointment was an irritant to the 
eyes of rabbits after single application (effects cleared within [ADDRESS_938197] dose). 
KX2-391 was negative in a bacterial mutage nicity study (Ames test). KX2-391 caused 
chromosomal aberrations in Chinese Hamster Ovary (CHO) cells at very high doses that are 
not likely to be clinically relevant. 
Studies of the effects of KX2-[ADDRESS_938198] been 
performed. In embryo-fetal development studies in rats and rabbits, KX2-391 was 
administered orally in order to increase systemic exposure.  Embryo and fetal toxicity, LQFOXGLQJLPSODQWDWLRQORVVDQGIHWDOPDOIRUPDWLRQVRFFXUUHGD WRUDOGRVHVRI¬ïPJNJ
(rats) and 3 mg/kg (rabbits). The no-effect doses for fetal and reproductive effects were 
0.5 mg/kg (rats) and 1 mg/kg (rabbits ). At these doses, maternal C
max and AUC 0-8 h systemic 
exposures to KX2-391 were 25.4 ng/mL and 82.4 h*ng/mL (rats, Day 17) and 144 ng/mL 
and 251 h*ng/mL (rabbits, Day 18), respectivel y. Systemic plasma exposure (AUC) in 
humans could not be determined due to the lack of quantifiable plasma concentrations across 
multiple timepoints. However, maternal C max values at the NOAEL in rats and rabbits are 
approximately 18 and 1 00 times greater than the highes t KX2-391 plasma concentration 
achieved clinically of 1.42 ng/mL (Study KX01-AK-002). 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 21 of 71 
 
 2.1.4 Clinical Experience with KX2-391 
[IP_ADDRESS] KX2-391 in Cancer (Oral) 
KX2-391 has been administered orally as a treatment for cancer to approximately 
120 patients with various types of malignancies in 4 clinical studies sponsored by [CONTACT_691789], 
Inc.  A summary of the safety information fro m these patients is provi ded in an appendix of 
the KX2-391 Ointment Investigator‚Äôs Brochure. 
Due to the differences in route of administra tion and short duration of  treatment (5 days), 
topi[INVESTIGATOR_691730]2-[ADDRESS_938199] the same toxicity 
profile as oral KX2-391. 
[IP_ADDRESS] KX2-391 as a Topi[INVESTIGATOR_691745], 2 clinical studies ha ve been conducted to evaluate  the activity and safety of 
KX2-391 Ointment 1% in subjects with AK. 
Study KX01-AK-01-US, a Phase 1, safety, tolerability, and pharmacokinetic study, 
demonstrated that KX2-391 Ointment 1% was we ll-tolerated and showed clinical activity in 
[ADDRESS_938200] subjects experienced mild to moderate 
and transient local skin reactions (LSRs).  The majority of the LSRs observed were erythema 
and flaking/scaling that peaked around Day 5-10, before returning to or close to baseline.  
Symptoms of pruritus, stinging, and burning at the treatment area were generally mild and transient.  There were  no serious adverse events (SAEs) or deaths, and no subjects 
discontinued due to an adverse event (AE). 
Study KX01-AK-002 , an ongoing Phase 2a, open-label, sequential group study, evaluated 
the activity and safety of KX2-391 Ointment 1% when applied daily in a treatment area of 
25 cm
2 for 3 consecutive days (n=84 subjects) or 5 consecutive days (n=84 subjects) in adults 
with AK on face or scalp.  Preliminary data showed that most of the 168 subjects treated had mild to moderate LSRs (primarily erythema an d flaking/scaling.  Eleven (6.5%) subjects had 
16 treatment-emergent adverse events (TEAEs) considered treatment-related by [CONTACT_737].  Eight of these subjects had mild application site reactions including pruritus, tenderness, or stinging.  The remaining AEs considered by [CONTACT_300338]-related were mild headache, mild to moderate dizziness, mild arthralgia, or mild darkening of hair color near the treatment area.  All treatment-related TEAEs resolved prior to or stabilized by [CONTACT_2006] 57.  Four subjects reported [ADDRESS_938201] discontinued treatment due to AEs. 
Thirty-six of 84 subjects (43%) in the 5-day regimen and 27 of 84 subjects (32%) in the 
3-day regimen had 100% clearance of AK lesions in the treatment area on Day 57. 
Plasma concentrations of KX2-391 were meas ured in Study KX01-AK-002 using a validated 
liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay with a lower limit of 
quantification (LLOQ) of 0.1 ng/mL.  Pharmaco kinetic results showed that following 3 or 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 22 of 71 
 
 5 consecutive days of treatment with KX2 -391 Ointment 1%, low systemic exposure 
(< 2 ng/mL) and limited drug accumulation were observed. 
Details of both studies are available in the KX2-391 Ointment Investigator‚Äôs Brochure. 
2.2 Study Rationale 
Actinic keratosis represents  the initial intra-epi[INVESTIGATOR_691746] (SCC).  
Squamous cell carcinoma is the second leading ca use of skin cancer deaths in the US, with 
up to 65% of SCC arising from pre-existing actinic keratoses .1,2  The risk of progression has 
been determined to be be tween 0.025% and 16% per year,1,3 and the calculated lifetime risk 
of malignant transformation for a patient w ith AK lesions followed up for 10 years is 
between 6.1% and 10.2%.[ADDRESS_938202] cosmetic outcomes. 
2.3 Potential Risks and Benefits 
Preliminary results of studies KX01-AK-01- US and KX01-AK-002 indicate that KX2-391 
Ointment 1% administered once daily for up to [ADDRESS_938203] th at the 5-day regimen of KX2-391 Ointment 
1% has greater activity (43%) than the 3-day regimen (32%). 
Preliminary safety results from both studies show ed that KX2-391 Ointment 1% is safe and 
well tolerated.  Even though LSRs (primarily erythema and/or flaking/scaling) were reported by [CONTACT_691790], they were generally mild or moderate in severity and mostly transient.  The treatment-related TEAEs that subjects experienced mainly consisted of mild application site reactions such as itching, burning, stinging, tenderness, and pain.  No subjects discontinued treatment due to AEs and no treatment-rela ted SAEs were reported.  
Based on these findings, the clinical benefit of treating actinic keratosis, a precancerous condition, with a short course of topi[INVESTIGATOR_691730]2-[ADDRESS_938204] 90 days after stoppi[INVESTIGATOR_056]. 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 23 of 71 
 
 3 STUDY OBJECTIVES AND ENDPOINTS 
3.1 Primary Objective and Endpoint 
The primary objective of the study is to evalua te the efficacy of t opi[INVESTIGATOR_691730]2-391 Ointment 
1% once daily for 5 consecutive days compar ed to vehicle control in terms of 100% 
clearance at Day 57 in the treatment of adults with AK, when applied to a contiguous area of 
25 cm2 on the face or scalp.  
The primary endpoint will be co mplete (100%) clearance rate of AK lesions, defined as the 
proportion of subjects at Day 57 with no clinical ly visible AK lesions in the treatment area. 
3.2 Secondary Objectives and Endpoints 
The secondary objectives of the study are: 
x To evaluate the safety of topi[INVESTIGATOR_691730]2- 391 Ointment 1% once daily for 5 consecutive 
days in terms of LSRs and other safety  evaluations such as AEs and laboratory 
assessments 
x To comSDUHWKHUDWHVRISDUWLDOUHVSRQGHUVGHILQHGDV¬ïFOHDUDQFH RI$.OHVLRQV
in the treatment area on the face or scal p at Day 57 between the KX2-391 Ointment 
1%-treated group and vehicle-treated group  
x To determine the recurrence of AK in the treatment area up to [ADDRESS_938205]-Day 57 
in subjects who had complete clearance at Day 57 after 5 consecutive days of 
treatment with KX2- 391 Ointment 1%  
x To evaluate the safety of topi[INVESTIGATOR_691730]2- 391 Ointment 1% within the treatment area 
during the Recurrence Follow-up Period. 
The secondary endpoints are: Efficacy: 
Key Secondary Endpoint: 
x Partial clearance rate of AK lesions, define d as the proportion of subjects at Day 57 
with a ¬ï75% reduction in the number of AK lesions identified at Baseline (Day 1 
predose) in the treatment area  
Additional Endpoint: 
x Recurrence rate of AK lesions in subjects who achieved complete clearance at Day 57  
Safety: 
Clinical Study Protocol_Amendment [ADDRESS_938206], clinical laboratory data, and other safety assessments (vital signs, physical examinations [PEs], electrocardiograms [ECGs])  
x AEs within the treatment area after Day [ADDRESS_938207]-Day 57 
4 INVESTIGATIONAL PLAN 
4.1 Overall Study Design and Plan 
This is a double-blind, vehicle-controlled, ra ndomized, parallel group, multicenter study to 
evaluate the efficacy and safety of KX2-391 Ointment 1% administered topi[INVESTIGATOR_691747]. 
Enrollment will be controlled so that approximately two thirds of subjects enrolled will be 
treated on the face and approximately one third of subjects enrolled will be treated on the 
scalp.  A sufficient number of subjects w ill be screened to ra ndomize approximately 
300 subjects.  At each site, a minimum of 10 subjects and a maximum of 20 subjects are 
projected to be enrolled. 
The study consists of Screening, Trea tment, a Response Assessment Period, and a 
Recurrence Follow-up Period.  After a Screening Period of up to 28 days, subjects will return 
to the site for confirmation of eligibility.  Eligible subjects will be randomized on Day 1 to treatment in a 1:1 (KX2-391 Ointment 1% or ve hicle) ratio in each treatment area subgroup. 
The treatment area will be marked with indelible  marker at Baseline (Day 1 predose) at the 
investigational site.  Subjects will be given verbal and written instructions on self-administration of study drug/vehicle and a stud y kit containing [ADDRESS_938208] unresolved LSRs, hypo - or hyper- pi[INVESTIGATOR_371], scarring in the 
treatment area, or treatment-related AEs at Da y 57 will return for additional follow-up, which 
includes standardized photography of the trea tment area, every 7 to 28 days until resolution, 
returned to baseline, or deemed stabilized by [CONTACT_32366]. 
Subjects who achieve 100% clearance of AK lesi ons in the treatment area at Day 57 will 
continue in the Recurrence Follow-up Period to determine recurrence rate and safety for up to 12 months following the Day 57 Visit.  Visits during the Recurrence Follow-up Period will occur every 3 months.  Subjects who develop AK  lesions in the treatment area during the 
Recurrence Follow-up Period will be discontinued at the time of recurrence. 
Clinical Study Protocol_Amendment 01 KX01-AK-004
 
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 25 of 71
 An overview of the study design is presented in Figure 1. 
Figure 1 Study Design for KX01-AK-004 
4.2 Screening Period 
Screening (Visit 1) will occur between Day ‚Äì28 and Day ‚Äì1.  Subject eligibility will be 
established during the Screening Period.   
Details of screening procedures /assessments are provided in Section 7.1 . 
4.3 Treatment Period 
The Treatment Period will be Days 1 to 5.  Protocol eligibility will be confirmed at Baseline 
(Day 1 predose). 
All screening and baseline a ssessments should be evaluated for acceptability prior to 
randomization of the subject.  Eligible subject s will be randomized separately for face and 
scalp to treatment in a 1:1 ratio of  KX2-391 Ointment 1% or vehicle (see Section 6.3 ). 
Baseline and Treatment Period procedures and assessments, and timing thereof, are shown in 
Table 1 ; details are provided in Section 7.2 and Section 7.3 , respectively. 

Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 26 of 71 
 
 4.4 Response Assessment Period 
Subjects will return to the clinical sites for Response Assessment Visits postdose on Day 5 
(Visit 3) and on Days 8, 15, 29, and 57 (Visits 4 th rough 7).  Procedures and assessments and 
timing thereof during the Response Assessment Period are shown in  Table [ADDRESS_938209] unresolved LSRs, hypo - or hyper-pi[INVESTIGATOR_371], scarring in the 
treatment area, or treatment-related AEs at Da y 57 will return for additional follow-up, which 
includes standardized photography of the trea tment area, every 7 to 28 days until resolution, 
returned to baseline, or deemed stabilized by [CONTACT_32366]. 
4.5 Recurrence Follow-up Period 
Subjects who achieve 100% clearance of AK lesions in the treatment area at Day [ADDRESS_938210]-Day 57. 
Procedures and assessments and timing thereof during the Recurrence Follow-up Period are 
shown in Table 1 and the details are provided in Section 7.5 .  Subjects who develop AK 
lesions in the treatment area during the Recurrence Follow-up Period will be discontinued at the time of recurrence.
 
4.6 Discussion of Study Design, Including Choice of Dosing and 
Control Groups 
This is a multicenter, randomized, double-bli nd, vehicle-controlled, parallel group, efficacy 
and safety study of KX2-391 Ointment 1% admin istered topi[INVESTIGATOR_691748] 5 consecutive days.   
The dosing regimen for this study is base d on the Phase 2a study (KX01-AK-002).  
KX01-AK-002 is an open-label,  sequential group, non-randomiz ed, multi-center study that 
evaluated the dosing regimen of daily dosing fo r either 3 or 5 consecutive days of KX2-391 
Ointment 1% on a treatment area of 25 cm2 on the face or scalp that contained 4 to 8 AK 
lesions in 168 adults ([ADDRESS_938211] s per cohort).  Preliminary analyses showed that a higher 
percentage of subjects achieved complete clearance of AK on Day 57 for the 5-day treatment group (43%) than the 3-day treatment group (32 %).  For both the 5-day and 3-day treatment 
groups, KX2-391 Ointment 1% was found to be safe, well tolerated a nd minimally absorbed 
throughout treatment and follow up for both cohorts .  Thus, these data support the evaluation 
of KX2-391 Ointment 1% once daily topi[INVESTIGATOR_609904] a 5-consecutive day dosing 
regimen for the treatment of adults with AK on th e face or scalp in this Phase 3 double-blind, 
vehicle-controlled study.  The 12-month Recu rrence Follow-up Period allows for long-term 
evaluation of AK recurrence rates and safety. 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 27 of 71 
 
 5 STUDY POPULATION 
Eligible subjects will be adults ¬ï\HDUVRIDJH with a diagnosis of clinically typi[INVESTIGATOR_691749]. 
A sufficient number of subjects will be screened  to randomize approximately [ADDRESS_938212] meet all the following criteria to be included in this study: 
1. 0DOHVDQGIHPDOHV¬ï\HDUVROG  
2. A treatment area on the face or scalp that: 
x is a contiguous area measuring 25 cm2 
x contains 4 to 8 clinically typi[INVESTIGATOR_2855], visible, and discrete AK lesions  
3. Subjects who in the judgment of the Investig ator, are in good general health based on: 
x medical history 
x physical examination (PE) findings 
x vital signs  
x ECGs, clinical chemistry, hematology, and urinalysis results  
4. Females must be postmenopaus al (>[ADDRESS_938213] 12 months of 
amenorrhea), surgically sterile (by [CONTACT_691791], bilateral oophorectomy, or tubal 
ligation); or, if of childbearing potential, must be using highly effective contraception for at least [ADDRESS_938214] on Day 1 prior to randomization. 
8. Willing to avoid excessive sunlight or ultraviolet (UV) light exposure, including the use 
of tanning beds, to the face or scalp  
9. Able to comprehend and are willing to sign the informed consent form (ICF). 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 28 of 71 
 
 5.2 Exclusion Criteria 
Subjects who meet any of the following criteria will be excluded from this study: 
1. Clinically atypi[INVESTIGATOR_199]/or rapi[INVESTIGATOR_547924], eg, 
hypertrophic, hyperkeratotic, recalcitrant disease (had cryosurgery on two previous occasions) and/or cutaneous horn 
2. Location of the treatment area is: 
x On any location other than the face or scalp 
x Within 5 cm of an incompletely healed wound 
x Within 5 cm of a suspected basal cell carcinoma (BCC) or SCC 
3. Been previously treated with KX2-391 Ointment 
4. Anticipated need for in-patient hospi[INVESTIGATOR_565808]-patient surgery from Day 1 to Day 57 
5. Treatment with 5-fluorourac il (5-FU), imiquimod, ingenol mebutate, diclofenac, 
photodynamic therapy, or other treatments fo r AK within the treatment area or within 
2 cm of the treatment area, within 8 weeks prior to the Screening visit 
6. Use of the following therapi[INVESTIGATOR_13265]/or medications within 2 weeks prior to the Screening 
visit: 
x Cosmetic or therapeutic procedures (eg, use of liquid nitrogen, surgical excision, 
curettage, dermabrasion, medium or greater depth chemical peel, laser resurfacing) 
within the treatment area or
 within 2 cm of the selected treatment area 
x Acid-containing therapeutic products (eg, sa licylic acid or fruit acids, such as alpha- 
and beta-hydroxyl acids and glycolic acids), topi[INVESTIGATOR_22775], or light chemical peels 
within the treatment area or  within 2 cm of the selected treatment area  
x Topi[INVESTIGATOR_142742] (non-medicated /non-irritant lotion and cream are acceptable) or topi[INVESTIGATOR_691732] 2 cm of the selected treatment area; 
artificial tanners within the treatment area or  within 5 cm of the selected treatment 
area 
7. Use of the following therapi[INVESTIGATOR_13265]/or medications within 4 weeks prior to the Screening 
visit:  
x Treatment with immunomodulators (eg, a zathioprine), cytotoxic drugs (eg, 
cyclophosphamide, vinblastine, chlorambucil, methotrexate) or interferons/interferon 
inducers 
x Treatment with systemic medications that suppress the immune system (eg, 
cyclosporine, prednisone, methot rexate, alefacept, infliximab) 
8. Use of systemic retinoids (eg, isotretinoin, ac itretin, bexarotene) within 6 months prior to 
the Screening visit 
9. A history of sensitivity and/or allergy to any of the ingredients in the study medication 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 29 of 71 
 
 10. A skin disease (eg, atopic dermatitis, psoriasi s, eczema) or condition (eg, scarring, open 
wounds) that, in the opi[INVESTIGATOR_689] , might interfere with the study conduct or 
evaluations, or which exposes the subject to  unacceptable risk by [CONTACT_28224] 
11. Other significant uncontrolled or unstable me dical diseases or conditions that, in the 
opi[INVESTIGATOR_689], would expose the subject to unacceptable risk by [CONTACT_28224] 
12. Females who are pregnant or nursing 
13. Participated in an investigational drug trial during which an investigational study 
medication was administered within  [ADDRESS_938215] Withdrawal / Discontinuation Criteria  
The Investigator may withdraw a subject from study treatment or withdraw the subject from 
the study at any time for safety or administ rative reasons.  The subject may decide to 
discontinue study treatment or withdraw from  the study at any time for any reason.  The 
Investigator must document the reason for discon tinuing a subject from treatment or from the 
study if known, or why the subject withdrew c onsent, if applicable.  Subject disposition 
information will be collected on the electronic case report form (eCRF). 
Subjects who do not complete 5 days of trea tment and withdraw from study treatment (for 
reasons other than death or withdrawal of consent) will be encouraged to continue the post-treatment visits.  At the time  of withdrawal from the study, the subject should complete 
the early termination assessments (Day 57 assessments) ( Table 1 ).  A subject who does not 
return for the post-treatment visits will be followed up by [CONTACT_2319], phone, or other means to 
gather information such as the reason for failure to return, the presence or absence of AEs, and clinical courses of signs and symptoms.  This information will be recorded in the eCRF. 
Subjects who discontinue early from the study w ill be discontinued for one of these primary 
reasons: 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 30 of 71 
 
 x AE(s) 
x Lost to follow-up 
x Withdrawal of consent (subjects will be asked but not required to provide a reason) 
x Study terminated by [CONTACT_2728] 
x Noncompliance (specify) 
x AK recurrence during the Recurrence Follo w-up Period prior to the 12-month visit 
x Investigator decision (specify) 
x Death 
x Other (specify) 
Subjects who do not achieve 100% clearance of AK lesions in the treatment area at Day [ADDRESS_938216] completed their participation in the study. 
6 STUDY TREATMENTS 
6.1 Identity of Study Drugs 
Treatments administered will be  topi[INVESTIGATOR_691730]2-391 Ointment 1% and vehicle ointment. 
6.1.1 Formulation, Packaging, and Labeling 
KX2-391 Ointment 1% will be supplied in sing le-use packets, each of which contains 
250 mg of the ointment, equivalent to 2.5 mg of KX2-391 free base.  Vehicle ointment will 
be supplied in the same single-use packets, e ach of which contains 250 mg of the ointment 
without the active drug.  Each packet is for use as a single-dose application.  Complete 
formulation contents for both KX2-391 Ointment  1% and vehicle ointment are provided in 
the KX2-391 Ointment Investigator‚Äôs Brochure. 
Each eligible randomized subject will be assigned an enrollment number and a study kit with 
the same enrollment number.  The study kit will contain 5 packets filled with either KX2-391 Ointment 1% or vehicle ointme nt.  Each packet and study kit will be labeled in accordance 
with national regulations.  Detailed information regarding the study drugs, including labeling 
information, will be in the Pharma cy Manual provided to the site. 
The following treatments will be administered to subjects in this study ( Table 2 ).  
Clinical Study Protocol_Amendment [ADDRESS_938217]  Strength Size of 
Treatment 
Area Number Applications and 
Frequency Study Days 
Administered 
KX2-391 Ointment 1% 1% 25 cm2 1 application once daily for 
5 consecutive days  Days 1-5 
Vehicle Ointment N/A 25 cm2 1 application once daily for 
5 consecutive days  Days 1-5 
N/A = not applicable 
6.1.2 Storage Conditions 
Study drug will be stored in accordan ce with labeled storage conditions. 
6.2 Dosage and Administration of Study Drugs 
6.2.1 Administration of Study Drugs 
At Baseline (Day 1 predose), subjects will receive verbal and written instructions on how to 
apply the topi[INVESTIGATOR_691750] ( Appendix 1 ). 
The study medication is for external topi[INVESTIGATOR_691751].  The treatment area 
will be marked with indelible marker at Baseline (Day 1 predose) at the investigational site (see Section 7.2.3 ).  Subjects will be provided with a study kit comprised of individual plastic 
bags with 5 single-dose packets containing e ither KX2-391 Ointment 1% or vehicle ointment 
and a dosing log. 
The first dose will be administered by [CONTACT_691792] [ADDRESS_938218] instructions also contain additional details including precautions associated with ointment application during the 5 days of  treatment and throughout the study.   
[IP_ADDRESS] Instructions in the Event of Ocular Exposure 
Subjects will be instructed to avoid getting ointment in their eyes.  If ointment does get in the 
eyes, the subject is to flush their eyes with water immediately and extensively.  The subject must immediately contact [CONTACT_691793]_Amendment [ADDRESS_938219]‚Äôs assessment w ill be included in the 
report of ocular exposure as an event of special interest (see  Section 8.2.3 ). 
6.2.2 Criteria for Interruption of Treatment/Dose Adjustments 
Not applicable; dose adjustment is not allowed. 
6.3 Randomization/Method of Assigning Subjects to Treatment 
Groups 
Enrollment will be controlled so that approximately two thirds of subjects enrolled will be 
treated on the face and approximately one third of subjects enrolled will be treated on the 
scalp.  Eligible subjects will be randomized to treatment in a 1:1 (KX2-391 Ointment 1% or 
vehicle) ratio in each treatment area subgroup. 
Subjects will be assigned to treatments in a double-blinded manner based on a computer-
generated randomization scheme.  Based on the randomization scheme, 2 lists of enrollment numbers will be issued to each site; one list will be for subjects with the treatment area on the face and the other list will be for subjects with  the treatment area on the scalp.  Study kits 
bearing corresponding enrollment numbers will be pr ovided to the site.  One set of kits will 
be provided for subjects with the treatment area on the face and the second set of kits will be provided for subjects with the treatment area on the scalp. 
Enrollment numbers and study kits are distributed sequentially.  The first eligible subject 
with AK lesion on the face will be assigned the first enrollment number for treatment of the face and given a study kit bearing the same enrollment number on Day [ADDRESS_938220] research organizations (CROs) involved in  the clinical conduct of the 
study, the Investigators, study site personnel  and study subjects will be blinded to the 
treatment that is assigned to each subject.  The integrity of this clinical study must be maintained by [CONTACT_58956].  See Section 8.2.5 for breaking the blind. 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 33 of 71 
 
 6.4 Prior and Concomitant Medications / Therapy 
6.4.1 Prior Medications / Therapy 
All medications (prescription and nonpres cription including vitamins and dietary 
supplements), treatments, and procedures take n 28 days before Day 1 are considered prior 
therapy and will be recorded in the eCRF.  An AK treatment history of the face or scalp will be recorded on the AK Treatment History eCRF (see Section 7.1.4 ). 
6.4.2 Concomitant Medications/Therapy 
Concomitant medication/therapi[INVESTIGATOR_691752].  Concomitant 
medication/therapi[INVESTIGATOR_42214]. 
Use of sunblock from Day [ADDRESS_938221] or any to pi[INVESTIGATOR_691753] 57. 
During the Recurrence Follow-up Period, sunbl ock and non-medicated topi[INVESTIGATOR_691754].  During the Recurrence Follow-up Period, only concomitant medications/therapi[INVESTIGATOR_691755]. 
6.4.3 Prohibited Medication/Therapy  
Use of any treatment for AK lesions other than study drug on the treatment area is prohibited 
during the study.  Subjects will be reminded that AK lesions located outside the treatment area may be treated by [CONTACT_240765]-directed treatment only, eg, cryotherapy or biopsy. 
Prohibited medications are as follows: Prohibited drug products and trea tments that might influence or mask the effects of treatment 
until Day 57 include:  immunomodulators or immunos uppressive therapi[INVESTIGATOR_014], cytotoxic drugs, 
interferon/interferon inducers, topi[INVESTIGATOR_547948], 5-FU, ingenol mebutate, 
imiquimod, diclofenac, topi[INVESTIGATOR_691756], topi[INVESTIGATOR_112933], bichloroacetic 
acid, trichloroacetic acid, aci d-containing therapeutic pr oducts, benzoyl peroxide, 
chemodestruction, medicated/therap eutic topi[INVESTIGATOR_142742], photodynamic therapy, psoralen plus 
UVA or UVB therapy, artificial tanner, excessi ve or prolonged exposure to UV light source.
9 
Subjects are prohibited from applying any t opi[INVESTIGATOR_49186], including but not limited to, 
lotions, creams, and ointments, moisturizers, sunscreen, artificial tanners, or make-up to the treatment area up until the end of Day 57 (Visit 7), except when those medications are prescribed by [CONTACT_691794].  Subjects should avoid direct sun 
or UV exposure to the treatment area throughout the study.  However, from Day [ADDRESS_938222] unrestricted us e of nonmedicated topi[INVESTIGATOR_691757]. 
During the Recurrence Follow-up Period, use of treatments that may interfere with the 
assessment of AK recurrence in the treatment area are prohibited. This includes use of AK treatment and medicated topi[INVESTIGATOR_691758] 
(eg, immunosuppressive agents and systemic AK  treatment) that may interfere with the 
assessment of AK recurrence. 
Any subjects who start systemic or topi[INVESTIGATOR_691759]. 
The decision to administer a prohibited medicati on/treatment is done with  the safety of the 
study subject as the primary consideration. 
6.4.4 Other Prohibitions and Restrictions during Study 
There are no restrictions during the study on smoking/tobacco use, diet, alcohol/caffeine, 
water or other beverages, or physical activity. 
After self-application, subjects will avoid to uching or wetting the treatment area for 
approximately [ADDRESS_938223] be kept in an appropriate secure area (eg, locked cabinet) and stored 
according to the conditions specified on the drug labels. 
The Investigator and study staff will be resp onsible for the accountability of all clinical 
supplies (eg, shipment, dispensing, inventory, and record keepi[INVESTIGATOR_007]) following the Sponsor‚Äôs 
instructions.  In this matter, the Investigator  and study staff must adhere to Good Clinical 
Practice (GCP) guidelines, as well as  local or regional requirements. 
Under no circumstances will the Investigator allow the study drugs to be used other than as 
directed by [CONTACT_3181].  Clinical supplie s will be dispensed only by [CONTACT_548033]. 
An accurate and timely record of the receipt of all clinical supplies and dispensing of study 
drug to the subject must be maintained. 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 35 of 71 
 
 All forms will be provided by [CONTACT_1034] (or its  designee).  Any comparable forms that the 
investigational site wishes to use must be a pproved by [CONTACT_1034].  A copy of the drug 
accountability record must be provided to the Sponsor (or its designee). 
The clinical research associate (CRA) will revi ew drug accountability during monitoring site 
visits. 
The Investigator (or site personnel) must not de stroy any drug labels or any partly used or 
unused drug supply.  Post-Day 57, and as appropr iate during the study, the Investigator (or a 
designated pharmacist) will return all used and unused drug packets, study kits, drug labels, 
and a copy of the completed drug disposition form to the clinical supply vendor. 
Refer to the Pharmacy Manual for inst ructions and contact [CONTACT_3031]. 
6.5.2 Treatment Compliance 
Subjects will return the used ointment packets (or unused ointment, if not administered) back 
to the clinical site on Day 5 (Visit 3) postdose, to check compliance. 
The dosing logs for each subject will be kept during the study.  The CRAs will review 
treatment compliance during monitoring site visits. 
[ADDRESS_938224] provides informed consent (Table 1 ).  Screening (Visit 1) will occur between Day -[ADDRESS_938225] of any screening procedur es or assessments.  Documentation will be 
required (documented in the clinic notation) to confirm that the Investigator ensured that the 
informed consent process was done correctly,  the subject understood what to expect, and 
agreed to participate. 
Procedures to be followed when obtaining informed consent are detailed in  Section 10.3.2 . 
7.1.2 Inclusion/Exclusion Criteria 
Subject eligibility will be confirmed per the inclusion/exclusion criteria at Screening. 
Clinical Study Protocol_Amendment [ADDRESS_938226] demography information will be collected at Screening.  Demography information 
includes age at time of consent, sex, race/ethnicity. 
7.1.4 Medical/Surgical and Actinic Keratosis History 
Medical and surgical history and current medical conditions will be recorded at Screening. 
Medical history will include:  
x Significant medical and surgical history; childhood diseases and common colds are 
not required unless it is ongoing at Screening 
x The initial diagnosis date of AK on the face or scalp, depending on the selection of 
the treatment area for the study 
x An AK treatment history of the face  or scalp including all commercial and 
investigational products and surgical modalities dating back to the initial diagnosis.  
x History of cancers including skin cancers, eg, BCC, SCC, melanoma. 
7.1.5 Prior Medications 
All medications (prescription and nonpres cription including vitamins and dietary 
supplements), treatments, and th erapi[INVESTIGATOR_32546] 28 days before Day 1 will be recorded at 
Screening. 
7.1.6 Fitzpatrick Skin-Type Classification 
The Fitzpatrick Skin-Type is a skin classification system8 which measures 2 components 
(genetic disposition and reaction to sun exposure).  Skin-types range from very fair (Type I) 
to very dark (Type VI).  Subjects‚Äô skin will be typed using this classification system at Screening. 
7.1.[ADDRESS_938227] (Investigator or Subinvestigator) will identify a 
contiguous treatment area affected with AK on  the face or scalp fo r each subject that 
measures [ADDRESS_938228] (Investigator or Subinvestigator) will perform a count of AK lesions (lesion count) for all subjects. 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 37 of 71 
 
 7.1.9 Physical Examinations  
A complete PE will be performed at Screening and will include weight and an assessment of 
the head, eyes, ears, nose, and throat (HEENT), gastrointestinal, cardiovascular, respi[INVESTIGATOR_696], 
musculoskeletal, and neurological systems.  Height will be measured at Screening only.  An expanded dermatological ex amination will be conducte d at Screening only ( Section 7.1.7 ).  
The complete PE will be part of the baseline assessments. 
7.1.10 Vital Signs 
Vital signs will be recorded at Screening.  Vital sign (pulse rate, systolic and diastolic blood 
pressure, respi[INVESTIGATOR_697], and body temperature) measurements will be taken after the subject has been seated for at least [ADDRESS_938229] being randomized. 
ECGs will be transferred electroni cally to the central ECG vendor. 
7.1.12 Laboratory Measurements 
Samples for clinical laboratory testing (hematology, chemistry, urinalysis) will be collected 
at Screening.  Clinical laboratory testing will be part of the baseline assessments.  See Section [IP_ADDRESS] for further details about laboratory tests. 
7.1.[ADDRESS_938230] be reviewed before randomization of subjects. 
7.2 Baseline Assessments 
All baseline assessments should be completed by [CONTACT_2006] 1 (Visit 2) prior to randomization, 
according to the Schedule of Procedures and Assessments ( Table 1 ). 
7.2.1 Inclusion/Exclusion Criteria 
Subject eligibility will be re-confirmed per the inclusion/exclusion criteria at Baseline. 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 38 of 71 
 
 7.2.2 Prior Medications 
All prior medications (presc ription and nonprescription including vitamins and dietary 
supplements), treatments, and therap ies will be confir med at Baseline. 
7.2.3 Treatment Area Identification 
At Baseline (Day 1 predose), the Investigator will confirm the 25 cm2 treatment area affected 
with 4 to 8 AK lesions on the face or scalp that was identified at Screening. 
At Baseline (Day 1 predose), the location and shape of the treatment area and the specific 
AK lesions will be recorded on an acetate transparency sheet gridded with 1 cm2 squares.  
The Investigator or Subinvestigator will identify the treatment area by:  
1. Placing the transparency sheet over the treatment area 
2. With a fine-tip indelible marker: 
x Mark at least [ADDRESS_938231]‚Äôs skin, outline the treatment area with dots and dashes with the 
indelible marker. 
The transparency sheet will be kept at the site  and will be used to locate the treatment area 
and AK lesions during the follow-up visits. 
7.2.[ADDRESS_938232] (Investigator or Subinvestigator) will perform a count of clinically visible AK 
lesions (lesion count) for all subjects at Baseline (Day 1 predose).  The same Investigator or Subinvestigator will conduct th e lesion count at all visits  for an individual subject. 
For this assessment, an AK lesion should be c ounted only if it is completely inside the 
treatment area. 
7.2.5 Focused Dermatological Exam of Treatment Area 
At Baseline (Day 1 predose), the focused dermatological exam of treatment area will include 
evaluation for LSRs, hypo- or hyper-pi[INVESTIGATOR_293644], and scarring (see below).  These 
assessments will be used as  baseline assessments. 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 39 of 71 
 
 [IP_ADDRESS] Local Skin Reactions 
At Baseline (Day 1 predose), after the assessment of AEs, the Investigator or Subinvestigator 
will assess for LSRs on the treatment area.  The same Investigator or Subinvestigator will 
conduct the LSR assessment at all vi sits for an individual subject. 
LSR signs on the treatment area include the following:  erythema, flaking/scaling, crusting, 
swelling, vesiculation/pustulation, and erosion/ulceration.  These signs will be assessed using 
a 4-point grading scale; 0=absent, 1=mild (slight ly, barely perceptible) , 2=moderate (distinct 
presence), and 3=severe  (marked, intense).  
Application site reactions not classified as LS Rs (eg, itching, burning, stinging, tenderness, 
pain) will be reported as AEs. 
LSRs will be reported separately from AEs. 
[IP_ADDRESS] Pi[INVESTIGATOR_691760], hypo- and hyper-pi[INVESTIGATOR_691761]. 
Pi[INVESTIGATOR_691762] (Day 1 predose), after the assessment 
of adverse events.  The same Investigator or Subinvestigator will assess pi[INVESTIGATOR_691763]. 
7.2.6 Standardized Photography 
At Baseline (Day 1 predose), the Investigator  or a qualified staff member must obtain 
standardized photography of each subject‚Äôs treatment area before application of study 
medication. 
Care must be taken to ensure the same ligh ting, background, subject positioning relative to 
the camera and camera settings are used fo r each photograph.  Equipment, supplies and 
detailed instructions for obtai ning and managing the photogra phs will be provided to the 
investigational center prior to the initiation of subject enrollment. 
The photographs are to document the appearance of  the subjects‚Äô treatment area and to assist 
with the identification and conf irmation of the location of the treatment area throughout the 
study. 
7.2.7 Vital Signs 
Vital signs will be measured at Baseline (Day 1 predose).  See Section 7.1.10 for details. 
7.2.8 Electrocardiograms 
A 12-lead ECG will be obtained at Baseline (Day 1 predose).  See Section 7.1.[ADDRESS_938233] will be performed at the site at 
Baseline (Day 1 predose).  Test results must  be reviewed before randomization on Day 1. 
7.2.[ADDRESS_938234]‚Äôs eligibility to participate in the 
study, he/she will be assigned the next enrollment number appropriate for the area being treated (see Section 6.3 ). 
7.2.11 Instructions for Self-administration of Study Treatment, Dispensing, and 
Return of Study Treatment 
At Baseline (Day 1 predose), subjects will receive both verbal and written instructions 
(Appendix 1 ) for daily self-administration of study treatment.  Any questions will be 
answered by [CONTACT_46683]. 
Randomized subjects will be assigned an enrollment number and a study kit with the same 
enrollment number.  The study kit will have 5 single-dose packets (1 for each day of treatment) containing either KX2-391 Oi ntment 1% or vehicle ointment (see Section 6.1.1 ).  
The study kit will include a dosing log where the subjects will record the date and time of study drug self-administration. 
Subjects will be instructed to place the used packets (including torn pi[INVESTIGATOR_6928]) into the plastic 
bags in which they came, seal the plastic bags, put them back into the study kit, and return the study kit containing used and unused packets and the dosing log to the clinical site after 
self-administration on Day 5 to check compliance ( Section 6.5.2 ). 
7.3 Treatment Period and Response Assessment Period 
7.3.1 Treatment Administration ‚Äì Days 1-[ADDRESS_938235] under the supervision of study site personnel.  Subjects will then take 
home the study kit containing the remaining sing le-dose packets of study drug for daily self-
administration on the next 4 consecutive days. 
7.3.2 Efficacy Assessments 
[IP_ADDRESS] Actinic Keratosis Lesion Count 
A dermatologist (Investigator or Subinvestigator) will perform a count of clinically visible AK 
lesions (lesion count) for all subjects at the Re sponse Assessment Visits on Days 8, 15, 29, and 
57 (Table 1 ).  The same Investigator or Subinves tigator will conduct the lesion count at all 
visits for an individual subject. 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 41 of 71 
 
 The Investigator or Subinvestigator may use the transparency and/or photograph from Baseline 
to locate the treatment area.  AK lesion counts from previous visits should not be used to assist in the assessment of AK lesion count at the current visit.  Only AK lesions completely within the treatment area will be counted. 
7.3.[ADDRESS_938236]. 
At each study visit, subjects will be asked a ge neral question ‚ÄúHow have you been since the 
last visit?‚Äù.  Adverse events will be recorded at each study visit, before assessment of LSRs, 
pi[INVESTIGATOR_371], and scarring in the treatment area.   Adverse events will be reported separately 
from LSRs. 
Safety assessments will also include vital signs, the performance of PEs, ECGs, laboratory 
evaluation of hematology, bioche mistry, and urinalyses, as detailed in the sections below. 
[IP_ADDRESS] Adverse Events  
All AEs will be assessed periodically through Day 57 ( Table 1 ). 
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered an investigationa l product.  An AE does not necessarily have a causal 
relationship with the medicinal product.  Fo r this study, the study drugs are KX2-391 
Ointment 1% and vehicle ointment. 
The criteria for identifying AEs in this study are: 
x Any unfavorable and unintended sign (inc luding an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of an investigational product, 
whether or not considered relate d to the investigational product  
x Any new disease or exacerbation of an existing disease 
x Any deterioration in non-protoc ol-required measurements of a laboratory value or other 
clinical test (eg, ECG or x-ray) that results in symptoms, a change in treatment, or discontinuation of study drug 
x Recurrence of an intermittent medical conditi on (eg, headache) not present pretreatment 
(Baseline) 
All AEs, regardless of relationship to study dr ug or procedure, should be collected beginning 
from the time the subject signs the study ICF through the final subject contact [CONTACT_307257].  Subjects who have unresolved LSRs, hypo- or hy per-pi[INVESTIGATOR_371], scarri ng in the treatment 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 42 of 71 
 
 area, or treatment-related AEs at Day 57 will return for additional follow-up every 
7 to 28 days until resolution, returned to baseline,  or deemed stabilized by [CONTACT_32366]. 
Subjects who fail screening primarily due to AE(s) must have the AE(s) recorded in the AE 
eCRF and screen failure  reported on the eCRF. 
Subjects with onset of a study treatment-rel ated AEs will be followed until resolution, under 
medical care, or deemed stabilized by [CONTACT_737].  All SAEs must be followed to resolution or, if resolution is unlikely, to stabilization. 
All AEs observed during the study will be reported on the eCRF. 
Laboratory Adverse Events 
A treatment-emergent abnor mal laboratory test result should be considered as a TEAE if the 
identified laboratory abnormality leads to any type of intervention whether prescribed in the protocol or not. 
An abnormal laboratory result shoul d be considered by [CONTACT_548014]: 
x Results in the withdrawal of study drug 
x Results in an intervention, based on medical  evaluation (eg, potassium supplement for 
hypokalemia) 
x Results in any out-of-range laboratory value that in the Investigator‚Äôs judgment fulfills 
the definitions of an AE with rega rd to the subject‚Äôs medical profile 
Abnormal laboratory values should not  be listed as separate AEs if  they are considered to be 
part of the clinical syndrome that is being repo rted as an AE.  It is the responsibility of the 
Investigator to review all laboratory findings in all subjects and determine if they constitute an AE.  Medical and scientific judgment should be exercised in deciding whether an isolated 
laboratory abnormality should be classified  as an AE.  Any laboratory abnormality 
considered to constitute an AE should be reported on the Adverse Event eCRF. 
Electrocardiogram Changes 
Any changes from the baseline ECG will be evaluated for clinical significance.  ECG 
changes that are determined to be clinically significant, regardless of relationship, will be reported as an AE. 
For symptomatic ECG abnormalities meeting criteria as SAEs, the study site must submit an 
SAE report, including the ECG report to the Sponsor or designee, using the SAE reporting 
procedures ( Section 8.1 ). 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 43 of 71 
 
 [IP_ADDRESS].[ADDRESS_938237] be made by [CONTACT_691795]. 
Adverse events will be graded on a 3-point scale (mild, moderate, severe) and reported in 
detail indicated on the eCRF.  The definitions are as follows: 
Mild Discomfort noticed, but no di sruption of normal daily activity 
Moderate Discomfort sufficient to re duce or affect normal daily activity 
Severe  Incapacitating, with inability to work or to perform normal daily activity The criteria for assessing severity are differe nt than those used for seriousness (see 
Section [IP_ADDRESS] for the definition of an SAE). 
[IP_ADDRESS].[ADDRESS_938238] be made by [CONTACT_691796]. 
Items to be considered when assessing the rela tionship of an AE to the study treatment are: 
x Temporal relationship of the onset of the event to the initiation of the study treatment  
x The course of the event, especially the eff ect of discontinuation of study treatment or 
reintroduction of study tr eatment, as applicable  
x Whether the event is known to be associated with the study treatment or with other 
similar treatments  
x The presence of risk factors in the study subject known to increase the occurrence of the 
event  
x The presence of non-treatment-related factors th at are known to be associated with the 
occurrence of the event.  
Classification of Causality 
The relationship of each AE to the study drug will be recorded on the eCRF using the 
following criteria: 
Definitely Related:   A clinical event, including laboratory test abnormality, occurring in a 
plausible time relationship to drug adminis tration, and which cannot be explained by 
[CONTACT_691797] e or other drugs or conditions 
Probably Related:   A clinical event, including laboratory test abnormality, with a reasonable 
time sequence to administration of the drug, unlikely to be attributed to concurrent or underlying disease or other drugs or conditions  
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 44 of 71 
 
 Possibly Related:   A clinical event, including laborato ry test abnormality, with a reasonable 
time sequence to administration of the drug, but which could also be explained by [CONTACT_691798]:   The AE is clearly not related to inves tigational product and is  clearly related to 
underlying disease, environmental or toxi c factor(s), or other drug therapy. 
[IP_ADDRESS] Serious Adverse Events  
All SAEs will be asse ssed during the Treatment and Re sponse Assessment Periods, on 
Days 1, 5, 8, 15, 29, and 57 ( Table 1 ). 
A SAE is any untoward medical occurrence that at any dose: 
x Results in death 
x Is life-threatening (ie, the subject was at immediate risk of death from the AE as it 
occurred; this does not include an event that , had it occurred in a more severe form or 
was allowed to continue, might have caused death) 
x Requires inpatient hos pi[INVESTIGATOR_1081] 
x Results in persistent or significant disability/incapacity 
x Is a congenital anomaly/birth defect (in the child of a subject who was exposed to the 
study drug) 
Other important medical events that may not be immediately life-threatening or result in 
death or hospi[INVESTIGATOR_313], when based on ap propriate medical judgment, may jeopardize 
the subject or may require intervention to prev ent one of the outcomes in the definition of 
SAE listed above should also be considered SAEs.  Medical a nd scientific judgment should 
be exercised in deciding whether expedited re porting is appropriate in such situations.  
All SAEs must be followed to resolution or, if resolution is unlikely, to stabilization. 
[IP_ADDRESS] Events of Special Interest 
All events of special interest will be assesse d during the Treatment and Response Assessment 
Periods, on Days 1, 5, 8, 15, 29, and 57 ( Table 1 ). 
In addition to the AEs and SAEs described a bove, events of special interest are to be 
captured and reported in the appr opriate eCRF and Events of Special Interest Forms (see 
Section 8.2 ).  Events of special interest will be consid ered as SAEs if they meet the criteria 
for an SAE ( Section [IP_ADDRESS]) . 
Clinical Study Protocol_Amendment [ADDRESS_938239] during the Treatment  and Response Assessment Periods (Days 1 to 
57) are as follows: 
x Overdose of study medication  
x Pregnancy  
x Ocular exposures to study medication 
x Skin cancers (including BCC, SCC, and melanoma); location and treatment will be 
reported.  
[IP_ADDRESS] Concomitant Medications 
Concomitant medications will be assessed during the Treatme nt and Response Assessment 
Periods, on Days 1, 5, 8, 15, 29, and 57 ( Table 1 ).  Any medication (including 
nonprescription medications) or therapy administere d to the subject during the course of the 
study (starting at the date of informed consent) will be recorded on the Concomitant Medication eCRF up to Day 57.  The Investigator  will record any AE on the Adverse Event 
eCRF for which the concomitant medication/therapy was administered. 
Use of sunblock from Day [ADDRESS_938240] or any to pi[INVESTIGATOR_691764] 57. 
[IP_ADDRESS] Focused Dermatological Exam of Treatment Area and Standard Photography 
The focused dermatological exam of the treatment area includes evaluation of LSRs, pi[INVESTIGATOR_371], and scarring (see Section [IP_ADDRESS].1 and Section [IP_ADDRESS].2 , respectively). 
Standardized photography will be performed at the Response Assessment Visits (Days 5, 8, 
15, 29, and 57) and at additional follow-up vi sits after Day [ADDRESS_938241] 
unresolved LSRs, hypo- or hyper- pi[INVESTIGATOR_386078], or scarring in the treatment area ( Table 1 ).  
See Section 7.2.6 for details. 
[IP_ADDRESS].1 L OCAL SKIN REACTIONS  
After the assessment of AEs at the Response Assessment Visits (Days 5, 8, 15, 29, and 57) 
(Table 1 ), the Investigator or Subinvestigator will assess for LSRs in the treatment area.  See 
Section [IP_ADDRESS]  for details.  The same Investigator  or Subinvestigator  will conduct the LSR 
assessment at all visits for an individual subject. 
All application site reactions and LSRs will be followed to re solution, or if resolution is 
unlikely, to stabilization. 
Treatment for any LSR will be recorded on the Concomitant Medications eCRF.  
Interruption/discontinuation of study treatment for an LSR will be recorded on the eCRF. 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 46 of 71 
 
 [IP_ADDRESS].2 P IGMENTATION AND SCARRING  
Hypo- and hyper-pi[INVESTIGATOR_691765] e treatment area will be assessed at the 
Response Assessment Visits (Days 5, 8, 15, 29, and 57) ( Table 1 ).  See Section [IP_ADDRESS] for 
details.  The same Investigator or Subinvestigator will assess pi[INVESTIGATOR_691766]. 
[IP_ADDRESS] Physical Examinations  
A complete PE will be performed on Day 57 ( Table 1 ) and will include weight and an 
assessment of the head, eyes, ears, nose, and throat (HEENT), integumentary, gastrointestinal, cardiovascular, respi[INVESTIGATOR_696], musculoskeletal, and neurological systems.  
Height will be measured at Screening only. 
Documentation of the PE will be included in the source documentation at the site(s).  
Changes from screening PE to findings at the last visit that meet the definition of an AE will be recorded on the Adverse Event eCRF. 
[IP_ADDRESS] Vital Signs 
Vital signs will also be recorded at the Response Assessment Visits on Days 5 and 57 
(Table 1 ).  Vital sign (pulse rate, systolic and diastolic blood pr essure, respi[INVESTIGATOR_697], and 
body temperature) measurements will be taken after the subject has been seated for at least 5 minutes.  Serial vital signs may be obtained to confirm accurate readings. 
Clinically significant abnormal vital signs, as assessed by [CONTACT_737], will be reported as 
adverse events. 
[IP_ADDRESS] Electrocardiograms 
Electrocardiograms will be obtained at the Re sponse Assessment Visits on Days 5 and 15 
(Table 1 ).  See Section 7.1.11  for details. 
Any ECG abnormality that the Investigator consider s as an AE should be recorded as such on 
the Adverse Event eCRF. 
[IP_ADDRESS] Laboratory Measurements 
Blood will be collected for clinical laboratory tests at Response Assessment Visits on Days 8 and 15 ( Table 1 ).  Collection of blood and urine (including samples for pregnancy 
testing, where applicable) will be conducted at the clinic site.  Approximately [ADDRESS_938242] during the study.  All sample s will be sent to a 
central laboratory for testing. 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 47 of 71 
 
 Microscopic urinalysis will be conducted only when clinically indicated based on dipstick 
results (laboratory protocol) or as deter mined by [CONTACT_737].  When conducted, 
microscopic urinalysis results will be recorded on the eCRF. 
The clinical laboratory tests to be measur ed during the study are provided in Table 3.  
Table 3 Clinical Laboratory Tests 
Category Parameters 
Hematology red blood cells (RBC), hemoglobin, hematocrit, platelets, and white 
blood cells (WBC) with differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils 
Chemistry  
 Electrolytes chloride, potassium, sodium, bicarbonate (HCO 3) 
 Liver function tests alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate 
aminotransferase (AST), direct bilirubin, total bilirubin 
 Renal function tests blood urea/blood urea nitrogen, creatinine 
 Other Albumin, calcium, cholesterol, glucose, lactate dehydrogenase (LDH), 
phosphorus, total protein, triglycerides, uric acid 
Urinalysis (dipstick) hydrogen ion concentration (pH), specific gravity, protein, glucose, 
ketones, leukocyte esterase, nitrite, bilirubin, urobilinogen, blood 
Pregnancy Testing serum pregnancy test or urine pregnancy test (see  Table 1 ) 
 
A laboratory abnormality may meet the criteria to qualify as an AE as described in this 
protocol (see Section [IP_ADDRESS] ).  In these instances, the AE corresponding to the laboratory 
abnormality will be recorded on the Adverse Event eCRF. 
For laboratory abnormalities meeting the criteria of SAEs (see Section [IP_ADDRESS] ), the site must 
report the SAE, including the laboratory report (as regionally required), to the Sponsor using 
the SAE form (see Section 8.1 ). 
7.3.[ADDRESS_938243] will be performed on Day 57/early termination at the clinical site ( Table 1 ).  Serum samples will be sent to a central laboratory 
for testing. 
7.[ADDRESS_938244] (Investigator or Subinvestigator) will perform a count of clinically visible AK 
lesions (lesion count) for subjects who achieve 100% clearance of AK lesions in the treatment area at Day 57 during the Recurrence Follow-up Period at the 3-, 6-, 9- and 12-month visits (Table 1 ).  The Investigator or Subinvestigator performing the lesion count should be the 
same Investigator or Subinvestigator who eval uated the subject previously during the study. 
An AK lesion should be counted if it is within the treatment area.  All AK lesions within the 
treatment area must be counted and recorded in the eCRF as an AK recurrence. 
When AK lesions are identified in the treatment area, the transparency which was used to 
map the AK lesions at Baseline should be used to  determine if the lesion(s) is new (ie, one 
which was not identified in the target treatment area at Baseline and emergent during the Recurrence Follow-up Period) or recurred (ie, one which is at the same AK lesion location 
identified at Baseline and resolved at Day 57). 
For subjects who have complete response at Day [ADDRESS_938245] their Final Visit at the visit when the AK recurrence is identified.  Subjects who develop 
AK lesions in the treatment area during the Recurrence Follow-up Period will be discontinued at the time of recurrence. 
7.5.2 Safety Assessments 
During the Recurrence Follow-up Period, safety assessments will include the monitoring and 
recording of AEs and SAEs within the treatment  area at the 3-, 6-, 9- and 12-month visits 
(Table 1 ).  See Section [IP_ADDRESS] for further information on the assessments of AEs.   
Concomitant medications/therapi[INVESTIGATOR_691767]/therapi[INVESTIGATOR_691768]-up Period at the 3-, 6-, 9- and 12-month visits ( Table 1 ) and will be recorded on the Concomitant 
Medication eCRF.  The Investigator will record any AE within the treatment area on the Adverse Event eCRF for which the concomitant medication/therapy was administered. 
Events of special interest during the Recurrence Follow-up Period include skin cancers 
(including BCC, SCC, melanoma) within the tr eatment area and pregnancy.  Information on 
skin cancers will be collected during the Recurrence Follow-up Period at the 3-, 6-, 9- and 12-month visits and reported as an event of sp ecial interest and as an AE in the Adverse 
Event eCRF (see  Section 8.2.4 ). 
Clinical Study Protocol_Amendment [ADDRESS_938246] (overdos e of study medication, 
pregnancy, ocular exposure to study medication, and skin cancers [including BCC, SCC, and 
melanoma]) are to be reported to the Sponsor within 1 business day of the Investigator becoming aware of the event.  Specific forms for reporting each type of event will be provided to the sites. 
The Sponsor (or its designee) must inform Investigators and regu latory authorities of 
reportable events, in compliance with applicable regulatory requirements, on an expedited basis (ie, within specific timeframes).  For this reason, it is imperative that sites provide complete SAE and events of special interest  information in the manner described below. 
In determining what SAEs meet criteria for expedited reporting, the current version of the 
KX2-391 Ointment Investigator‚Äôs Brochure will be  used as the referenc e safety information 
for KX2-391 Ointment 1%. 
8.[ADDRESS_938247] is discontinued from 
the Recurrence Follow-up Period, SAEs will no longer be collected.  
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 50 of 71 
 
 Any SAE event judged by [CONTACT_449129] (definitely, probably, or possibly 
related) to study treatment shoul d be reported to the Sponsor re gardless of the length of time 
that has passed since study completion.  
Deaths and life-threatening events should be reported immediately by [CONTACT_756].  The 
initial report must be submitted within 1 business day by [CONTACT_691799].  
It is very important that the SAE Report Form be filled out as completely as possible at the 
time of the initial report.  This includes the Investigator‚Äôs assessment of causality.  All supporting documents should be se nt de-identified and should c ontain the subject‚Äôs assigned 
enrollment number.  Only supporting documents di rectly related to the event should be sent. 
Any follow-up information received on SAEs should be forwarded as soon as possible.  If the 
follow-up information changes the Investigator‚Äôs assessment of causality, this should also be 
noted on the follow-up SAE form. 
Preliminary SAE reports should be followed as soon as possible by [CONTACT_691800][INVESTIGATOR_691769], autopsy reports, and other documents 
requested by [CONTACT_1034]. 
8.[ADDRESS_938248] be repor ted; pregnancies in female partners of male subjects for 
which the estimated date of conception was within [ADDRESS_938249] information for the reporting of 
pregnancies is provided in  the Investigator File. 
If an adverse outcome of a pregnancy is suspected to be related to study drug exposure, this 
should be reported regardless of the length of time that has pa ssed since the exposure to study 
treatment. 
A congenital anomaly, death dur ing perinatal period, an induced  abortion, or a spontaneous 
abortion are considered to be SAEs and should be reported in the same  timeframe and in the 
same format as all other SAEs (see  Section 8.1 ). 
All pregnancies must be followed to outcome .  The outcome of the pregnancy must be 
reported as soon as possible but no later than [ADDRESS_938250]‚Äôs assessment must be provided as a follow-up on the Ocular Exposure Report Form.  The 
contact [CONTACT_691801].   
Ocular exposure to study medication must be captured on the appropriate eCRF.  If the 
ocular exposure is associated with an AE, th e AE must be captured on the Ocular Exposure 
Report Form and the Adverse Event eCRF.  If the ocular exposure  is associated with an SAE, 
an SAE Report Form should be completed and sent along with Ocular Exposure Report 
Form. 
8.2.4 Skin Cancer 
During the Treatment and Response Assessmen t Periods (Days 1 to 57), all skin cancers 
(including BCC, SCC, and melanoma) will be reported as events of special interest.  The 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 52 of 71 
 
 location and treatment will be reported.  During the Recurrence Follow-up Period, skin 
cancers (including BCC, SCC, and melanoma) within the treatment area will be reported as events of special interest.  The treatment  of the skin cancer will be reported. 
The Skin Cancer Report Form must be used for reporting.  The skin cancer must be reported 
by [CONTACT_691802] [ADDRESS_938251]‚Äôs treatment  allocation for this study.  The Investigator 
may request to unblind the treatment assignment of any subject when this is needed for proper medical management of a medical emerge ncy or SAE.  Agreement of the Sponsor‚Äôs 
Medical Monitor or designee should be sought  prior to unblinding.  Instructions for 
requesting unblinding of a subject will be provided in the Pharmacy Manual. 
The Pharmacovigilance departme nt may unblind individual cases when required for safety 
reporting.  The treatment assignment will be included on the MedWatch or CIOMS form for suspected unexpected serious adverse reac tion (S[LOCATION_003]R) reports provided to health 
authorities.
 
[ADDRESS_938252] resolved, returned to baseline, or 
been deemed stabilized by [CONTACT_32366], the data collected before the Recurrence Follow-up Period will be locked and the randomization c ode will be released to the Sponsor only.  
The endpoint analyses, except for the recurrence  rate and AEs in the treatment area after 
Day 57, will be performed. 
For the second step, after the entire study has been completed, the data collected during the 
Recurrence Follow-up Period will be locked and th e randomization code wi ll be released to 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 53 of 71 
 
 the study sites as well.  Then, the recurrence rate and AEs in the treatment area after Day 57 
will be analyzed. 
Statistical analyses will be performed using SAS software or other validated statistical 
software as required.  The statisti cal analyses of the study data are described in this section.  
Further details of the statistical analyses will be included in a separate statistical analysis plan (SAP), which will be written and signed off prior to unblinding of Day [ADDRESS_938253] dose of study treatment. 
9.1.1 Study Endpoints 
[IP_ADDRESS] Efficacy 
[IP_ADDRESS].1 P RIMARY ENDPOINT  
Complete (100%) clearance rate of AK lesi ons, defined as the proportion of subjects at 
Day 57 with no clinically visible AK lesions in the treatment area. 
[IP_ADDRESS].2 S ECONDARY ENDPOINTS  
Key Secondary Endpoint: 
x Partial clearance rate of AK lesions, define d as the proportion of subjects at Day 57 
ZLWKD¬ïUHGXFWLRQLQWKHQXPEHURI$.OHVLRQVLGHQWLILHGDW Baseline (Day 1 
predose) in the treatment area 
Additional Endpoint: 
x Recurrence rate of AK lesions in subjects who achieved complete clearance at Day 57 
[IP_ADDRESS] Safety 
x Evaluation of LSRs, pi[INVESTIGATOR_691770], AEs, SAEs, 
events of special interest, clinical laboratory data, and other safety assessments (vital signs, PEs, ECGs) 
x AEs within the treatment area after Da y [ADDRESS_938254]-Day 57 
9.1.2 Definitions of Analysis Sets 
Intent-To-Treat (ITT) Population:   all randomized subjects.  This is the primary efficacy 
population. 
Per-Protocol (PP)/Evaluable Population:   all randomized subjects who have received at 
least [ADDRESS_938255] efficacy, and returned for the final visit on Day 57. 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 54 of 71 
 
 Safety Population :  all randomized subjects who have received at least one dose of study 
treatment. 
Recurrence Follow-up Population: all subjects who achieved complete clearance at 
Day 57, regardless of which treatment they received. 
9.1.[ADDRESS_938256] deviation (SD), median, and minimum and maximum values.  For categorical (nominal or ordinal) variables, the number and percentage of subjects will be summarized for each category. 
9.1.[ADDRESS_938257] ed in the eCRF will be coded using the WHO 
Drug Dictionary. 
Prior medications will be defined as medications/therapi[INVESTIGATOR_32546] 28 days before Day 1. 
Concomitant medications/therapi[INVESTIGATOR_691771]/therapi[INVESTIGATOR_3508] (1) started before the first dose of study drug and were continuing at the time of the first dose of study drug or (2) started on or after the date of the first dose of study drug. 
Prior and concomitant medications will be further coded to the appropriate Anatomical-
Therapeutic-Chemical (ATC) code indicating therapeutic classification.  A summary of concomitant medications by [CONTACT_691803].   
All prior and concomitant medications/therapi[INVESTIGATOR_691772]. 
9.1.6 Efficacy Analyses 
[IP_ADDRESS] Primary Efficacy Endpoint Analysis 
To achieve statistical significance in the study, the Day 57 complete clearance rate will be 
analyzed using a Cochran-Mantel-Haenszel (CMH) model controlling for treatment location and treatment group.  Before applying th e CMH method, a Breslow-Day test with a 
significance level of 10% will be used to ex plore heterogeneity of the odds ratios across 
treatment location subgroups. 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 55 of 71 
 
 Further, the Pearson Chi Square (used to power the study) will be applied to demonstrate 
basic agreement with the CMH. 
The primary efficacy analysis will be performed with the ITT population, and will be 
repeated with the PP/Evaluable population to s upport the primary efficacy analysis results. 
Low enrollment sites will be pooled to analysis s ites with approximately 20 subjects in each 
pool. For example, the number of  subjects enrolled will be graphically displayed by [CONTACT_691804] (face or scalp) from the smallest number to the largest, with bars depi[INVESTIGATOR_691773]. Then, analysis sites will be defined for approximately every [ADDRESS_938258] at a 
significance level of 10% will be applied. A finding of statistical significance in this test will be followed by [CONTACT_691785]. 
The outlier sites will be discussed and an exploratory analysis excluding the outlier sites may 
be carried out to estimate the impact of site-by-treatment interactions. This process will be documented as an appendix to the final version of the SAP, prior to the first database lock. 
[IP_ADDRESS] Secondary Efficacy Endpoint Analyses 
Partial clearance rate will be analyzed in th e same way as the primary efficacy endpoint 
(complete clearance rate).  However, to control for multiplicity, partial clearance rate as the key secondary efficacy endpoint will be exa mined using a step-down gatekeepi[INVESTIGATOR_691774] I error rate. In other words, the primary endpoint will serve as a gatekeeper for the key secondary endpoint. Th e complete clearance rate will be tested 
initially; if, and only if it is statistically sign ificant at the 0.[ADDRESS_938259]-
Day 57 visit.  Subjects with missing AK assessments in the Recurrence Follow-up Period will be considered as censored. 
[IP_ADDRESS] Additional AK Lesion Count Analysis 
The number of AK lesions and the change from baseline in lesion count at each visit will be 
summarized using descriptive statistics (ie, mean, SD, median, minimum and maximum) by [CONTACT_662193] (face or scalp) a nd treatment group for the ITT population. 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 56 of 71 
 
 [IP_ADDRESS] Missing Data Handling and Sensitivity Analysis 
For the primary and the key secondary efficacy endpoint analyses, all missing data caused by 
[CONTACT_691805] a last observation carried forward (LOCF) method.  
In addition, the following approaches will be us ed as sensitivity analyses for the primary and 
key secondary efficacy endpoints: 
1. Observed Cases (OC): Those subjects with missing AK lesion counts at Day 57 visit will 
be excluded from the analysis populations (ITT and PP/Evaluable) and then the primary and 
key secondary endpoint analyses described above  will be repeated to show concordance. 
2. Subjects without Day 57 AK lesion counts due to  early termination or other reasons will 
be considered as non-responders for comp lete/partial clearance rate analysis  
3. Multiple Imputation (MI): A multiple imput ation method may be applied to impute 
missing values (only for the primary an d key secondary efficacy variables). 
[IP_ADDRESS] Subgroup Analysis 
To indicate concordance with the overall results , the primary and the key secondary efficacy 
endpoints will be tabulated and di splayed graphically in subgroups such as treatment location 
IDFHRUVFDOSJHQGHUDJHRU¬ï\HDUVEDVHOLQH$.OH VLRQFRXQWRU and 
skin type (Fitzpatrick I/II or III/IV/V/VI).  Outliers will be clinically explained in the clinical study report. 
9.1.7 Safety Analyses 
All subjects in the Safety Analysis Set will be included in the safety analyses. 
Safety data will be summarized  by [CONTACT_2070] (eg, n, mean, 
SD, median, minimum, maximum fo r continuous variables; n [%] for categorical variables).  
Safety variables include evaluation of LSRs, pi [INVESTIGATOR_691775], 
AEs, SAEs, events of special interest, clinical  laboratory data, and ot her safety assessments 
(vital signs, PEs, ECGs). 
Safety data collected through Day 57 and during the Recurrence Follow-up Period will be 
analyzed separately. 
[IP_ADDRESS] Extent of Exposure 
The actual number of doses for each subject will be summarized by [CONTACT_1570]. 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 57 of 71 
 
 [IP_ADDRESS] Adverse Events 
For AEs, verbatim terms on the eCRF will be mapped to preferred terms (PTs) and system 
organ classes (SOCs) using the Medical Dictionary for Regulatory Activities (MedDRA) (version 16.0 or higher). 
All AEs, treatment-emergent or otherwise, will be presented in subject data listings.  Only 
those AEs that are treatment-emergent will be included in summary tables.   
Treatment-emergent AEs are defined as: 
x either those AEs with an onset after the first dose or  
x those pre-existing AEs that worsen after the first dose. 
TEAEs will be summarized by [CONTACT_1570].  The incidence of TEAEs  will be reported as 
the number (percentage) of subjects with TE AEs by [CONTACT_12130] a nd PT and treatment 
group.  A subject will be counted only once within an SOC and PT, even if the subject experienced more than 1 TEAE within a specific SOC and PT.  The number (percentage) of subjects with TEAEs will also be summarized by [CONTACT_764] (by [CONTACT_691806], moderate or severe rating) a nd by [CONTACT_691807].  Treatment-related TEAEs 
include those events considered by [CONTACT_691808] (definitely, probably, or 
possibly related) to study treatment. 
By-subject listings of all SAEs and events of special interest will be provided.  If any deaths 
occur in the study, a by-subject listing of all AEs leading to death will be provided. 
A subject data listing of all AEs leading to discontinuation from the study will be provided. For subjects who have treatment-related AEs at Day 57, all safety endpoints observed during 
any additional follow-up assessments will be listed. 
During the Recurrence Follow-up Period, TEAEs in the treatment area will be summarized 
separately. 
[IP_ADDRESS] Laboratory Values 
Laboratory parameters will be summarized using descriptive statistics at baseline and at each subsequent timepoint by [CONTACT_12922].  Changes from baseline will also be summarized 
by [CONTACT_1570].   
In addition, shift tables (ie, lo w-normal-high at baseline versus  low-normal-high at follow-up 
in a 3-by-3 contingency table) will be provided to assess changes in laboratory values from baseline to Day [ADDRESS_938260]. 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 58 of 71 
 
 [IP_ADDRESS] Pregnancy Tests 
Results of pregnancy tests will be listed for all subjects, as applicable. 
[IP_ADDRESS] Vital Signs 
Vital sign values will be listed by [CONTACT_1130]. 
[IP_ADDRESS] Electrocardiograms 
All ECG data will be listed for each subject.  A by-subject listing of clinically significant 
ECG abnormality data  will be provided. 
[IP_ADDRESS] Physical Examinations 
Physical examination findings will be listed for each subject. 
[IP_ADDRESS] Local Skin Reactions and Pi[INVESTIGATOR_691776], hyper- or hypo-pi[INVESTIGATOR_691777] [ADDRESS_938261] listings. 
9.1.8 Determination of Sample Size 
The sample size was estimated based on the primary efficacy endpoint for the comparison of 
KX2-391 Ointment 1% and vehicle control.  By [CONTACT_2329] a Pearson Chi-square method, a 
sample size of 100 scalp-treated subjects a nd 200 face-treated subjects, both of which are 
with a 1:1 treatment allocation ratio, will give a greater than 90% power to detect a 20% difference (30% for active treatment and 10% for vehicle control) with a two-tailed significant level 0.05. 
9.1.9 Interim Analysis 
No interim analysis is planned for this study. 
9.1.10 Other Statistical/Analytical Issues 
Not applicable 
Clinical Study Protocol_Amendment [ADDRESS_938262] accordance with the protocol (refer to 
ICH E67, Section 4.5). 
10.1 Access to Source Data / Documents 
The Sponsor‚Äôs CRA will maintain contact [CONTACT_691809], letter, or ema il between study visits.  Monitoring visits to each site will be 
conducted by [CONTACT_691810].  The Investigator will 
allow the CRA to inspect the clinical, laboratory, and pharmacy facilities to assure compliance with GCP and local regulatory requirements.  The eCRFs and subject‚Äôs corresponding original medical records (source documents) are to be fully available for 
review by [CONTACT_1034]‚Äôs represen tatives at regular intervals.  These reviews verify adherence 
to study protocol and data accuracy in accordance with local regulations.  All records at the site are subject to inspection by [CONTACT_691811] (IRB) review. 
In accordance with ICH E6, Section 1.52, sour ce documents include, but are not limited to 
the following: 
x Clinic, office, or hospi[INVESTIGATOR_1332] 
x Copi[INVESTIGATOR_691778] 
x Recorded data from automated instruments such as x-rays, and other imaging reports, 
(eg, sonograms, CT scans, magnetic res onance images, radioactive images, ECGs, 
rhythm strips, EEGs, polysomnographs, pulm onary function tests) regardless of how 
these images are stored, including microfiche and photographic negatives 
x Medical history or other questi onnaires completed by [CONTACT_1766] 
x Records of telephone contacts 
x Diaries or evaluation checklists 
x Drug distribution and accountability logs main tained in pharmacies or by [CONTACT_3244] 
x Laboratory results and other laboratory test  outputs (eg, urine pregnancy test result 
documentation and urine dip-sticks) 
x Correspondence regarding a study subject‚Äôs tr eatment between physicians or memoranda 
sent to the IRB 
In addition to the routine monitoring proce dures, qualified personnel designated by [CONTACT_691812]‚Äôs 
standard operating procedures (SOPs) to eval uate compliance with the principles of ICH 
GCP and all applicable local regulations.  If a government regulatory authority requests an 
Clinical Study Protocol_Amendment [ADDRESS_938263] inform the Sponsor 
immediately. 
10.2 Quality Control and Quality Assurance 
This study will be organized, performed, and reported in compliance with the protocol, SOPs, working practice documents, and applicable  regulations and guidelines.  Site audits 
will be made periodically by [CONTACT_1034]‚Äôs or  the CRO‚Äôs qualified compliance auditing team, 
which is an independent function from the study team responsible for conduct of the study. 
10.2.1 Data Collection 
Data required by [CONTACT_691813] a validated electronic data capture (EDC) system. 
Responsible site pers onnel will enter the information re quired by [CONTACT_691814].  A CRA will 
visit each site as documented in the monitoring plan to verify the data on eCRFs for completeness and accuracy against the source documents.  
The Investigator has ultimate re sponsibility for the collection a nd reporting of all clinical, 
safety, and laboratory da ta entered on the eCRF. 
Data that are provided by [CONTACT_691815]. 
All data derived from the study will be the property of the S ponsor and should not be made 
available in any form to third parties wit hout written permission from the Sponsor, except for 
authorized representatives of the Sponsor or appropriate regulatory authorities. 
10.2.2 Clinical Data Management 
There will be a Data Management Plan to detail all relevant data management activities, from 
eCRF design to database lock. 
Quality control for all relevant data management activities and data validation procedures 
will be applied to ensure the validit y and accuracy of the clinical data. 
10.3 ETHICS 
This study will be conducted in accordance with  SOPs of the Sponsor (or designee), which 
are designed to ensure adherence to GCP guidelines as required by [CONTACT_716]: 
x Principles of the World Medical Associ ation Declaration of Helsinki (2013) 
x ICH E6 GCP guidelines  
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 62 of 71 
 
 x Title 21 of the US Code of Federal Regulations (US 21 CFR) regarding clinical studies, 
including Part [ADDRESS_938264] consent and IRB regulations 
and applicable sections of US 21 CFR Part 312 
10.3.1 Institutional Review Boards 
The protocol, any protocol amendments, and ICF will be reviewed and approved by [CONTACT_364400] E6 (GCP), Section 3, and any local regulations.  Any protocol amendment and/or revision to the ICF will receive appropriate 
approval prior to impleme ntation.  Verification of unconditiona l approval of the protocol will 
be transmitted to the Sponsor prior to the ship ment of drug supplies to the investigational 
site.  The Investigators or the Sponsor will submit, depending on local regulations, periodic 
reports and inform the IRB of any reportable AEs per ICH guidelines and local IRB standards of practice. 
A signed letter of study approval from the IRB chairman must be sent to the Principal 
Investigator [CONTACT_4490] a copy to the Sponsor before study start and the release of any study drug to 
the site by [CONTACT_4885] (ICH E 6, Section 4.4).  If the IRB decides to suspend 
or terminate the study, the Investigator will immediately send the notice of study suspension or termination by [CONTACT_345724]. 
Study progress is to be reporte d to IRB annually (or as required) by [CONTACT_425826], depending on local regulatory obligations .  If the Investigator is required to report 
to the IRB, he/she will forward a copy to the Sponsor at the time of each periodic report.  The Investigator(s) or the Sponsor will submit, de pending on local regulations, periodic reports 
and inform the IRB of any reportable AEs per ICH guidelines and local IRB standards of practice.  Upon completion of the study, the I nvestigator will provide the IRB with a brief 
report of the outcome of the study, if required. 
At the end of the study, the Sponsor should notify the IRB within 90 days. In the case of early termination/temporary halt of  the study, the Investigator should notify the 
IRB within 15 calendar days, and a detailed written explanation of the reasons for the termination/halt should be given. 
10.3.[ADDRESS_938265] Information and Informed Consent 
As part of administering the informed consent document, the Investigator (or designee) must 
explain to each subject the nature of the st udy, its purpose, the procedures involved, the 
expected duration, the potential risks and be nefits involved, any potential discomfort, 
potential alternative procedure(s) or course(s) of treatment avai lable to the subject, and the 
extent of maintaining confidentiality of the subject‚Äôs records.  Each subject must be informed that participation in the study is voluntary, that he/she may withdraw from the study at any time, and that withdrawal of consent will not af fect his/her subsequent medical treatment or 
relationship with the treating physician. 
Clinical Study Protocol_Amendment [ADDRESS_938266] can 
enter the study before his/her info rmed consent has been obtained. 
An approved ICF must be prepared in ac cordance with ICH E6, and all applicable 
regulations.  Each subject must sign an approv ed ICF before study participation.  The form 
must be signed and dated by [CONTACT_36585].  The original, signed ICF for each subject will be verified by [CONTACT_691816]. 
The subject should be informed in a timely manner if new information becomes available 
that may be relevant to the subject‚Äôs willingness to continue participation in the study.  The communication of this information should be documented. 
10.[ADDRESS_938267] the corresponding source documents.  
10.4.3 Retention of Records 
The circumstances of completion or termin ation of the study notwithstanding, the 
Investigator is responsible fo r retaining all study documents, including but not limited to the 
protocol, copi[INVESTIGATOR_1495], the Investigator's  Brochure, and regulatory agency registration 
documents, ICFs, and IRB correspondence.  In  addition, the Sponsor will send a list of 
treatment codes by [CONTACT_691817].  The sites should plan to retain  study documents, as directed by [CONTACT_1034], 
for at least [ADDRESS_938268] of preserving the 
safety of all subjects included in the study.  If an immediate change to the protocol is felt by [CONTACT_501561], the Sponsor‚Äôs Medical Monitor and the 
IRB for the site(s) must be notified immediatel y.  The Sponsor must notify the health or 
regulatory authority as required per local re gulations.  A protocol  change intended to 
eliminate an immediate hazard may be implemented immediately, provided the health or regulatory authority and IRBs are immediately notified and appropriate documentation of the urgent protocol change are submitted per local regulations. 
Protocol amendments that affect only administrative aspects of the study may not require 
submission to health or regulatory authority or the IRB, but the health or regulatory authority and IRB  should be kept informed of such change s as required by [CONTACT_427].   
10.6.2 Disclosure and Confidentiality 
The contents of this protocol and any ame ndments and results obtained during the study 
should be kept confidential by [CONTACT_737], the Investigator‚Äôs staff, and the IRB, and will 
not be disclosed in whole or in part to others, or used for an y purpose other than reviewing or 
performing the study, without the written consent of the Sponsor.  No data collected as part 
of this study will be used in any written wo rk, including publications, without the written 
consent of the Sponsor.  These obligations of confidentiality and non-use shall in no way 
diminish such obligations as set forth in either the Confidentiality Agreement or Clinical Trial Agreement executed between the Spons or/CRO and the institution/Investigator. 
All persons assisting in the performance of th is study must be bound by [CONTACT_3603]-use set forth in either the Confidentiality Agreement or Clinical Trial Agreement executed between the instituti on/Investigator and the Sponsor/CRO. 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 65 of 71 
 
 10.6.3 Discontinuation of Study 
The Sponsor reserves the right to discontinue  the study for medical reasons or any other 
reason at any time.  If a study is prematurel y terminated or suspended, the Sponsor will 
promptly inform the Investigators/institutions and regulatory authorities of the termination or suspension and the reason(s) for the termina tion or suspension.  The IRB will also be 
informed promptly and provided the reason(s)  for the termination or suspension by [CONTACT_691818]/institution, as  specified by [CONTACT_3605](s). 
The Investigator reserves the right to disc ontinue the study should his/her judgment so 
dictate.  If the Investigator terminates or suspends a study without prior agreement of the 
Sponsor, the Investigator should inform the institution where applicable, and the Investigator/institution should promptly inform  the Sponsor and the IRB and provide them 
with a detailed written ex planation of the termination or su spension.  Study records must be 
retained as noted above. 
Clinical Study Protocol_Amendment [ADDRESS_938269] 
1. Marks R, Rennie G, Selwood TS.  Malignant  transformation of solar keratoses to 
squamous cell carcinoma.  Lancet 1988;1(8589):795-7. 
2. Criscione VD, Weinstock MA, Naylor MF, et  al. Actinic keratoses: natural history 
and risk of malignant tran sformation in the Veterans Affairs Topi[INVESTIGATOR_691779]. Cancer 2009;115(11):2523-30. 
3. Glogau RG. The risk of progression to i nvasive disease. J Am Acad Dermatol 
2000;42(1 Pt 2):23-4. 
4. Salasche SJ. Epi[INVESTIGATOR_691780]. J Am 
Acad Dermatol 2000;42(1 Pt 2):4-7. 
5. Guidelines for the Management of Ac tinic Keratoses.  2004/2005 European 
Dermatology Forum.  Available from: h ttp://www.euroderm.org  [Accessed 02 July 
2012]. 
6. Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for actinic keratoses. 
Committee on Guidelines of Care. J Am  Acad Dermatol 1995;32(1):95-8. 
7. ICH E6: Guidance for Industry - E6 Good Clinical Practice: Consolidated Guidance, 
US Department of Health and Human Serv ices, Food and Drug Administration, April 
1996. 
8. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through IV. 
Arch Dermatol 1998;124(6):869-71. 
9. Draft Guidance on ingenol mebutate, January 2016.  
http://www.fda.gov/downloads/Drugs/Guida nceComplianceRegulatoryInformation/G
uidances/UCM481827.pdf 
 
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 67 of 71 
 
 12 APPENDICES 
  
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 68 of 71 
 
 APPENDIX 1 INSTRUCTIONS FOR SUBJECTS‚Äô SELF-
ADMINISTRATION OF STUDY TREATMENT  
The study kit contains: 
x 5 packets filled with study drug, inside individual plastic bags  
x A dosing log 
Storage: 
Store the study kit at room temperature and in a secure place, out of direct sunlight, and away 
from food products, children, and pets. 
Patient Instructions: 
Application of study drug is preferably done ea rly in the day and at approximately the same 
time every day for a total of [ADDRESS_938270] dose will be self-administered in the clinic. 
Follow these steps to apply study drug: 
x Take the dosing log in the study kit and record the date and time of dosing. 
x Open the plastic bag and remove a single-dose packet. 
x Tear the packet open along the perforations. 
x Squeeze a small amount of ointment from th e packet on your fingertip and apply it 
evenly over the entire treatment area (Note:  Each packet contains more than the 
amount needed for 1 treatment application.). 
x Place the used packet (including torn pi[INVESTIGATOR_6928]) into the plastic bag in which it came, 
seal the plastic bag, and put it back into the study kit. 
x Wash hands immediately  with water and soap. 
x Place the dosing log back into the study kit and store away the study kit, as instructed 
above, in a secure place. 
x Repeat the above steps for each day of trea tment at about the same time each day. 
x On Day 5, apply treatment before  returning to clinic.  Bring the study kit (containing 
all used and unused packets) and the dosing log with you. 
  
Clinical Study Protocol_Amendment 01 KX01-AK-004 
 
  
Athenex, Inc. 
FINAL v2.0_18 Feb 2018 Confidential Page 69 of 71 
 
 Precautions on Treatment Days (Days 1-5): 
x Subjects who wear contact [CONTACT_691819] d put on their contact [CONTACT_691820]. 
x Avoid touching or wetting the treatment area for approximately [ADDRESS_938271] on the other person or pet should be washed immediately. 
x Do not cover the treatment area with bandages, band aids, tight-fitting scarfs, or caps. 
Precautions Throughout the Study: 
x When washing the treatment area, wash it gently with a mild, non-abrasive, non-
medicated soap or shampoo. 
x Do not expose the treatment area to excessi ve sun light or ultraviolet light, including 
tanning beds.  When outdoors, wear protectiv e loose clothing over the treatment area.  
x Do not use moisturizers, sunscreen, artif icial tanners, make- up or other over the 
counter-topi[INVESTIGATOR_691781] 57.  If you are unsure of 
what to use, ask your study doctor.  After 15 days, if you are unable to avoid excessive sun light or ultraviolet light to the treatment area, the study doctor may allow you to use sunblock.  
x Do not use medications not a pproved by [CONTACT_6814]. 
x After Day 57, sunblock and non-medicated topi[INVESTIGATOR_691782]. 
 
&OLQLFDO6WXG\3URWRFROB$PHQGPHQW .;$.


$WKHQH[,QF
),1$/YB)HE&RQILGHQWLDO 3DJHRI

,19(67,*$7256,* 1$785(3$*(
6WXG\3URWRFRO1XPEHU .;$.
6WXG\3URWRFRO7LWOH $3KDVH'RXEOH%OLQG9HKLFOH&RQWUROOHG5DQGRPL]HG3DUDOO HO
*URXS0XOWLFHQWHU(IILFDF\DQG6DIHW\6WXG\RI.;2LQWPH QW
LQ$GXOW6XEMHFWVZLWK$FWLQLF.HUDWRVLVRQWKH)DFHRU6FDO S
,QYHVWLJDWLRQDO3URGXFW
1DPH.;2LQWPHQW
,1'1XPEHU 
8711XPEHU 8 

,KDYHUHDGWKLVSURWRFRODQGDJUHHWRFRQGXFWWKLVVWXG\LQDF FRUGDQFHZLWKDOOVWLSXODWLRQVRI
WKHSURWRFRODQGLQDFFRUGDQFH ZLWK,QWHUQDWLRQDO&RXQFLOIRU+ DUPRQLVDWLRQRI7HFKQLFDO
5HTXLUHPHQWVIRU5HJLVWUDWLRQRI3KDUPDFHXWLFDOVIRU+XPDQ8VH ,&+DQGDOODSSOLFDEOH
ORFDO*RRG&OLQLFDO3UDFW LFH*&3JXLGHOLQHVLQFOXGLQJWKH'H FODUDWLRQRI+HOVLQNL

1DPHRILQVWLWXWLRQ!
0HGLFDO,QVWLWXWLRQ

1DPHGHJUHHV!    
,QYHVWLJDWRU  6LJQDWXUH  'DWH

&OLQLFDO6WXG\3URWRFRO .;$.
$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI7,7/(3$*(

&OLQLFDO6WXG\3URWRFRO
6WXG\3URWRFRO
1XPEHU.;$.
6WXG\3URWRFRO
7LWOH$3KDVH'RXEOH%OLQG9HKLFOH &RQWUROOHG5DQGRPL]HG3DUDOO HO
*URXS0XOWLFHQWHU(IILFDF\DQG6DIHW\6WXG\RI.;2LQWPH QW
LQ$GXOW6XEMHFWVZLWK$FWLQLF .HUDWRVLVRQWKH)DFHRU6FDO S
6SRQVRU $WKHQH[,QF
&RPPHUFH'ULYH&UDQIRUG1-86$7HO
,QYHVWLJDWLRQDO
3URGXFW1DPH.;2LQWPHQW
,QGLFDWLRQ $FWLQLFNHUDWRVLVRQIDFHRUVFDOS
3KDVH 
$SSURYDO'DWH  Y -XQRULJLQDOSURWRFRO
,1'1XPEHU 
8711XPEHU 8 
*&36WDWHPHQW 7KLVVWXG\LVWREHSHUIRUPHGLQIXOOFRPSOLDQFHZLWK,QWHUQDWL RQDO
&RXQFLO IRU +DUPRQLVDWLRQ RI 7 HFKQLFDO 5HTXLUHPHQWV IRU
5HJLVWUDWLRQ RI 3KDUPDFHXWLFDOV IRU +XPDQ 8VH ,&+ DQG DOO
DSSOLFDEOHORFDO*RRG&OLQLFDO3 UDFWLFH*&3DQGUHJXODWLRQV $OO
UHTXLUHG VWXG\ GRFXPHQWDWLRQ ZLOO EH DUFKLYHG DV UHTXLUHG E\UHJXODWRU\DXWKRULWLHV
&RQILGHQWLDOLW\
6WDWHPHQW7KLVGRFXPHQWLVFRQILGHQWLDO ,WFRQWDLQVSURSULHWDU\LQIRUPD WLRQRI
$WKHQH[,QFWKH6SRQVRU$Q\ YLHZLQJRUGLVFORVXUHRIVXFK 
LQIRUPDWLRQWKDWLVQRWDXWKRUL]HGLQZULWLQJE\WKH6SRQVRULV VWULFWO\
SURKLELWHG6XFKLQIRUPDWLRQPD \EHXVHGVROHO\IRUWKHSXUSRV HRI
UHYLHZLQJRUSHUIRUPLQJWKLVVWXG\

&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
&/,1,&$/[ZIP_CODE]&2/6<1236,6
&RPSRXQG1R .; 
1DPHRI$FWLYH,QJUHGLHQW 1EHQ]\OPRUSKROLQRHWKR[\SKHQ\OS\ULGLQ\ODFHWDP LGH
6WXG\3URWRFRO7LWOH
$3KDVH'RXEOH%OLQG9HKLFOH&RQWUROOHG5DQGRPL]HG3DUDOO HO*URXS0XOWLFHQWHU(IILFDF\
DQG6DIHW\6WXG\RI.;2LQWPHQWLQ$GXOW6XEMHFWVZLWK $FWLQLF.HUDWRVLVRQWKH)DFHRU
6FDOS
6LWHV
$SSUR[LPDWHO\WRVLWHVLQWKH8QLWHG6WDWHV 
6WXG\3HULRGDQG3KDVHRI'HYHORSPHQW
)LUVWVXEMHFWLQWRODVWVXEMHFWRXWDSSUR[LPDWHO\PRQWKV
3KDVH
6WXG\+\SRWKHVLV
7UHDWPHQWZLWK.;2LQWPHQWWRSLFDORQFHGDLO\IRUFRQ VHFXWLYHGD\VZLOOGHPRQVWUDWHD
JUHDWHUFRPSOHWHFOHDUDQFHGHILQHGDVFOHDUDQFHRIFOLQLF DOO\W\SLFDODQGYLVLEOHDFWLQLF
NHUDWRVLV>$.@OHVLRQVDW'D\WKDQYHKLFOHRLQWPHQWRQFHGD LO\IRUFRQVHFXWLYHGD\VLQDGXOWV
ZLWK$.RQWKHIDFHRUVFDOS
2EMHFWLYHV
3ULPDU\2EMHFWLYH
x7RHYDOXDWHWKHHIILFDF\RIWRSLFDO.;2LQWPHQWRQFHGD LO\IRUFRQVHFXWLYHGD\V
FRPSDUHGWRYHKLFOHFRQWUROLQWHUPVRIFOHDUDQFHDW'D\ LQWKHWUHDWPHQWRIDGXOWV
ZLWK$.ZKHQDSSOLHGWRDFRQWLJXRXVDUHDRIFPRQWKHIDFHRUVFDOS
6HFRQGDU\2EMHFWLYHV
x7RHYDOXDWHWKHVDIHW\RIWRSLFDO.;2LQWPHQWRQFHGDLO \IRUFRQVHFXWLYHGD\VLQ
WHUPVRIORFDOVNLQUHDFWLRQV/65VDQGRWKHUVDIHW\HYDOXDWLR QVVXFKDVDGYHUVHHYHQWV
$(VDQGODERUDWRU\DVVHVVPHQWV
x7RFRPSDUHWKHUDWHVRISDUWLDOUHVSRQGHUVGHILQHGDV¬ïFOHD UDQFHRI$.OHVLRQVLQWKH
WUHDWPHQWDUHDRQWKHIDFHRUVFDOSDW'D\EHWZHHQWKH.; 2LQWPHQWWUHDWHG
JURXSDQGYHKLFOHWUHDWHGJURXS
x7RHYDOXDWHWKHUHGXFWLRQLQ$.OHVLRQVFRXQWVIURP'D\WKURX JK'D\
x7RGHWHUPLQHWKHUHFXUUHQFHRI$.LQWKHWUHDWPHQWDUHDXSWR PRQWKVSRVW'D\LQ
VXEMHFWVZKRKDGFRPSOHWHFOHDUDQFHDW'D\DIWHUFRQVHFXWL YHGD\VRIWUHDWPHQWZLWK
.;2LQWPHQW 
x7RHYDOXDWHWKHVDIHW\RIWRSLFDO.;2LQWPHQWZLWKLQWK HWUHDWPHQWDUHDGXULQJWKH
5HFXUUHQFH)ROORZXS3HULRG 
6WXG\'HVLJQ
7KLVLVDGRXEOHEOLQGYHKLFOHFRQWUROOHGUDQGRPL]HGSDUDOOH OJURXSPXOWLFHQWHUVWXG\WRHYDOXDWH
WKHHIILFDF\DQGVDIHW\RI.;2LQWPHQWDGPLQLVWHUHGWRS LFDOO\RQWKHIDFHRUVFDOSRIDGXOW
VXEMHFWVZLWK$.
(QUROOPHQWZLOOEHFRQWUROOHGVRWKDWDSSUR[LPDWHO\WZRWKLUGV RIVXEMHFWVHQUROOHGZLOOEHWUHDWHGRQ
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
WKHIDFHDQGDSSUR[LPDWHO\RQHWKLUGRIVXEMHFWVHQUROOHGZLOO EHWUHDWHGRQWKHVFDOS
7KHVWXG\FRQVLVWVRI6FUHHQLQJ7UHDWPHQW5HVSRQVH$VVHVVPHQW 3HULRGDQGD5HFXUUHQFH)ROORZ
XS3HULRG$IWHUD6FUHHQLQJ3HULRGRIXSWRGD\VVXEMHFWV ZLOOUHWXUQWRWKHVLWHIRUFRQILUPDWLRQ
RIHOLJLELOLW\(OLJLEOHVXEMHFWVZLOOEHUDQGRPL]HGRQ'D\ WRWUHDWPHQWLQD.;
2LQWPHQWRUYHKLFOHUDWLRLQHDFKWUHDWPHQWDUHDVXEJURXS
7KH WUHDWPHQW DUHD ZLOOEH PDUNHG ZLWK LQGHOLEOH PDUNHU DW %DVH OLQH 'D\  SUHGRVH DW WKH
LQYHVWLJDWLRQDOVLWH6XEMHFWVZLOOEHJLYHQYHUEDODQGZULWWH QLQVWUXFWLRQVRQVHOIDGPLQLVWUDWLRQRI
VWXG\GUXJYHKLFOHDQGDVWXG\NLWFRQWDLQLQJGDLO\VLQJOHGR VHSDFNHWVIRUHDFKGD\RIWUHDWPHQW 
7KHILUVWGRVHZLOOEHDSSOLHGE\WKHVXEMHFWXQGHUWKHVXSHUYL VLRQRIVWXG\VLWHSHUVRQQHO6XEMHFWV
ZLOOWKHQWDNHKRPHWKHVWXG\NLWFRQWDLQLQJWKHUHPDLQLQJVLQJ OHGRVHSDFNHWVRIVWXG\GUXJIRUGDLO\
VHOIDGPLQLVWUDWLRQRQWKHQH[WFRQVHFXWLYHGD\V
6XEMHFWVZLOOUHWXUQWRWKHFOLQLFDOVLWHVIRUDVVHVVPHQWVDWW KH5HVSRQVH$VVHVVPHQW9LVLWVRQ'D\V
DQG
$OOVXEMHFWVZKRKDYHXQUHVROYHG/65VK\SRRUK\SHUSLJPHQWD WLRQVFDUULQJLQWKHWUHDWPHQWDUHD
RUWUHDWPHQWUHODWHG$(VDW'D\ZLOOUHWXUQIRUDGGLWLRQDOI ROORZXSHYHU\WRGD\VXQWLO
UHVROXWLRQUHWXUQHGWREDVHOLQHRUGHHPHGVWDELOL]HGE\WKH, QYHVWLJDWRUV
6XEMHFWVZKRDFKLHYHFOHDUDQFHRI$.OHVLRQVLQWKHWUHDWP HQWDUHDDW'D\ZLOOFRQWLQXHLQ
WKH5HFXUUHQFH)ROORZXS3HULRGWRGHWHUPLQHUHFXUUHQFHUDWHDQ GVDIHW\IRUXSWRPRQWKV
IROORZLQJ WKH 'D\9LVLW 9LVLWV GXULQJ WKH 5HFXUUHQFH )ROOR ZXS 3HULRG ZLOO RFFXU HYHU\
PRQWKV6XEMHFWVZKRGHYHORS$.OHVLRQVLQWKHWUHDWPHQWDUH DGXULQJWKH5HFXUUHQFH)ROORZXS
3HULRGZLOOEHGLVFRQWLQXHGDWWKHWLPHRIUHFXUUHQFH 
1XPEHURI6XEMHFWV
$VXIILFLHQWQXPEHURIVXEMHFWVZLOOEHVFUHHQHGWRUDQGRPL]HD SSUR[LPDWHO\VXEMHFWV$WHDFK
VLWHDPLQLPXPRIVXEMHFWVD QGDPD[LPXPRIVXEMHFWVDUH SURMHFWHGWREHHQUROOHG 
,QFOXVLRQ&ULWHULD
0DOHVDQGIHPDOHV¬ï\HDUVROG
$WUHDWPHQWDUHDRQWKHIDFHRUVFDOSWKDW
xLVDFRQWLJXRXVDUHDPHDVXULQJFP
xFRQWDLQVWRFOLQLFDOO\W\SLFDOYLVLEOHDQGGLVFUHWH$.OH VLRQV
6XEMHFWVZKRLQWKHMXGJPHQWRIWKH,QYHVWLJDWRUDUHLQJRRGJ HQHUDOKHDOWKEDVHGRQ
xPHGLFDOKLVWRU\
xSK\VLFDOH[DPLQDWLRQ3(ILQGLQJV
xYLWDOVLJQV
xHOHFWURFDUGLRJUDP(&*FOLQLFDOFKHPLVWU\KHPDWRORJ\DQGXU LQDO\VLVUHVXOWV  
)HPDOHVPXVWEHSRVWPHQRSDXVDO!\HDUVRIDJHZLWKDWOHDVW PRQWKVRIDPHQRU[LOCATION_006]HD
VXUJLFDOO\ VWHULOH E\ K\VWHUHFWRP\ ELODWHUDO RRSKRUHFWRP\ RU  WXEDO OLJDWLRQ RU LI RI
FKLOGEHDULQJSRWHQWLDOPXVWEHXVLQJKLJKO\HIIHFWLYHFRQWUDFH SWLRQIRUDWOHDVWGD\VRU
PHQVWUXDOF\FOHZKLFKHYHULVORQJHUSULRUWRVWXG\WUHDWPHQ WDQGPXVWDJUHHWRFRQWLQXHWRXVH
KLJKO\HIIHFWLYHFRQWUDFHSWLRQIRUDWOHDVWGD\VIROORZLQJW KHLUODVWGRVHRIVWXG\WUHDWPHQW 
+LJKO\HIIHFWLYHFRQWUDFHSWLRQLQFOXGHVRUDOKRUPRQDOFRQWUDFHS WLYHVKRUPRQDOFRQWUDFHSWLYH
LPSODQWLQMHFWLRQRUSDWFKLQWUDXWHULQHGHYLFHRUFRPSOHWHDE VWLQHQFHIURPVH[XDOLQWHUFRXUVH
6H[XDOO\DFWLYHPDOHVZKRKDYHQRWKDGDYDVHFWRP\DQGZKRVHS DUWQHULVUHSURGXFWLYHO\
FDSDEOHPXVWDJUHHWRXVHEDUULHUFRQWUDFHSWLRQIURP6FUHHQLQJ WKURXJKGD\VDIWHUWKHLUODVW
GRVHRIVWXG\WUHDWPHQW
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
$OOVXEMHFWVPXVWDJUHHQRWWRGRQDWHVSHUPRUHJJVRUDWWHPSW FRQFHSWLRQIURP6FUHHQLQJ
WKURXJKGD\VIROORZLQJWKHLUODVWGRVHRIVWXG\WUHDWPHQW
)HPDOHVRIFKLOGEHDULQJSRWHQWLDOPXVWKDYHDQHJDWLYHVHUXPSU HJQDQF\WHVWDW6FUHHQLQJDQGD
QHJDWLYHXULQHSUHJQDQF\WHVWRQ'D\SULRUWRUDQGRPL]DWLRQ
:LOOLQJWRDYRLGH[FHVVLYHVXQOLJKWRUXOWUDYLROHW89OLJKWH [SRVXUHLQFOXGLQJWKHXVHRI
WDQQLQJEHGVWRWKHIDFHRUVFDOS
$EOHWRFRPSUHKHQGDQGDUHZLOOLQJWRVLJQWKHLQIRUPHGFRQVHQW IRUP,&)
([FOXVLRQ&ULWHULD
&OLQLFDOO\DW\SLFDODQGRUUDSLGO\FKDQJLQJ$.OHVLRQVRQWKHW UHDWPHQWDUHDHJK\SHUWURSKLF
K\SHUNHUDWRWLFUHFDOFLWUDQWGLVHDVHKDGFU\RVXUJHU\RQWZRSU HYLRXVRFFDVLRQVDQGRUFXWDQHRXV
KRUQ
/RFDWLRQRIWKHWUHDWPHQWDUHDLV
x2QDQ\ORFDWLRQRWKHUWKDQWKHIDFHRUVFDOS
x:LWKLQFPRIDQLQFRPSOHWHO\KHDOHGZRXQG
x:LWKLQFPRIDVXVSHFWHGEDVDOFHOOFDUFLQRPD%&&RUVTXDPR XVFHOOFDUFLQRPD6&&
%HHQSUHYLRXVO\WUHDWHGZLWK.;2LQWPHQW
$QWLFLSDWHGQHHGIRULQSDWLHQWKRVSLWDOL]DWLRQRULQSDWLHQWV XUJHU\IURP'D\WR'D\
7UHDWPHQWZLWKIOXRURXUDFLO )8LPLTXLPRGLQJHQROPHEXWD WHGLFORIHQDFSKRWRG\QDPLF
WKHUDS\RURWKHUWUHDWPHQWVIRU$.ZLWKLQWKHWUHDWPHQWDUHDR U ZLWKLQFPRIWKHWUHDWPHQW
DUHDZLWKLQZHHNVSULRUWRWKH6FUHHQLQJYLVLW
8VHRIWKHIROORZLQJWKHUDSLHV DQGRUPHGLFDWLRQVZLWKLQZHHN VSULRUWRWKH6FUHHQLQJYLVLW
x&RVPHWLFRUWKHUDSHXWLFSURFHGXUHVHJXVHRIOLTXLGQLWURJHQ VXUJLFDOH[FLVLRQFXUHWWDJH
GHUPDEUDVLRQPHGLXPRUJUHDWHUGHSWKFKHPLFDOSHHOODVHUUHVX UIDFLQJZLWKLQWKHWUHDWPHQW
DUHDRU  ZLWKLQFPRIWKHVHOHFWHGWUHDWPHQWDUHD
x$FLGFRQWDLQLQJWKHUDSHXWLFSURGXFWVHJVDOLF\OLFDFLGRUIUX LWDFLGVVXFKDVDOSKDDQG
EHWDK\GUR[\ODFLGVDQGJO\FROLFDFLGVWRSLFDOUHWLQRLGVRU OLJKWFKHPLFDOSHHOVZLWKLQWKH
WUHDWPHQWDUHDRU  ZLWKLQFPRIWKHVHOHFWHGWUHDWPHQWDUHD
x7RSLFDO VDOYHV QRQPHGLFDWHGQRQLUULWDQW ORWLRQ DQG FUHDP DUH  DFFHSWDEOH RU WRSLFDO
VWHURLGVZLWKLQWKHWUHDWPHQWDUHDRU  ZLWKLQFPRIWKHVHOHFWHGWUHDWPHQWDUHDDUWLILFLDO
WDQQHUVZLWKLQWKHWUHDWPHQWDUHDRU  ZLWKLQFPRIWKHVHOHFWHGWUHDWPHQWDUHD
8VHRIWKHIROORZLQJWKHUDSLHV DQGRUPHGLFDWLRQVZLWKLQZHHN VSULRUWRWKH6FUHHQLQJYLVLW
x7UHDWPHQW ZLWK LPPXQRPRGXODWRUV HJ D]DWKLRSULQH F\WRWR[LF G UXJV HJ
F\FORSKRVSKDPLGH YLQEODVWLQH FKORUDPEXFLO PHWKRWUH[DWH RU L QWHUIHURQVLQWHUIHURQ
LQGXFHUV
x7UHDWPHQWZLWKV\VWHPLFPHGLFDWLRQVWKDWVXSSUHVVWKHLPPXQHV\ VWHPHJF\FORVSRULQH
SUHGQLVRQHPHWKRWUH[DWHDOHIDFHSWLQIOL[LPDE
8VHRIV\VWHPLFUHWLQRLGVHJLVRWUHWLQRLQDFLWUHWLQEH[DURW HQHZLWKLQPRQWKVSULRUWRWKH
6FUHHQLQJYLVLW
$KLVWRU\RIVHQVLWLYLW\DQGRUDOOHUJ\WRDQ\RIWKHLQJUHGLHQ WVLQWKHVWXG\PHGLFDWLRQ  
$VNLQGLVHDVHHJDWRSLFGHUPDWLWLVSVRULDVLVHF]HPDRUFR QGLWLRQHJVFDUULQJRSHQZRXQGV
WKDWLQWKHRSLQLRQRIWKH,QYHVWLJDWRUPLJKWLQWHUIHUHZLWK WKHVWXG\FRQGXFWRUHYDOXDWLRQVRU
ZKLFKH[SRVHVWKHVXEMHFWWRXQDFFHSWDEOHULVNE\VWXG\SDUWLFL SDWLRQ
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
2WKHUVLJQLILFDQWXQFRQWUROOHGRUXQVWDEOHPHGLFDOGLVHDVHVRU FRQGLWLRQVWKDWLQWKHRSLQLRQRI
WKH,QYHVWLJDWRUZRXOGH[SRVHWKHVXEMHFWWRXQDFFHSWDEOHULVN E\VWXG\SDUWLFLSDWLRQ
)HPDOHVZKRDUHSUHJQDQWRUQXUVLQJ
3DUWLFLSDWHGLQDQLQYHVWLJDWLRQDOGUXJWULDOGXULQJZKLFKDQL QYHVWLJDWLRQDOVWXG\PHGLFDWLRQZDV
DGPLQLVWHUHGZLWKLQGD\VRUKDOI OLYHVRIWKHLQYHVWLJDWLRQDOSURGXFWZKLFKHYHULVORQJHU
EHIRUHGRVLQJ
6WXG\7UHDWPHQWV
.;2LQWPHQWRUYHKLFOHRLQWPHQWZLOOEHDSSOLHGWRSLFDO O\RQFHGDLO\IRUFRQVHFXWLYH
GD\V
'XUDWLRQRI6WXG\
)RUWKH6FUHHQLQJ7UHDWPHQWDQG5HVSRQVH$VVHVVPHQW3HULRGV HDFKVXEMHFWZLOOSDUWLFLSDWHIRUXS
WRGD\VVFUHHQLQJXSWRGD\VSULRUWR'D\WUHDWPHQWI RUFRQVHFXWLYHGD\VDQGIROORZXS
XQWLO'D\7KH5HFXUUHQFH)ROORZXS3HULRGZLOOEHIRUXSW RPRQWKVSRVW'D\7KXVWKH
PD[LPXPRYHUDOOGXUDWLRQRISDUWLFLSDWLRQIRUHDFKVXEMHFWLVD SSUR[LPDWHO\PRQWKV 
&RQFRPLWDQW'UXJ7KHUDS\
8VHRIDQ\WUHDWPHQWIRU$.OHVLRQVRWKHUWKDQVWXG\GUXJRQWK HWUHDWPHQWDUHDLVSURKLELWHGGXULQJ
WKHVWXG\ 
$VVHVVPHQWVGXULQJWKH7UHDWPHQWDQG5HVSRQVH$VVHVVPHQW3HULRG V'D\WKURXJK'D\
(IILFDF\$VVHVVPHQWV$GHUPDWRORJLVW,QYHVWLJDWRURU6XELQYHVWLJDWRUZLOOSHUIRUP DFRXQWRIFOLQLFDOO\YLVLEOH$.OHVLRQV
OHVLRQFRXQWIRUDOOVXEMHFWVDW6FUHHQLQJ%DVHOLQH'D\S UHGRVHDQGDWWKH5HVSRQVH$VVHVVPHQW
9LVLWVRQ'D\VDQG
6DIHW\$VVHVVPHQWV
6DIHW\ZLOOEHDVVHVVHGSHULRGLFDOO\WKURXJK'D\E\UHFRUGLQ J$(VVHULRXVDGYHUVHHYHQWV
6$(V/65VDQGHYHQWVRIVSHFLDOLQWHUHVW
6DIHW\DVVHVVPHQWVZLOODOVRLQFOXGHYLWDOVLJQVWKHSHUIRUPDQ FHRI3(V(&*VODERUDWRU\HYDOXDWLRQ
RIKHPDWRORJ\ELRFKHPLVWU\DQGXULQDO\VHVDQGHYDOXDWLRQRI SLJPHQWDWLRQDQGVFDUULQJ LQWKH
WUHDWPHQWDUHDDWSUHVSHFLILHGWLPHSRLQWV 7DEOH6FKHGXOHRI3URFHGXUHVDQG$VVHVVPHQWV
$WHDFKVWXG\YLVLWVXEMHFWVZLOOEHDVNHGDJHQHUDOTXHVWLRQ ¬≥+RZKDYH\RXEHHQVLQFHWKHODVW
YLVLW"¬¥  $GYHUVH HYHQWV ZLOO EH UHFRUGHG DW HDFK VWXG\ YLVLW EHIRUH DVVHVVPHQW RI /65V
SLJPHQWDWLRQDQGVFDUULQJLQWKHWUHDWPHQWDUHD$(VZLOOEH UHSRUWHGVHSDUDWHO\IURP/65V
/65$VVHVVPHQWV
7KH/65DVVHVVPHQWLVWKH,QYHVWLJDWRU¬∂VRU6XELQYHVWLJDWRU¬∂V DVVHVVPHQWRIWKHIROORZLQJVLJQVRQWKH
WUHDWPHQW DUHD  HU\WKHPD IODNLQJVFDOLQJ FUXVWLQJ VZHOOLQJ  YHVLFXODWLRQSXVWXODWLRQ DQG
HURVLRQXOFHUDWLRQ7KHVHVLJQVZLOOEHDVVHVVHGXVLQJDJUDGL QJVFDOHUDQJLQJIURP DEVHQW PLOG
VOLJKWO\ EDUHO\ SHUFHSWLEOH  PRGHUDWH GLVWLQFW SUHVHQFH  DQG  VHYHUH PDUNHG LQWHQVH
,QDGGLWLRQWR/65VK\SRDQGK\SHUSLJPHQWDWLRQDQGVFDUULQJ RQWKHWUHDWPHQWDUHDZLOOEH
DVVHVVHGDVEHLQJSUHVHQWRUDEVHQW$SSOLFDWLRQVLWHUHDFWLRQ VQRWFODVVLILHGDV/65VHJLWFKLQJ
EXUQLQJVWLQJLQJWHQGHUQHVVSDLQZLOOEHUHSRUWHGDV$(V 6WDQGDUGL]HGSKRWRJUDSK\ZLOOEH
SHUIRUPHGRQ'D\SULRUWRGRVLQJDQGRQ'D\VD QG
(YHQWVRI6SHFLDO,QWHUHVW
x2YHUGRVHRIVWXG\PHGLFDWLRQ
x3UHJQDQF\
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
x2FXODUH[SRVXUHVWRVWXG\PHGLFDWLRQ
x6NLQFDQFHUVLQFOXGLQJ%&&6&&DQGPHODQRPDWKHORFDWLRQD QGWUHDWPHQWZLOOEH
UHSRUWHG
$VVHVVPHQWVGXULQJWKH5HFXUUHQFH)ROORZXS3HULRGXSWRPR QWKVSRVW'D\
(IILFDF\$VVHVVPHQWV
$GHUPDWRORJLVW,QYHVWLJDWRURU6XELQYHVWLJDWRUZLOOSHUIRUP DFRXQWRIFOLQLFDOO\YLVLEOH$.
OHVLRQVOHVLRQFRXQWIRUVXEMHFWVZKRDFKLHYHFOHDUDQFH RI$.OHVLRQVLQWKHWUHDWPHQWDUHDDW
'D\GXULQJWKH5HFXUUHQFH)ROORZXS3HULRGDWWKH DQGPRQWKYLVLWV 
6DIHW\$VVHVVPHQWV
'XULQJ WKH 5HFXUUHQFH )ROORZXS 3HULRG VDIHW\ DVVHVVPHQWV ZLOO  LQFOXGH WKH PRQLWRULQJ DQG
UHFRUGLQJRI$(VDQG6$(VZLWKLQWKHWUHDWPHQWDUHDDWWKH DQGPRQWKYLVLWV
(YHQWVRI6SHFLDO,QWHUHVW
x6NLQFDQFHUVLQFOXGLQJ%&&6&&DQGPHODQRPDZLWKLQWKHWUHD WPHQWDUHD
x3UHJQDQF\
6WDWLVWLFDO0HWKRGV
3ULPDU\(QGSRLQW
x&RPSOHWHFOHDUDQFHUDWHRI$.OHVLRQVGHILQHGDVWKHSU RSRUWLRQRIVXEMHFWVDW
'D\ZLWKQRFOLQLFDOO\YLVLEOH$.OHVLRQVLQWKHWUHDWPHQWD UHD
6HFRQGDU\(QGSRLQWV
x(YDOXDWLRQRI/65VSLJPHQWDWLRQDQGVFDUULQJLQWKHWUHDWPHQW DUHD$(V6$(VHYHQWVRI
VSHFLDOLQWHUHVWFOLQLFDOODERUDWRU\GDWD DQGRWKHUVDIHW\DVVHVVPHQWVYLWDOVLJQV3(V
(&*V
x3DUWLDOFOHDUDQFHUDWHRI$.OHVLRQVGHILQHGDVWKHSURSRUWLRQ RIVXEMHFWVDW'D\ZLWKD
¬ïUHGXFWLRQLQWKHQXPEHURI$.OHVLRQVLGHQWLILHGDW%DVHOL QH'D\SUHGRVHLQWKH
WUHDWPHQWDUHD 
x5HGXFWLRQLQ$.OHVLRQFRXQWVGXULQJ'D\VWR
x5HFXUUHQFHUDWHRI$.OHVLRQVLQVXEMHFWVZKRDFKLHYHGFRPSOHWH FOHDUDQFHDW'D\
x$(VZLWKLQWKHWUHDWPHQWDUHDDIWHU'D\DQGXSWRPRQWKV SRVW'D\
$QDO\VLV3RSXODWLRQV
,QWHQW7R7UHDW,773RSXODWLRQ DOOUDQGRPL]HGVXEMHFWV7KLVLVWKHSULPDU\HIILFDF\SRSXODWL RQ
3HU3URWRFRO33(YDOXDEOH3RSXODWLRQ DOOUDQGRPL]HGVXEMHFWVZKRKDYHUHFHLYHGDWOHDVWRI
WKHGRVHVFRQIRUPHGWRWKHSURWRFRODVWRHQWU\FULWHULDGL GQRWUHFHLYHFRQFRPLWDQWPHGLFDWLRQV
WKDWFDQDIIHFWHIILFDF\DQGUHWXUQHGIRUWKHILQDOYLVLWRQ' D\
6DIHW\3RSXODWLRQ DOOUDQGRPL]HGVXEMHFWVZKRKDYHUHFHLYHGDWOHDVWRQHGRVH RIVWXG\WUHDWPHQW
5HFXUUHQFH )ROORZXS 3RSXODWLRQ DOOVXEMHFWVZKRDFKLHYHGFRPSOHWHFOHDUDQFHDW'D\
UHJDUGOHVVRIZKLFKWUHDWPHQWWKH\UHFHLYHG 
(IILFDF\$QDO\VHV
7RDFKLHYHVWDWLVWLFDOVLJQLILFDQFHLQWKHVWXG\DVDZKROHZLW KFRQFRUGDQFHLQERWKIDFHDQGVFDOS
WKH'D\FRPSOHWHFOHDUDQFHUDWHZLOOEHDQDO\]HGXVLQJD&RF KUDQ0DQWHO+DHQV]HO&0+PRGHO
FRQWUROOLQJ IRU WUHDWPHQW DQG WUHDWPHQW ORFDWLRQ IDFH DQG VFDO S SRVVLEOH WUHDWPHQWORFDWLRQ
LQWHUDFWLRQ ZLOO EH DGGUHVVHG E\ DQDO\]LQJ WKH WUHDWPHQW ORFDWL RQV LQGHSHQGHQWO\ WR VKRZ
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
FRQFRUGDQFH7KH3HDUVRQ&KL6TXDUHXVHGWRSRZHUWKHVWXG\ ZLOOEHXVHGWRGHPRQVWUDWHEDVLF
DJUHHPHQWZLWKWKH&0+3ULRUWRXQEOLQGLQJWKHGDWDWKHQXPE HURIVXEMHFWVHQUROOHGSHUVLWHZLOO
EHUHYLHZHGDQGDQLQYHVWLJDWRUVLWHDQDO\VLVRIKRZORZHQUROO PHQWVLWHVPLJKWEHFRPELQHGDQGWKH
LPSDFWRIKLJKHQUROOPHQWVLWHVZLOOEHIXOO\GLVFXVVHG
([SORUDWRU\DQDO\VHVPD\EHF RQGXFWHGWRLGHQWLI\RXWOLHUVWXG\ VLWHV7KHRXWOLHUVLWHVZLOOEH
GLVFXVVHGDQGDQH[SORUDWRU\DQDO\VLVH[FOXGLQJWKHRXWOLHUVLW HVPD\EHFDUULHGRXWWRHVWLPDWHWKH
LPSDFWRIVLWHE\WUHDWPHQWLQWHUDFWLRQV7KLVSURFHVVZLOOEH GRFXPHQWHG
7KHSULPDU\HIILFDF\DQDO\VLVZLOOEHSHUIRUPHGZLWKWKH,77SR SXODWLRQDQGZLOOEHUHSHDWHGZLWK
WKH33(YDOXDEOHSRSXODWLRQWRVXSSRUWWKHSULPDU\HIILFDF\DQD O\VLVUHVXOWV
3DUWLDOFOHDUDQFHUDWHZLOOEHDQDO\]HGLQWKHVDPHZD\DVWKH SULPDU\HIILFDF\HQGSRLQWFRPSOHWH
FOHDUDQFHUDWH
7KHQXPEHURI$.OHVLRQVDQGWKHFKDQJHIURPEDVHOLQHDWHDFKV FKHGXOHGYLVLWZLOOEHVX[COMPANY_003]UL]HG
XVLQJGHVFULSWLYHVWDWLVWLFVLHPHDQVWDQGDUGGHYLDWLRQ>6'@ PHGLDQPLQLPXPDQGPD[LPXPE\
WUHDWPHQWJURXSDQGWKHQFRQWUDVWHGIRUHDFKWUHDWPHQWJURXS
5HFXUUHQFHUDWHZLOOEHGHWHUPLQHGDWHDFKVFKHGXOHGYLVLWDIWH U'D\
6DIHW\$QDO\VHV
)RU$(VYHUEDWLPWHUPVRQWKHHOHFWURQLFFDVHUHSRUWIRUPH&5 )ZLOOEHPDSSHGWRSUHIHUUHGWHUPV
37VDQGV\VWHPRUJDQFODVVHV62&VXVLQJWKH0HGLFDO'LFWLRQ DU\IRU5HJXODWRU\$FWLYLWLHV
0HG'5$YRUKLJKHU
7UHDWPHQWHPHUJHQWDGYHUVHHYHQWV7($(VDUHGHILQHGDVHLWKHU WKRVH$(VZLWKDQRQVHWDIWHUWKH
ILUVWGRVHRUWKRVHSUHH[LVWLQJ$(VWKDWZRUVHQDIWHUWKHILUV WGRVH7KHLQFLGHQFHRI7($(VZLOOEH
VX[COMPANY_003]UL]HGE\WUHDWPHQWJURXS7($(VZLOODOVREHVX[COMPANY_003]UL]HGE \VHYHULW\DQGUHODWLRQVKLSWR
VWXG\WUHDWPHQW%\VXEMHFWOLV WLQJVRIDOO6$(VDQGHYHQWVRI VSHFLDOLQWHUHVWZLOOEHSURYLGHG 
/DERUDWRU\ SDUDPHWHUV ZLOO EH VX[COMPANY_003]UL]HG XVLQJ GHVFULSWLYH VWDW L V W L F V D W E D V H O L Q H D Q G D W H D F K 
VXEVHTXHQWWLPHSRLQWE\WUHDWPHQWJURXS&KDQJHVIURPEDVHOLQH ZLOODOVREHVX[COMPANY_003]UL]HGE\
WUHDWPHQWJURXS,QDGGLWLRQVKLIWWDEOHVLHORZQRUPDOKLJ KDWEDVHOLQHYHUVXVORZQRUPDOKLJKDW
IROORZXSLQDE\FRQWLQJHQF\WDEOHZLOOEHSURYLGHGWRDV VHVVFKDQJHVLQODERUDWRU\YDOXHVIURP
EDVHOLQHWR'D\DQGEDVHOLQHWR'D\LQHDFKWUHDWPHQWJURX S
/65K\SHURUK\SRSLJPHQWDWLRQDQGVFDUULQJDVVHVVPHQWUHVXOW VREWDLQHGWKURXJK'D\ZLOOEH
GLVSOD\HGDQGVX[COMPANY_003]UL]HGE\YLVLWDQGWUHDWPHQWJURXS
6DIHW\GDWDFROOHFWHGWKURXJK'D\DQGGXULQJWKH5HFXUUHQFH )ROORZXS3HULRGZLOOEHDQDO\]HG
VHSDUDWHO\ 
,QWHULP$QDO\VHV
1RLQWHULPDQDO\VLVLVSODQQHGIRUWKLVVWXG\ 
6DPSOH6L]H5DWLRQDOH
7KHVDPSOHVL]HZDVHVWLPDWHGEDVHGRQWKHSULPDU\HIILFDF\HQG SRLQWIRUWKHFRPSDULVRQRI
.;2LQWPHQWDQGYHKLFOHFRQWURO%\XVLQJD3HDUVRQ&K LVTXDUHPHWKRGDVDPSOHVL]HRI
VFDOSWUHDWHGVXEMHFWVDQGIDFH WUHDWHGVXEMHFWVERWKRIZKLFKDUHZLWKDWUHDWPHQW
DOORFDWLRQUDWLRZLOOJLYHDJUHDWHUWKDQSRZHUWRGHWHFW DGLIIHUHQFHIRUDFWLYH
WUHDWPHQWDQGIRUYHKLFOHFRQWUROZLWKDWZRWDLOHGVLJQLI LFDQWOHYHO 
),1$/YB-XQ

&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
6&+('8/(2)352&('85(6$1'$66(660(176
7DEOH 6FKHGXOHRI3URFHGXUHVDQG$VVHVVPHQWVLQ.;$. 
3HULRG 6FUHHQLQJ 7UHDWPHQW 5HVSRQVH$VVHVVPHQW 5HFXUUHQFH)RO ORZXSD
&OLQLF9LVLW  $WKRPHRQFH
GDLO\VHOI
DGPLQLVWUDWLRQ
RIWUHDWPHQW   
(DUO\
7HUPED
'D\ WR
%DVHOLQH     E0RQWKV
3RVW'D\F
9LVLWWLPHZLQGRZGD\V 1RQH 1RQH  1 R Q H  ¬ì  ¬ì  ¬ì  ¬ì   ¬ì   
,QIRUPHGFRQVHQW ;    
,QFOXVLRQ	H[FOXVLRQFULWHULD ; ;G   
'HPRJUDSKLFV ;    
0HGLFDOVXUJLFDOKLVWRU\ ;    
$.KLVWRU\$.WUHDWPHQWKLVWRU\ ;    
3ULRUDQGFRQFRPLWDQWPHGLFDWLRQVWKHUDSLHV ; ;G  ; ; ; ; ;  ; 
)LW]SDWULFNVNLQW\SHVFDOH ;    
([SDQGHGGHUPDWRORJLFDOH[DPH;    
7UHDWPHQWDUHDLGHQWLILFDWLRQ ; ;GI    
$.OHVLRQFRXQWLQWUHDWPHQWDUHD ; ;G   ; ; ; ; ;
3K\VLFDOH[DPLQDWLRQLQFOXGLQJZHLJKWDQG
KHLJKWJ;    ;  
9LWDOVLJQVK;  ;G  ;   ;  
(&*L;  ;G  ; ;   
&OLQLFDOFKHPLVWU\KHPDWRORJ\DQG8$ ;M   ; ;   
6HUXPSUHJQDQF\WHVWIRU:2&%3 ;    ;   ; 
8ULQHSUHJQDQF\WHVW  ;N   
$(VO;  ;G  ; ; ; ; ;  ;P
)RFXVHGGHUPDWRORJLFDOH[DPRIWUHDWPHQW
DUHD;G  ; ; ; ; ;  
/ 6 5 V   ;G  ; ; ; ; ;  
3 LJPHQWDWLRQDQGVFDUULQ J ;G  ; ; ; ;; 
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
7DEOH 6FKHGXOHRI3URFHGXUHVDQG$VVHVVPHQWVLQ.;$. 
3HULRG 6FUHHQLQJ 7UHDWPHQW 5HVSRQVH$VVHVVPHQW 5HFXUUHQFH)RO ORZXSD
&OLQLF9LVLW  $WKRPHRQFH
GDLO\VHOI
DGPLQLVWUDWLRQ
RIWUHDWPHQW   
(DUO\
7HUPED
'D\ WR
%DVHOLQH     E0RQWKV
3RVW'D\F
6WDQGDUGL]HG SKRWRJUDSK\ ;G  ; ; ; ; ;  
5DQGRPL]DWLRQ  ;   
,QVWUXFWLRQVIRUVHOIDGPLQLVWUDWLRQ
GLVSHQVHVWXG\PHGLFDWLRQ;G   
6WXG\PHGLFDWLRQDSSOLFDWLRQ;  ;   
6WXG\GUXJGRVLQJORJUHWXUQ   ;Q  
$( DGYHUVHHYHQW$. DFWLQLFNHUDWRVLV(&* HOHFWURFDUGLR JUDP+((17 KHDGH\HVHDUVQRVHDQGWKURDW/65 ORFDOV NLQUHDFWLRQ7HUP 7HUPLQDWLRQ8$ 
XULQDO\VLV:2&%3 ZRPHQRIFKLOGEHDULQJSRWHQWLDO
D)RU'D\FRPSOHWHUHVSRQGHUVRQO\
E7KHVHDUHDVVHVVPHQWVWREHFRPSOHWHGE\DOOVXEMHFWV)RUWKR VHZKRGRQRWKDYHFRPSOHWHUHVSRQVHDW'D\RUZKRDUHGLVFR QWLQXHGHDUO\IURPWKHVWXG\WKLVZLOOEHWKHLU
ILQDOYLVLW$OOVXEMHFWVZKRKDYHXQUHVROYHG/65VK\SRRUK \SHUSLJPHQWDWLRQVFDUULQJLQWKHWUHDWPHQWDUHDRUWUHDWPHQW UHODWHG$(VDW'D\ZLOOUHWXUQIRUDGGLWLRQDO
IROORZXSHYHU\WRGD\VXQWLOUHVROXWLRQUHWXUQHGWREDVH OLQHRUGHHPHGVWDELOL]HGE\WKH,QYHVWLJDWRUV
F)RUVXEMHFWVZKRKDYHFRPSOHWHUHVSRQVHDW'D\DQGQRUHFXUU HQFHPRQWKVSRVW'D\LVWKH)LQDO9LVLW7KRVHVXEMHFWV ZKRKDYH$.UHFXUUHQFHLQWKHWUHDWPHQW
DUHDZLOOKDYHWKHLUILQDODVVHVVPHQWVDWWKHYLVLWZKHQWKH$. UHFXUUHQFHLVLGHQWLILHG
G7KHVHDUHEDVHOLQHSURFHGXUHVDVVHVVPHQWVDQGZLOOEHSHUIRUPHG EHIRUHUDQGRPL]DWLRQ
H$QH[SDQGHGGHUPDWRORJLFDOH[DPLQDWLRQWRFRYHUWKHVXQH[SRVHG DUHDVZKHUHSKRWRGDPDJHLVOLNHO\ZLOOEHFRQGXFWHGDW6FUHHQ LQJRQO\
I7KHORFDWLRQDQGVKDSHRIWKHWUHDWPHQWDUHDZLOOEHPDUNHGRQ DQDFHWDWHWUDQVSDUHQF\VKHHWIRUUHFRUGLQJSXUSRVHVDQGRQWKH VXEMHFW¬∂VVNLQIRULGHQWLILFDWLRQRIWKH
WUHDWPHQWDUHDIRUGDLO\VHOIDGPLQLVWUDWLRQRIVWXG\RLQWPHQW 
J$FRPSOHWH3(ZLOOLQFOXGHZHLJKWDQGDQDVVHVVPHQWRI+((17L QWHJXPHQWDU\JDVWURLQWHVWLQDOFDUGLRYDVFXODUUHVSLUDWRU\PX VFXORVNHOHWDODQGQHXURORJLFDOV\VWHPV
+HLJKWZLOOEHPHDVXUHGDW6FUHHQLQJRQO\7KLVZLOOEHFRQVLG HUHGWKHEDVHOLQHDVVHVVPHQW
K9LWDOVLJQVPHDVXUHPHQWVZLOOEHWDNHQDIWHUWKHVXEMHFWKDVEH HQVHDWHGIRUDWOHDVWPLQXWHV
L6XEMHFWVPXVWEHLQWKHUHFXPEHQWSRVLWLRQIRUDSHULRGRIPL QXWHVSULRUWRWKH(&*%DVHOLQH(&*LVSHUIRUPHGSUHGRVH
M7KLVZLOOEHFRQVLGHUHGWKHEDVHOLQHDVVHVVPHQW
N)RUIHPDOHVRIFKLOGEHDULQJSRWHQWLDOXULQHSUHJQDQF\WHVWRQ 'D\EHIRUHUDQGRPL]DWLRQ
O$WHDFKVWXG\YLVLWVXEMHFWVZLOOEHDVNHGDJHQHUDOTXHVWLRQ ¬≥+RZKDYH\RXEHHQVLQFHWKHODVWYLVLW"¬¥$(VZLOOEHUHFRUGH GEHIRUHDVVHVVPHQWRI/65VSLJPHQWDWLRQDQG
VFDUULQJLQWKHWUHDWPHQWDUHD$(VZLOOEHUHSRUWHGVHSDUDWHO \IURP/65V
P2QO\$(VLQWKHWUHDWPHQWDUHDZLOOEHFROOHFWHG
Q2Q'D\9LVLWVXEMHFWVDUHWRFRPHLQWRWKHFOLQLFDIWHU VWXG\WUHDWPHQWLVVHOIDGPLQLVWHUHG6XEMHFWVDUHWREULQJDO OVWXG\GUXJSDFNHWVXVHGDQGXQXVHGLQWKHVWXG\
NLWDQGWKHGRVLQJORJEDFNWRWKHVLWH
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
7$%/(2)&217(176
7,7/(3$*(    
&/,1,&$/[ZIP_CODE]&2/6<1236,6   
6&+('8/(2)352&('85(6$1'$66(660(176   
7$%/(2)&217(176   
/,672)$%%5(9,$7,216$1''(),1,7,2162)7(506   
 ,19(67,*$7256$1'678'<3([ZIP_CODE](/   
 ,1752'8&7,21   
 %DFNJURXQG   
  ,QGLFDWLRQ   
  0HFKDQLVPRI$FWLRQ   
  1RQFOLQLFDO6WXGLHV   
  &OLQLFDO([SHULHQFHZLWK.;   
  .;LQ&DQFHU2UDO   
  .;DVD7RSLFDO7UHDWPHQW IRU$FWLQLF.HUDWRVLV   
 6WXG\5DWLRQDOH   
 3RWHQWLDO5LVNVDQG%HQHILWV   
 678'<2%-(&7,9(6$1'(1'32,176   
 3ULPDU\2EMHFWLYHDQG(QGSRLQW   
 6HFRQGDU\2EMHFWLYHVDQG(QGSRLQWV   
 ,19(67,*$7,21$/3/$1   
 2YHUDOO6WXG\'HVLJQDQG3ODQ   
 6FUHHQLQJ3HULRG   
 7UHDWPHQW3HULRG   
 5HVSRQVH$VVHVVPHQW3HULRG   
 5HFXUUHQFH)ROORZXS3HULRG   
 'LVFXVVLRQRI6WXG\'HVLJQ,QFO XGLQJ&KRLFHRI'RVLQJDQG&RQW URO*URXSV  
 678'<3238/$7,21   
 ,QFOXVLRQ&ULWHULD   
 ([FOXVLRQ&ULWHULD   
 6XEMHFW:LWKGUDZDO'LV FRQWLQXDWLRQ&ULWHULD   
 678'<75($70(176   
 ,GHQWLW\RI6WXG\'UXJV   
  )RUPXODWLRQ3DFNDJLQJDQG/DEHOLQJ   
  6WRUDJH&RQGLWLRQV   
 'RVDJHDQG$GPLQLVWUDWLRQRI6WXG\'UXJV   
  $GPLQLVWUDWLRQRI6WXG\'UXJV   
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
  ,QVWUXFWLRQVLQWKH(YH QWRI2FXODU([SRVXUH   
  &ULWHULDIRU,QWHUUXSWLRQRI7 UHDWPHQW'RVH$GMXVWPHQWV   
 5DQGRPL]DWLRQ0HWKRGRI$VVLJQLQJ 6XEMHFWVWR7UHDWPHQW*URXSV   
  %OLQGLQJ   
 3ULRUDQG&RQFRPLWDQW0HG LFDWLRQV7KHUDS\   
  3ULRU0HGLFDWLRQV7KHUDS\   
  &RQFRPLWDQW0HGLFDWLRQV7KHUDS\   
  3URKLELWHG0HGLFDWLRQ7KHUDS\   
  2WKHU3URKLELWLRQVDQG5HV WULFWLRQVGXULQJ6WXG\   
 'UXJ$FFRXQWDELOLW\DQG7U HDWPHQW&RPSOLDQFH   
  'UXJ6XSSOLHVDQG$FFRXQWDELOLW\   
  7UHDWPHQW&RPSOLDQFH   
 678'<352&('85(6$1'$66(660(176   
 6FUHHQLQJ$VVHVVPHQWV   
  ,QIRUPHG&RQVHQW   
  ,QFOXVLRQ([FOXVLRQ&ULWHULD   
  'HPRJUDSK\   
  0HGLFDO6XUJLFDODQG$FWLQLF .HUDWRVLV+LVWRU\   
  3ULRU0HGLFDWLRQV   
  )LW]SDWULFN6NLQ7\ SH&ODVVLILFDWLRQ   
  ([SDQGHG'HUPDWRORJL FDO([DPLQDWLRQ   
  7UHDWPHQW$UHD,GHQWLILFDWLRQD QG$./HVLRQ&RXQW([DPLQDWLRQ   
  3K\VLFDO([DPLQDWLRQV   
  9LWDO6LJQV   
  (OHFWURFDUGLRJUDPV   
  /DERUDWRU\0HDVXUHPHQWV   
  3UHJQDQF\7HVWLQJ   
 %DVHOLQH$VVHVVPHQWV   
  ,QFOXVLRQ([FOXVLRQ&ULWHULD   
  3ULRU0HGLFDWLRQV   
  7UHDWPHQW$UHD,GHQWLILFDWLRQ   
  $FWLQLF.HUDWRVLV/HVLRQ&RXQW   
  )RFXVHG'HUPDWRORJLFDO( [DPRI7UHDWPHQW$UHD   
  /RFDO6NLQ5HDFWLRQV   
  3LJPHQWDWLRQDQG6FDUULQJ   
  6WDQGDUGL]HG3KRWRJUDSK\   
  9LWDO6LJQV   
  (OHFWURFDUGLRJUDPV   
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
  3UHJQDQF\7HVWLQJ   
  5DQGRPL]DWLRQ   
  ,QVWUXFWLRQVIRU6HOIDGPLQLVWU DWLRQRI6WXG\7UHDWPHQW'LVSHQ VLQJ
DQG5HWXUQRI6WXG\7UHDWPHQW   
 7UHDWPHQW3HULRGDQG5HVSRQV H$VVHVVPHQW3HULRG   
  7UHDWPHQW$GPLQLVWU DWLRQ¬±'D\V   
  (IILFDF\$VVHVVPHQWV   
  $FWLQLF.HUDWRVLV/HVLRQ&RXQW   
  3KDUPDFRNLQHWLF3KDUPDFRG\QD PLF3KDUPDFRJHQRPLFDQG2WKHU
%LRPDUNHU$VVHVVPHQWV   
  6DIHW\$VVHVVPHQWV   
  $GYHUVH(YHQWV   
  $VVHVVLQJ6HYHULW\RI$GYHUVH(YHQWV   
  $VVHVVLQJ5HODWLRQVKLSWR6WXG\7UHDWPHQW   
  6HULRXV$GYHUVH(YHQWV   
  (YHQWVRI6SHFLDO,QWHUHVW   
  &RQFRPLWDQW0HGLFDWLRQV   
  )RFXVHG'HUPDWRORJLFDO([DPRI 7UHDWPHQW$UHDDQG6WDQGDUG
3KRWRJUDSK\   
  /RFDO6NLQ5HDFWLRQV   
  3LJPHQWDWLRQDQG6FDUULQJ   
  3K\VLFDO([DPLQDWLRQV   
  9LWDO6LJQV   
  (OHFWURFDUGLRJUDPV   
  /DERUDWRU\0HDVXUHPHQWV   
  3UHJQDQF\7HVWLQJ   
 $GGLWLRQDO)ROORZXS$VVHVVPHQWV   
 5HFXUUHQFH)ROORZXS3HULRG$VVHVVPHQWV   
  5HFXUUHQFH$VVHVVPHQWV   
  6DIHW\$VVHVVPHQWV   
 $SSURSULDWHQHVVRI0HDVXUHPHQWV   
 (;3(',7('5(3257,1*   
 5HSRUWLQJRI6HULRXV $GYHUVH(YHQWV   
 5HSRUWLQJRI(YHQWVRI6SHFLDO,QWHUHVW   
  3UHJQDQF\   
  6WXG\'UXJ2YHUGRVH   
  2FXODU([SRVXUH   
  6NLQ&DQFHU   
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
  %UHDNLQJWKH%OLQG   
 67$7,67,&$/0(7+2'6   
 6WDWLVWLFDODQG$QDO\WLFDO3ODQV   
  6WXG\(QGSRLQWV   
  3ULPDU\(QGSRLQW   
  6HFRQGDU\(QGSRLQWV   
  'HILQLWLRQVRI$QDO\VLV6HWV   
  6XEMHFW'LVSRVLWLRQ   
  'HPRJUDSKLFDQG2WKHU%DV HOLQH&KDUDFWHULVWLFV   
  3ULRUDQG&RQFRPLWD QW7KHUDS\   
  (IILFDF\$QDO\VHV   
  3ULPDU\(IILFDF\(QGSRLQW$QDO\VLV   
  6HFRQGDU\(IILFDF\( QGSRLQW$QDO\VHV   
  0LVVLQJ'DWD+DQGOLQJDQG6HQVLWLYLW\$QDO\VLV   
  6XEJURXS$QDO\VLV   
  6DIHW\$QDO\VHV   
  ([WHQWRI([SRVXUH   
  $GYHUVH(YHQWV   
  /DERUDWRU\9DOXHV   
  3UHJQDQF\7HVWV   
  9LWDO6LJQV   
  (OHFWURFDUGLRJUDPV   
  3K\VLFDO([DPLQDWLRQV   
  /RFDO6NLQ5HDFWLRQVDQG3 LJPHQWDWLRQDQG6FDUULQJ   
  'HWHUPLQDWLRQRI6DPSOH6L]H   
  ,QWHULP$QDO\VLV   
  2WKHU6WDWLVWLFDO$QDO\WLFDO,VVXHV   
  3URFHGXUHIRU5HYLVLQJ WKH3ODQQHG$QDO\VLV   
 352&('85(6$1',[ZIP_CODE]&7,216   
 $FFHVVWR6RXUFH'DWD'RFXPHQWV   
 4XDOLW\&RQWURODQG4XDOLW\$VVXUDQFH   
  'DWD&ROOHFWLRQ   
  &OLQLFDO'DWD0DQDJHPHQW   
 (7+,&6   
  ,QVWLWXWLRQDO5HYLHZ%RDUGV   
  6XEMHFW,QIRUPDWLRQDQG,QIRUPHG&RQVHQW   
 'DWD+DQGOLQJDQG5HFRUGNHHSLQJ   
  5HFRUGLQJRI'DWD   
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
  ,GHQWLILFDWLRQRI6RXUFH'DWD   
  5HWHQWLRQRI5HFRUGV   
 3XEOLFDWLRQ3ROLF\   
 2WKHU$GPLQLVWUDWLYH3ROLFLHV   
  &KDQJHVWRWKH3URWRFRO   
  'LVFORVXUHDQG&RQILGHQWLDOLW\   
  'LVFRQWLQXDWLRQRI6WXG\   
 5()(5(1&(/,67   
 $33(1',&(6   
$33(1',;  ,[ZIP_CODE]&7,216)2568%-(&76¬∂6(/)$'0,1,675$7,212)
678'<75($70(17   
[ZIP_CODE]&2/6,*1$785(3$*(6   

/,672),17(;77$%/(6
7DEOH  6FKHGXOHRI3URFHGXUHVDQG$ VVHVVPHQWVLQ.;$.   
7DEOH  7UHDWPHQWVLQ.;$.   
7DEOH  &OLQLFDO/DERUDWRU\7HVWV   

/,672),17(;7),*85(6
)LJXUH  6WXG\'HVLJQIRU.;$.   

/,672)$33(1',&(6
$SSHQGL[  ,QVWUXFWLRQVIRU6XEM HFWV¬∂6HOIDGPLQLVWUDWLRQRI6WXG\7UHDWPH QW  

&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
/,672)$%%5(9,$7,216$1''(),1,7,2162)7(506
$EEUHYLDWLRQ 7HUPV
$( DGYHUVHHYHQW$. DFWLQLFNHUDWRVLV%&& EDVDOFHOOFDUFLQRPD&)5 &RGHRI)HGHUDO5HJXODWLRQV
&0+ &RFKUDQ0DQWHO+DHQV]HO
&5$ FOLQLFDOUHVHDUFKDVVRFLDWH&52 FRQWUDFWUHVHDUFKRUJDQL]DWLRQ(&* HOHFWURFDUGLRJUDPH&5) HOHFWURQLFFDVHUHSRUWIRUP*&3 *RRG&OLQLFDO3UDFWLFH,&) LQIRUPHGFRQVHQWIRUP
,&+,QWHUQDWLRQDO&RXQFLOIRU+DUPRQLVDWLRQRI7HFKQLFDO5HTXLUHPHQ WVIRU
5HJLVWUDWLRQRI3KDUPDFHXWLFDOVIRU+XPDQ8VH
,5% ,QVWLWXWLRQDO5HYLHZ%RDUG,77 ,QWHQW7R7UHDW/65 ORFDOVNLQUHDFWLRQ0HG'5$ 0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV12$(/ QRREVHUYHGDGYHUVHHIIHFWOHYHO3( SK\VLFDOH[DPLQDWLRQ33 3HU3URWRFRO37 SUHIHUUHGWHUP6$( VHULRXVDGYHUVHHYHQW6$3 VWDWLVWLFDODQDO\VLVSODQ6&& VTXDPRXVFHOOFDUFLQRPD6' VWDQGDUGGHYLDWLRQ62& V\VWHPRUJDQFODVV623 VWDQGDUGRSHUDWLQJSURFHGXUH
7($( WUHDWPHQWHPHUJHQWDGYHUVHHYHQW
86 8QLWHG6WDWHV89 XOWUDYLROHWOLJKW


&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 ,19(67,*$7256$1' 678'<3([ZIP_CODE](/
7KLVVWXG\ZLOOEHFRQGXFWHGE\TXDOLILHG,QYHVWLJDWRUVXQGHUW KHVSRQVRUVKLSRI$WKHQH[
,QFWKH6SRQVRUDWDSSUR[ LPDWHO\WRLQYHVW LJDWLRQDOVL WHVLQWKH8QLWH G6WDWHV86
7KHQDPHWHOHSKRQHQXPEHUDQGHP DLODGGUHVVRIWKH0HGLFDO0R QLWRUDQGRWKHUFRQWDFW
SHUVRQQHODWWKH6SRQVRUDUHOLV WHGLQWKH5HJXODWRU\%LQGHUSU RYLGHGWRHDFKVLWH
 ,1752'8&7,21
 %DFNJURXQG
 ,QGLFDWLRQ
,QWKLVVWXG\WKHHIILFDF\DQGVDIHW\RI.;2LQWPHQWZ LOOEHHYDOXDWHGLQDGXOW
VXEMHFWVZLWKDGLDJQRVLVRIFOLQL FDOO\W\SLFDODFWLQLFNHUDWRV LV$.RQWKHIDFHRUVFDOS
 0HFKDQLVPRI$FWLRQ
.;UHIHUUHGWRDV.;LQVWXG\SURWRFROQXPEHUVLVDV\ QWKHWLFDQGKLJKO\VHOHFWLYH
LQKLELWRURI6UFW\URVLQHNLQDVHVLJQDOLQJDQGWXEXOLQSRO\PHUL ]DWLRQ.;2LQWPHQWLV
EHLQJGHYHORSHGDVDWRSLFDOWU HDWPHQWIRU$..;LVDOVR EHLQJGHYHORSHGDVDQRUDO
DJHQWIRURQFRORJ\LQGLFDWLRQV
.;SURPRWHVWKHLQGXFWLRQRI S*0DUUHVWRISUROLIHUD WLQJFHOOSRSXODWLRQVDQG
VXEVHTXHQWDSRSWRVLVYLDWKHVWLPX ODWLRQRI&DVSDVHDQG3$53 FOHDYDJH3RWHQWLQKLELWLRQ
RIWKHJURZWKRISULPDU\KXPDQNHUDWLQRF\WHVDQGVHYHUDOPHODQR PDFHOOOLQHVLQYLWUR
JURZWKLQKLELWLRQ>*, YDOXHV@¬îQ0VXJJHVWVWKDW.;KDVWKHSRWHQWLDOWRLQ KLELW
WKHSUROLIHUDWLYHH[SDQVLRQDQG SURPRWHDSRSWRVLVRIDEQRUPDOO\ SUROLIHUDWLQJFHOOVLQWKH
HSLGHUPDODQGGHUPDOOD\HUVXSRQWRSLFDODSSOLFDWLRQ.; KDVDOVREHHQREVHUYHGWR
LQKLELW7FHOOPLJUDWLRQDQGHQGRW KHOLDOWXEXOHIRUPDWLRQLQYL WURVXJJHVWLQJDGGLWLRQDO
SRWHQWLDOWKHUDSHXWLFEHQHILWVIRUFRQGLWLRQVZKHUHSDWKRORJ\L VVXSSRUWHGE\O\PSKRF\WH
LQILOWUDWLRQLQI OD[COMPANY_003]WLRQDQGRUD QJLRJHQHVLV
 1RQFOLQLFDO6WXGLHV
'HWDLOV UHJDUGLQJ .; QRQFOLQL FDO VWXGLHV DUH SURYLGHG LQ W KH .; 2LQWPHQW
,QYHVWLJDWRU¬∂V%URFKXUH
7KHELRDYDLODELOLW\RI.;DI WHUGHUPDODGPLQLVWUDWLRQWRU DWVDQGUDEELWV
WRGHSHQGLQJRQFRQFHQ WUDWLRQZDVORZ3ODVPDF RQFHQWUDWLRQVRI.;
LQFUHDVHGZLWKUHSHDWGHUPDODGPLQLVWUDWLRQDQGLQUDWVWKHSO DVPDOHYHOVDIWHUGD\VGHUPDO
GRVLQJUHDFKHGRUH[FHHGHGOHYHOV SURGXFHGE\RUDODGPLQLVWUDWL RQRI.;DWWKHQR
REVHUYHGDGYHUVHHIIHFWOHYHO12$(/GRVHPJNJGRVHLQ DGD\WZLFHGDLO\RUDO
WR[LFLW\VWXG\)ROORZLQJGD\VRI.;WRSLFDODGPLQLVWUD WLRQDWLQFUHDVLQJGRVHV
DQGLQUDWVDQGPLQLSLJVDQLQFUHDVHLQ.; SODVPDH[SRVXUHZDV
REVHUYHGIURP'D\WR'D\VXJJHVWLQJVOLJKWGUXJDFFXPXODW LRQ
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
,QGD\UHSHDWGRVHWR[LFRORJ\ VWXGLHV.;RLQWPHQWZDV DGPLQLVWHUHGWRUDWVDQG
PLQLSLJVDWGRVHVWUHQJWKVDQG2LQWPHQWYROXPHVR IP/NJERG\ZHLJKW
ZHUHDSSOLHGWRDSSUR[LPDWHO\RIWKHERG\VXUIDFHDUHDRIW KHVNLQ7KHDGPLQLVWUDWLRQ
VLWHVZHUHRFFOXGHGZLWKJDX]HDQGWKHDSSOLFDWLRQVOHIWIRU KGD\LQUDWV7KHDSSOLFDWLRQ
VLWH ZDV VHPLRFFOXGHG IRU  KRXUV LQ PLQLSLJV 7KHVH GRVHV  FRQWDLQHG   RU
PJNJ.;UHVSHFWLYHO\HTXLYDOHQWWRRUP JPLQUDWVDQGRU
PJP LQ PLQLSLJV 6\VWHPLF H[SRVXUHV RQ 'D\  WR .; IROORZLQJ G D L O \ 
DSSOLFDWLRQ RI  RLQWPHQW ZHUH & PD[  QJP/ PDOH QJP/ IHPDOH DQG
$8&K  K
QJP/ PDOH K
QJP/ IHPDOH LQ UDWV DQG & PD[  QJP/
PDOH QJP/ IHPDOH $8& K  K
QJP/ PDOH K
QJP/ IHPDOH LQ
PLQLSLJV([SRVXUH$8&LQKXPDQVZDVQRWFDOFXODWHGGXHWRWK HODFNRITXDQWLILDEOH
SODVPDFRQFHQWUDWLRQVIROORZLQJWRSLFDO.;DGPLQLVWUDWLRQ +RZHYHUWKHPD[LPXP
&PD[YDOXHDWWKH12$(/LQUDWVDQGPLQLSLJVLVDSSUR[LPDWHO\DQ GWLPHVJUHDWHUWKDQ
WKH PD[LPXP SODVPD .; FRQFHQWUDWLRQ RI  QJP/ DFKLHYHG  LQ WKH FOLQLF
6WXG\.;$.
2WKHU GHUPDO WR[LFLW\ VWXGLHV ZLWK .; VKRZHG WKDW .; RLQWPHQW PD\ EH
VHQVLWL]LQJWRWKHVNLQ%XHKOHUDVVD\DQGPXULQHORFDOO\PSKQ RGHDVVD\WKDW.;
RLQWPHQWZDVQHJDWLYHIRUSKRWRW R[LFLW\DQGWKDW.;RLQWP HQWZDVDQLUULWDQWWRWKH
H\HVRIUDEELWVDIWHUVLQJOHD SSOLFDWLRQHIIHFWVFOHDUHGZLWKL QGD\VSRVWGRVH
.;ZDVQHJDWLYHLQDEDFWHUL DOPXWDJHQLFLW\VWXG\$PHVWH VW.;FDXVHG
FKURPRVRPDODEHUUDWLRQVLQ&KLQHVH+DPVWHU2YDU\&+2FHOOVDW YHU\KLJKGRVHVWKDWDUH
QRWOLNHO\WREHFOLQLFDOO\UHOHYDQW
6WXGLHVRIWKHHIIHFWVRI.; RUDORQUHSURGXFWLRQDQGIHWD OGHYHORSPHQWKDYHEHHQ
SHUIRUPHG ,Q HPEU\RIHWDO GHYH ORSPHQW VWXGLHV LQ UDWV DQG UDEE LWV .; ZDV
DGPLQLVWHUHG RUDOO\ LQ RUGHU WR L QFUHDVH V\VWHPLF H[SRVXUH (PE U\R DQG IHWDO WR[LFLW\
LQFOXGLQJLPSODQWDWLRQORVVDQGIHWDOPDOIRUPDWLRQVRFFXUUHGD WRUDOGRVHVRI¬ïPJNJ
UDWVDQGPJNJUDEELWV7KH QRHIIHFWGRVHVIRUIHWDODQG UHSURGXFWLYHHIIHFWVZHUH
PJNJUDWVDQGPJNJUDEELWV$WWKHVHGRVHVPDWHUQD O&PD[DQG$8& KV\VWHPLF
H[SRVXUHVWR.;ZHUHQJP/DQGK
QJP/UDWV'D \DQGQJP/
DQGK
QJP/UDEELWV'D\UHVSHFWLYHO\6\VWHPLFSODVP DH[SRVXUH$8&LQ
KXPDQVFRXOGQRWEHGHWHUPLQHGGXHWRWKHODFNRITXDQWLILDEOH SODVPDFRQFHQWUDWLRQVDFURVV
PXOWLSOHWLPHSRLQWV+RZHYHUPDWHUQDO& PD[YDOXHVDWWKH12$(/LQUDWVDQGUDEELWVDUH
DSSUR[LPDWHO\DQGWLPHVJUHDWHUWKDQWKHKLJKHVW.; SODVPDFRQFHQWUDWLRQ
DFKLHYHGFOLQLFDOO\RIQJ P/6WXG\.;$.
 &OLQLFDO([SHULHQFHZLWK.;
 .;LQ&DQFHU2UDO
.; KDV EHHQ DGPLQLVWHUHG RU DOO\ DV D WUHDWPHQW IRU FDQFHU WR DSSUR[LPDWHO\
SDWLHQWVZLWKYDULRXVW\SHVRIPDOLJQDQFLHVLQFOLQLFDOV WXGLHVVSRQVRUHGE\$WKHQH[
,QF$VX[COMPANY_003]U\RIWKHVDIHW\LQIRUPDWLRQIURPWKHVHSDWLHQWVL VSURYLGHGLQDQDSSHQGL[RI
WKH.;2LQWPHQW,QYHVWLJDWRU¬∂V%URFKXUH
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
'XHWRWKHGLIIHUHQFHVLQURXWH RIDGPLQLVWUDWLRQDQGVKRUWGXU DWLRQRIWUHDWPHQWGD\V
WRSLFDO.;KDVPLQLPDOV\VWH PLFH[SRVXUHDQGLVQRWOLNHO\ WRKDYHWKHVDPHWR[LFLW\
SURILOHDVRUDO.;
 .;DVD7RSLFDO7UHDWPHQWIRU$FWLQLF.HUDWRVLV
7RGDWHFOLQLFDOVWXGLHVKDY HEHHQFRQGXFWHGWRHYDOXDWHWKH  DFWLYLW\ DQG VDIHW\ RI
.;2LQWPHQWLQVXEMHFWVZLWK$.
6WXG\ .;$.86 D 3KDVH  VDIHW\ WROHUDELOLW\ DQG SKDUPDFRNLQHWLF VWXG\
GHPRQVWUDWHGWKDW.;2LQWPH QWZDVZHOOWR OHUDWHGDQGVK RZHGFOLQLFDODFWLYLW\LQ
DGXOWV ZLWK $. RQ GRUVDO IRUHDUP ZKHQ JLYHQ DW  RU PJ GDLO\ RYHU  RU
FRQVHFXWLYHGD\VLQDQDUHDRIRUFP0RVWVXEMHFWVH[SHULHQFHGPLOGWRPRGHUDWH
DQGWUDQVLHQWORFDOVNLQUHDFWLRQV/65V7KHPDMRULW\RIWKH /65VREVHUYHGZHUHHU\WKHPD
DQGIODNLQJVFDOLQJWKDWSHDNHGDURXQG'D\EHIRUHUHWXUQL QJWRRUFORVHWREDVHOLQH
6\PSWRPVRISUXULWXVVWLQJLQJDQGEXUQLQJDWWKHWUHDWPHQWDU HDZHUHJHQHUDOO\PLOGDQG
WUDQVLHQW  7KHUH ZHUH QR VHULRXV DGYHUVH HYHQWV 6$(V RU GHDWKV DQG QR VXEMHFWV
GLVFRQWLQXHGGXHWRDQDGY HUVHHYHQW$(
6WXG\.;$. DQRQJRLQJ3KDVHDRSHQODEH OVHTXHQWLDOJURXSVWXG\HYDO XDWHG
WKHDFWLYLW\DQGVDIHW\RI.; 2LQWPHQWZKHQDSSOLHGGDL O\LQDWUHDWPHQWDUHDRI
FPIRUFRQVHFXWLYHGD\VQ VXEM HFWVRUFRQVHFXWLYHGD\V Q VXEMHFWVLQDGXOWV
ZLWK$.RQIDFHRUVFDOS3UHOLPLQDU\GDWDVKRZHGWKDWPRVWRI WKHVXEMHFWVWUHDWHGKDG
PLOGWRPRGHUDWH/65VSULPDULO\HU\WKHPDDQGIODNLQJVFDOLQJ (OHYHQVXEMHFWVKDG
 WUHDWPHQWHPHUJHQW DGYHUVH HYHQWV 7($(V FRQVLGHUHG WUHDWPH QWUHODWHG E\ WKH
,QYHVWLJDWRU(LJKWRIWKHVHVXEMHFWVKDGPLOGDSSOLFDWLRQVLW HUHDFWLRQVLQFOXGLQJSUXULWXV
WHQGHUQHVVRUVWLQJLQJ7KHUHPDLQLQJ$(VFRQVLGHUHGE\WKH, QYHVWLJDWRUWREHWUHDWPHQW
UHODWHGZHUHPLOGKHDGDFKHPLOGWRPRGHUDWHGL]]LQHVVPLOGDU WKUDOJLDRUPLOGGDUNHQLQJRI
KDLU FRORU QHDU WKH WUHDWPHQW DUHD  $OO WUHDWPHQWUHODWHG 7($( V UHVROYHG SULRU WR RU
VWDELOL]HGE\'D\)RXUVXEMHFW VUHSRUWHGWUHDWPHQWHPHUJ HQW6$(V$OO6$(VZHUH
FRQVLGHUHGXQUHODWHGWRVWXG\GU XJ1RVXEMHFWGLVFRQWLQXHGWU HDWPHQWGXHWR$(V
7KLUW\VL[RIVXEMHFWVLQWKHGD\UHJLPHQDQGRI VXEMHFWVLQWKH
GD\UHJLPHQKDGFOHDUDQFHRI $.OHVLRQVLQWKHWUHDWPHQW DUHDRQ'D\
3ODVPDFRQFHQWUDWLRQVRI.;ZHUHPHDVXUHGLQ6WXG\.;$. XVLQJDYDOLGDWHG
OLTXLGFKURPDWRJUDSK\WDQGHPPDVVVSHFWURPHWU\/&0606DVVD\ ZLWKDORZHUOLPLWRI
TXDQWLILFDWLRQ//24RIQJP/3KDUPDFRNLQHWLFUHVXOWVVK RZHGWKDWIROORZLQJRU
FRQVHFXWLYH GD\V RI WUHDWPHQW ZLWK .; 2LQWPHQW ORZ V \VWHPLF H[SRVXUH
QJP/DQGOLPLWHGGUXJDFFX PXODWLRQZHUHREVHUYHG
'HWDLOVRIERWKVWXGLHV DUHDYDLODEOHLQW KH.;2LQWPHQW, QYHVWLJDWRU¬∂V%URFKXUH
 6WXG\5DWLRQDOH
$FWLQLF NHUDWRVLV UHSUHVHQWV WKH LQLWLDO LQWUDHSLGHUPDO PDQLIH VWDWLRQ RI DEQRUPDO
NHUDWLQRF\WHSUROLIHUDWLRQKDYLQJ WKHSRWHQWLDOWRSURJUHVVWR VTXDPRXVFHOOFDUFLQRPD6&&
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
6TXDPRXVFHOOFDUFLQRPDLVWKH VHFRQGOHDGLQJFDXVHRIVNLQFDQ FHUGHDWKVLQWKH86ZLWK
XSWRRI6&&DULVLQJIURPSUHH[LVWLQJDFWLQLFNHUDWRVHV7KHULVNRISURJUHVVLRQKDV
EHHQGHWHUPLQHGWREHEHWZHHQDQGSHU\HDUDQGWKHFDOFXODWHGOLIHWLPHULVN
RIPDOLJQDQWWUDQVIRUPDWLRQIR UDSDWLHQWZLWK$.OHVLRQVIROOR ZHGXSIRU\HDUVLV
EHWZHHQDQG7KHUDWLRQDOHEHKLQGWUHDWLQJHYHU\$.OHVLRQLVEDVHGRQWKH
GLIILFXOW\LQSUHGLFWLQJ ZKLFKVLQJOH$.OHVLRQZLOOSURJUHVVW R6&&7KH JRDORI
WUHDWPHQWLVWRFRPSOHWHO\HOLPLQDWH$.OHVLRQVWKHUHE\PLQLPL ]LQJWKHLUULVNRISURJUHVVLRQ
WRLQYDVLYH6&&DQGUHGXFLQJWK HSRWHQWLDOWRPHWDVWDVL]HDQG FDXVHGHDWKZKLOHREWDLQLQJ
WKHEHVWFRVPHWLFRXWFRPHV
 3RWHQWLDO5LVNVDQG%HQHILWV
3UHOLPLQDU\UHVXOWVRIVWXGLHV.;$.86DQG.;$.LQ GLFDWHWKDW.;
2LQWPHQWDGPLQLVWHUHGRQFHGDLO\IRUXSWRGD\VGHPRQVWUDW HVFOLQLFDOO\UHOHYDQW
DFWLYLW\LQWKHWUHDWPHQWRI$.OHVLRQVRQERWKWKHIDFHDQGVF DOSDVZHOODVRQWKHGRUVDO
IRUHDUP'DWDIURP.;$.VXJJHVWWKDWWKHGD\UHJLPHQ RI.;2LQWPHQW
KDVJUHDWHUDFWLYLW\ WKDQWKHGD\UHJLPHQ
3UHOLPLQDU\VDIHW\UHVXOWVIURPERWKVWXGLHVVKRZHGWKDW.; 2LQWPHQWLVVDIHDQG
ZHOOWROHUDWHG(YHQWKRXJK/65VSULPDULO\HU\WKHPDDQGRUIO DNLQJVFDOLQJZHUHUHSRUWHG
E\WKHPDMRULW\RIWUHDWHGVXEMHFWVWKH\ZHUHJHQHUDOO\PLOGR UPRGHUDWHLQVHYHULW\DQG
PRVWO\WUDQVLHQW7KHWUHDWPH QWUHODWHG7($(VWKDWVXEMHFWVH[ SHULHQFHGPDLQO\FRQVLVWHGRI
PLOGDSSOLFDWLRQVLWHUHDFWLRQVVXFKDVLWFKLQJEXUQLQJVWLQJ LQJWHQGHUQHVVDQGSDLQ1R
VXEMHFWVGLVFRQWLQXHGWUHDWPHQW GXHWR$(VDQGQRWUHDWPHQWUHO DWHG6$(VZHUHUHSRUWHG
%DVHGRQWKHVHILQGLQJVWKHFOLQLFDOEHQHILWRIWUHDWLQJDFWLQ LFNHUDWRVLVDSUHFDQFHURXV
FRQGLWLRQZLWKDVKRUWFRXUVHR IWRSLFDO.;RXWZHLJKVWKH ULVNRIWUDQVLHQW/65V
REVHUYHG
$WV\VWHPLF.;FRQFHQWUDWLRQVWKDWZHUHVLJQLILFDQWO\KLJK HUWKDQWKRVHREVHUYHG
IROORZLQJWRSLFDODGPLQLVWUDWLRQLQKXPDQV.;ZDVDVVRFLD WHGZLWKWHVWLFXODUWR[LFLW\
LQPXOWLSOHGRVHQRQFOLQLFDOWR[LFLW\VWXGLHVLQDQLPDOV$VD SUHFDXWLRQPDOHVXEMHFWVPXVW
DJUHHWRSUDFWLFHPHGLFDOO\DFFHSWDEOHFRQWUDFHSWLRQGXULQJVWX G\SDUWLFLSDWLRQDQGIRUDW
OHDVWGD\VDIWHUVWRSSLQJWUHDWPHQW
 678'<2%-(&7,9(6$1'(1'32,176
 3ULPDU\2EMHFWLYHDQG(QGSRLQW
7KHSULPDU\REMHFWLYHRIWKHVWXG\LVWRHYDOXDWHWKHHIILFDF\ RIWRSLFDO.;2LQWPHQW
RQFHGDLO\IRUFRQVHFXWLYHGD\V FRPSDUHGWRYHKLFOHFRQWUR OLQWHUPVRI
FOHDUDQFHDW'D\LQWKHWUHDWPHQWRIDGXOWVZLWK$.ZKHQDS SOLHGWRDFRQWLJXRXVDUHDRI
FPRQWKHIDFHRUVFDOS
7KHSULPDU\HQGSRLQWZLOOEHFRPSOHWHFOHDUDQFHUDWHRI $.OHVLRQVGHILQHGDVWKH
SURSRUWLRQRIVXEMHFWVDW'D\Z LWKQRFOLQLFDOO\YLVLEOH$. OHVLRQVLQWKHWUHDWPHQWDUHD
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 6HFRQGDU\2EMHFWLYHVDQG(QGSRLQWV
7KHVHFRQGDU\REMHFWLYHVRIWKHVWXG\DUH
x7RHYDOXDWHWKHVDIHW\RIWRSL FDO.;2LQWPHQWRQFHGDLO \IRUFRQVHFXWLYH
GD\VLQWHUPVRI/65VDQGRWKHU VDIHW\HYDOXDWLRQVVXFKDV$(V DQGODERUDWRU\
DVVHVVPHQWV
x7RFRPSDUHWKHUDWHVRISDUWLDOUHVSRQGHUVGHILQHGDV¬ïFOHD UDQFHRI$.OHVLRQV
LQWKHWUHDWPHQWDUHDRQWKHIDFHRUVFDOSDW'D\EHWZHHQWK H.;2LQWPHQW
WUHDWHGJURXSDQGYHKLFOHWUHDWHGJURXS
x7RHYDOXDWHWKHUHGXFWLRQLQ $.OHVLRQVFRXQWVIURP'D\WKURX JK'D\
x7RGHWHUPLQHWKHUHFXUUHQFHRI$ .LQWKHWUHDWPHQWDUHDXSWR PRQWKVSRVW'D\
LQVXEMHFWVZKRKDGFRPSO HWHFOHDUDQFHDW'D\DIWHUFRQVHF XWLYHGD\VRI
WUHDWPHQWZLWK.; 2LQWPHQW
x7RHYDOXDWHWKHVDIHW\RIWRSLFDO.;2LQWPHQWZLWKLQWK HWUHDWPHQWDUHD
GXULQJWKH5HFXUUHQFH)ROORZXS3HULRG
7KHVHFRQGDU\HQGSRLQWVDUH
x(YDOXDWLRQRI/65VSLJPHQWDWLRQ DQGVFDUULQJLQWKHWUHDWPHQW DUHD$(V6$(V
HYHQWVRIVSHFLDOLQWHUHVWFOLQLFDOODERUDWRU\GDWDDQGRWKHU VDIHW\DVVHVVPHQWVYLWDO
VLJQVSK\VLFDOH[DPLQDWLRQV>3( V@HOHFWURFDUGLRJUDPV>(&*V@ 
x3DUWLDOFOHDUDQFHUDWHRI$.OHVL RQVGHILQHGDVWKHSURSRUWLRQ RIVXEMHFWVDW'D\
ZLWKD¬ïUHGXFWLRQLQWKHQXPEHURI$.OHVLRQVLGHQWLILHGDW %DVHOLQH'D\
SUHGRVHLQWKHWUHDWPHQWDUHD 
x5HGXFWLRQLQ$.OHVLRQFRXQWVGXULQJ'D\VWKURXJK
x5HFXUUHQFHUDWHRI$.OHVLRQVL QVXEMHFWVZKRDFKLHYHGFRPSOHWH FOHDUDQFHDW'D\
x$(VZLWKLQWKHWUHDWPHQWDU HDDIWHU'D\XSWRPRQWKVSRVW 'D\
 ,19(67,*$7,21$/3/$1
 2YHUDOO6WXG\'HVLJQDQG3ODQ
7KLVLVDGRXEOHEOLQGYHKLFOH FRQWUROOHGUDQGRPL]HGSDUDOOH OJURXSPXOWLFHQWHUVWXG\WR
HYDOXDWHWKHHIILFDF\DQGVDIHW\RI.;2LQWPHQWDGPLQLV WHUHGWRSLFDOO\RQWKHIDFH
RUVFDOSRIDGXOWVXEMHFWVZLWK$.
(QUROOPHQWZLOOEHFRQWUROOHGVRWKDWDSSUR[LPDWHO\WZRWKLUGV RIVXEMHFWVHQUROOHGZLOOEH
WUHDWHGRQWKHIDFHDQGDSSUR[LPDWHO\RQHWKLUGRIVXEMHFWVHQU ROOHGZLOOEHWUHDWHGRQWKH
VFDOS  $ VXIILFLHQW QXPEHU RI VXEMHFWV ZLOO EH VFUHHQHG WR UDQ GRPL]H DSSUR[LPDWHO\
VXEMHFWV$WHDFKVLWHDPLQLPXPRIVXEMHFWVDQGDPD[ LPXPRIVXEMHFWVDUH
SURMHFWHGWREHHQUROOHG
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
7KH VWXG\ FRQVLVWV RI 6FUHHQLQJ 7UHDWPHQW D 5HVSRQVH $VVHVVPH QW 3HULRG DQG D
5HFXUUHQFH)ROORZXS3HULRG$IWHUD6FUHHQLQJ3HULRGRIXSWR GD\VVXEMHFWVZLOOUHWXUQ
WRWKHVLWHIRUFRQILUPDWLRQRIHOLJLELOLW\(OLJLEOHVXEMHFWV ZLOOEHUDQGRPL]HGRQ'D\WR
WUHDWPHQWLQD.;2LQWPH QWRUYHKLFOHUDWLRLQHD FKWUHDWPHQWDUHDVXEJURXS
7KHWUHDWPHQWDUHDZLOOEHPDUNHGZLWKLQGHOLEOHPDUNHUDW%DVH OLQH'D\SUHGRVHDWWKH
LQYHVWLJDWLRQDO VLWH  6XEMHFWV ZLOO EH JLYHQ YHUEDO DQG ZULWWH Q LQVWUXFWLRQV RQ VHOI
DGPLQLVWUDWLRQRIVWXG\GUXJYHKLFOHDQGDVWXG\NLWFRQWDLQLQJ GDLO\VLQJOHGRVHSDFNHWV
RQHIRUHDFKGD\RIWUHDWPHQW7 KHILUVWGRVHZLOOEHDSSOLHG E\WKHVXEMHFWXQGHUWKH
VXSHUYLVLRQRIVWXG\VLWHSHUVRQQHO6XEMHFWVZLOOWKHQWDNHK RPHWKHVWXG\NLWFRQWDLQLQJWKH
UHPDLQLQJ VLQJOHGRVH SDFNHWV RI VWXG\ GUXJ IRU GDLO\ VHOIDGPL QLVWUDWLRQ RQ WKH QH[W
FRQVHFXWLYHGD\V
6XEMHFWVZLOOUHWXUQWRWKHFOLQLFDOVLWHVIRUDVVHVVPHQWVDWW KH5HVSRQVH$VVHVVPHQW9LVLWVDW
'D\VDQG
$OOVXEMHFWVZKRKDYHXQUHVROYHG /65VK\SRRUK\SHUSLJPHQWD WLRQVFDUULQJLQWKH
WUHDWPHQWDUHDRUWUHDWPHQWUHODWHG$(VDW'D\ZLOOUHWXUQ IRUDGGLWLRQDOIROORZXSHYHU\
WRGD\VXQWLOUHVROXWLRQUHWXUQHGWREDVHOLQHRUGHHPHG VWDELOL]HGE\WKH,QYHVWLJDWRUV
6XEMHFWVZKRDFKLHYHFOHDUDQ FHRI$.OHVLRQVLQWKHWUHDWP HQWDUHDDW'D\ZLOO
FRQWLQXHLQWKH5HFXUUHQFH)ROORZXS3HULRGWRGHWHUPLQHUHFXUU HQFHUDWHDQGVDIHW\IRUXS
WRPRQWKVIROORZLQJWKH'D\9LVLW9LVLWVGXULQJWKH5HF XUUHQFH)ROORZXS3HULRGZLOO
RFFXUHYHU\PRQWKV6XEMHFWVZ KRGHYHORS$.OHVLRQVLQWKHW UHDWPHQWDUHDGXULQJWKH
5HFXUUHQFH)ROORZXS3HULRGZLOO EHGLVFRQWLQXHGDWWKHWLPHRI UHFXUUHQFH
$QRYHUYLHZRIWKHVWXG\GHVLJQLVSUHVHQWHGLQ )LJXUH
&OLQLFDO6WXG\3URWRFRO .;$.
$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI)LJXUH 6WXG\'HVLJQIRU.;$.
 6FUHHQLQJ3HULRG
6FUHHQLQJ9LVLWZLOORFFXUEHWZHHQ'D\¬±DQG'D\¬±6XE MHFWHOLJLELOLW\ZLOOEH
HVWDEOLVKHGGXULQJWKH6FUHHQLQJ3HULRG
'HWDLOVRIVFUHHQLQJSURFHGXUHV DVVHVVPHQWVDUHSURYLGHGLQ 6HFWLRQ 
 7UHDWPHQW3HULRG
7KH7UHDWPHQW3HULRGZLOOEH'D\VWR3URWRFROHOLJLELOLW\ ZLOOEHFRQILUPHGDW%DVHOLQH
'D\SUHGRVH
$OO VFUHHQLQJ DQG EDVHOLQH DVVH VVPHQWV VKRXOG EH HYDOXDWHG IRU DFFHSWDELOLW\ SULRU WR
UDQGRPL]DWLRQRIWKHVXEMHFW (OLJLEOHVXEMHFWVZLOOEHUDQGRP L]HGVHSDUDWHO\IRUIDFHDQG
VFDOSWRWUHDWPHQWLQDUDWL RRI.;2LQWPHQWRUYHK LFOHVHH6HFWLRQ 
%DVHOLQHDQG7UHDWPHQW3HULRGSU RFHGXUHVDQGDVVHVVPHQWVDQGW LPLQJWKHUHRIDUHVKRZQLQ
7DEOHGHWDLOVDUHSURYLGHGLQ 6HFWLRQ DQG6HFWLRQ UHVSHFWLYHO\
 5HVSRQVH$VVHVVPHQW3HULRG
6XEMHFWVZLOOUHWXUQWRWKHFOLQLFDOVLWHVIRU5HVSRQVH$VVHVVP HQW9LVLWVSRVWGRVHRQ'D\
9LVLWDQGRQ'D\VDQG9LVLWVWKURXJK3 URFHGXUHVDQGDVVHVVPHQWVDQG

&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
WLPLQJWKHUHRIGXULQJWKH5HVSRQVH$VVHVVPHQW3HULRGDUHVKRZQ LQ7DEOHDQGWKHGHWDLOV
DUHSURYLGHGLQ 6HFWLRQ 
$OO VXEMHFWV ZKR KDYH XQUHVROYHG /65V K\SR RU K\SHUSLJPHQWDW LRQ VFDUULQJ LQ WKH
WUHDWPHQWDUHDRUWUHDWPHQWUHODWHG$(VDW'D\ZLOOUHWXUQ IRUDGGLWLRQDOIROORZXSHYHU\
WRGD\VXQWLOUHVROXWLRQUHWXUQHGWREDVHOLQHRUGHHPHG VWDELOL]HGE\WKH,QYHVWLJDWRUV
 5HFXUUHQFH)ROORZXS3HULRG
6XEMHFWVZKRDFKLHYHFOHDUDQFHRI$.OHVLRQVLQWKHWUHDWP HQWDUHDDW'D\ZLOOEH
HOLJLEOHWRFRQWLQXHLQWKH5HFXUUHQFH)ROORZXS3HULRGWRGHWH UPLQH$.UHFXUUHQFHUDWHV
DQGHYDOXDWHFRQFRPLWDQWPHGLFDWLRQVDQG$(VLQWKHWUHDWPHQWD UHDIRUXSWRPRQWKV
SRVW'D\
3URFHGXUHVDQGDVVHVVPHQWVDQGWLPLQJWKHUHRIGXULQJWKH5HFXUU HQFH)ROORZXS3HULRGDUH
VKRZQLQ7DEOHDQGWKHGHWDLOVDUHSURYLGHGLQ 6HFWLRQ 6XEMHFWVZKRGHYHORS$.
OHVLRQVLQWKHWUHDWPHQWDUHDGXULQJWKH5HFXUUHQFH)ROORZXS3 HULRGZLOOEHGLVFRQWLQXHGDW
WKHWLPHRIUHFXUUHQFH 
 'LVFXVVLRQRI6WXG\'HVLJQ,QFOXGLQJ&KRLFHRI'RVLQJDQG
&RQWURO*URXSV
7KLVLVDPXOWLFHQWHUUDQGRPL]HGGRXEOHEOLQGYHKLFOHFRQWUR OOHGSDUDOOHOJURXSHIILFDF\
DQGVDIHW\VWXG\RI.;2LQWPHQWDGPLQLVWHUHGWRSLFDOO\ RQWKHIDFHRUVFDOSRI
DGXOWVXEMHFWVZLWK$.IRUFRQVHFXWLYHGD\V
7KH GRVLQJ UHJLPHQ IRU WKLV VWXG\ LV EDVHG RQ WKH 3KDVH D VWXG \ .;$.
.;$.LVDQRSHQODEHOV HTXHQWLDOJURXSQRQUDQGRPL]HG PXOWLFHQWHUVWXG\WKDW
HYDOXDWHGWKHGRVLQJUHJLPHQRIGDLO\GRVLQJIRUHLWKHURU FRQVHFXWLYHGD\VRI.;
2LQWPHQWRQDWUHDWPHQWDUHDRIFPRQWKHIDFHRUVFDOSWKDWFRQWDLQHGWR$.
OHVLRQVLQDGXOWVVXEMHFW VSHUFRKRUW3UHOLPLQDU\DQ DO\VHVVKRZHGWKDWDKLJKHU
SHUFHQWDJHRIVXEMHFWVDFKLHYHGFRPSOHWHFOHDUDQFHRI$.RQ'D\ IRUWKHGD\WUHDWPHQW
JURXSWKDQWKHGD\WUHDWPHQWJURXS)RUERWKWKH GD\DQGGD\WUHDWPHQW
JURXSV.;2LQWPHQWZDV IRXQGWREHVDIHZHOOWROHUDWH GDQGPLQLPDOO\DEVRUEHG
WKURXJKRXWWUHDWPHQWDQGIROORZXSIRUERWKFRKRUWV7KXVWKH VHGDWDVXSSRUWWKHHYDOXDWLRQ
RI.;2LQWPHQWRQFHGDLO\WRSLFDODSSOLFDWLRQIRUDF RQVHFXWLYHGD\GRVLQJ
UHJLPHQIRUWKHWUHDWPHQWRIDGXOWVZLWK$.RQWKHIDFHRUVFDO SLQWKLV3KDVHGRXEOHEOLQG
YHKLFOHFRQWUROOHGVWXG\7KH PRQWK5HFXUUHQFH)ROORZXS3H ULRGDOORZVIRUORQJWHUP
HYDOXDWLRQRI$.UHFXUUHQFHUDWHVDQGVDIHW\
 678'<3238/$7,21
(OLJLEOHVXEMHFWVZLOOEHDGXOWV¬ï\HDUVRIDJHZLWKDGLDJ QRVLVRIFOLQLFDOO\W\SLFDO$.
RQWKHIDFHRUVFDOS
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
$VXIILFLHQWQXPEHURIVXEMHFWVZLOOEHVFUHHQHGWRUDQGRPL]HD SSUR[LPDWHO\VXEMHFWVDW
DSSUR[LPDWHO\WRVLWHV$ PLQLPXPRIVXEMHFWVDQGDP D[LPXPRIVXEMHFWVDUH
SURMHFWHGWREHHQU ROOHGDWHDFKVLWH
 ,QFOXVLRQ&ULWHULD
6XEMHFWVPXVWPHHWDOOWKHIROORZLQJFULWHULDWREHLQFOXGHGLQ WKLVVWXG\
0DOHVDQGIHPDOHV¬ï\HDUVROG
$WUHDWPHQWDUHDRQWKH IDFHRUVFDOSWKDW
xLVDFRQWLJXRXVDUHDPHDVXULQJFP
xFRQWDLQVWRFOLQLFDOO\W\SL FDOYLVLEOHDQGGLVFUHWH$.OH VLRQV
6XEMHFWVZKRLQWKHMXGJPHQWRIW KH,QYHVWLJDWRUDUHLQJRRGJ HQHUDOKHDOWKEDVHGRQ
xPHGLFDOKLVWRU\
xSK\VLFDOH[DPLQDWLRQ3(ILQGLQJV
xYLWDOVLJQV
x(&*VFOLQLFDOFKHPLVWU\KHPDWR ORJ\DQGXULQDO\VLVUHVXOWV  
)HPDOHV PXVW EH SRVWPHQRSDXVDO !  \HDUV RI DJH ZLWK DW OHDVW PRQWKV RI
DPHQRU[LOCATION_006]HD VXUJLFDOO\ VWHULOH E\ K\VWHUHFWRP\ ELODWHUDO RRS KRUHFWRP\ RU WXEDO
OLJDWLRQRULIRIFKLOGEHDULQJSRWHQWLDOPXVWEHXVLQJKLJK O\HIIHFWLYHFRQWUDFHSWLRQIRU
DWOHDVWGD\VRUPHQVWUXDOF\FOHZKLFKHYHULVORQJHUSUL RUWRVWXG\WUHDWPHQWDQG
PXVWDJUHHWRFRQWLQXHWRXVHKLJKO\HIIHFWLYHFRQWUDFHSWLRQIR UDWOHDVWGD\VIROORZLQJ
WKHLUODVWGRVHRIVWXG\WUHDWPH QW+LJKO\HIIHFWLYHFRQWUDFHS WLRQLQFOXGHVRUDOKRUPRQDO
FRQWUDFHSWLYHVKRUPRQDOFRQWUD FHSWLYHLPSODQWLQMHFWLRQRUSD WFKLQWUDXWHULQHGHYLFHRU
FRPSOHWHDEVWLQHQFHIUR PVH[XDOLQWHUFRXUVH
6H[XDOO\ DFWLYH PDOHV ZKR KDYH QRW KDG D YDVHFWRP\ DQG ZKRVH S DUWQHU LV
UHSURGXFWLYHO\FDSDEOHPXVWDJUHHWRXVHEDUULHUFRQWUDFHSWLRQ IURP6FUHHQLQJWKURXJK
GD\VDIWHUWKHLUODVWGRVHRIVWXG\WUHDWPHQW
$OO VXEMHFWV PXVW DJUHH QRW WR GRQDWH VSHUP RU HJJV RU DWWHPSW FRQFHSWLRQ IURP
6FUHHQLQJWKURXJKGD\VIROORZLQJ WKHLUODVWGRVHRIVWXG\WU HDWPHQW
)HPDOHV RI FKLOGEHDULQJ SRWHQWLDO PXVW KDYH D QHJDWLYH VHUXP SU HJQDQF\ WHVW DW
6FUHHQLQJDQGDQHJDWLYHXULQH SUHJQDQF\WHVWRQ'D\SULRUWR UDQGRPL]DWLRQ
:LOOLQJWRDYRLGH[FHVVLYHVXQOLJKWRUXOWUDYLROHW89OLJKWH [SRVXUHLQFOXGLQJWKHXVH
RIWDQQLQJEHGVWRWKHIDFHRUVFDOS
$EOHWRFRPSUHKHQGDQGDUHZLOOLQJWRVLJQWKHLQIRUPHGFRQVHQW IRUP,&)
 ([FOXVLRQ&ULWHULD
6XEMHFWVZKRPHHWDQ\RIWKHIROOR ZLQJFULWHULDZLOOEHH[FOXGH GIURPWKLVVWXG\
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
&OLQLFDOO\ DW\SLFDO DQGRU UDSLGO\ FKDQJLQJ $. OHVLRQV RQ WKH W UHDWPHQW DUHD HJ
K\SHUWURSKLF K\SHUNHUDWRWLF UHFDOFLWUDQW GLVHDVH KDG FU\RVXU JHU\ RQ WZR SUHYLRXV
RFFDVLRQVDQGRUFXWDQHRXVKRUQ
/RFDWLRQRIWKHWUHDWPHQWDUHDLV
x2QDQ\ORFDWLRQRWKHUWK DQWKHIDFHRUVFDOS
x:LWKLQFPRIDQLQFRPSOHWHO\KHDOHGZRXQG
x:LWKLQFPRIDVXVSHFWHGED VDOFHOOFDUFLQRPD%&&RU6&&
%HHQSUHYLRXVO\WUHDWHGZLWK.;2LQWPHQW
$QWLFLSDWHGQHHGIRULQSDWLHQW KRVSLWDOL]DWLRQRU LQSDWLHQWV XUJHU\IURP'D\WR'D\
7UHDWPHQW ZLWK IOXRURXUDFLO ) 8 LPLTXLPRG LQJHQRO PHEXWD WH GLFORIHQDF
SKRWRG\QDPLFWKHUDS\RURWKHUW UHDWPHQWVIRU$.ZLWKLQWKHWUH DWPHQWDUHDRUZLWKLQ
FPRIWKHWUHDWPHQW DUHDZLWKLQZHHNVSULRUWRWKH6FUHHQL QJYLVLW
8VHRIWKHIROORZLQJWKHUDSLHV DQGRUPHGLFDWLRQVZLWKLQZHHN VSULRUWRWKH6FUHHQLQJ
YLVLW
x&RVPHWLFRUWKHUDSHXWLFSURFHGXUHVHJXVHRIOLTXLGQLWURJHQ VXUJLFDOH[FLVLRQ
FXUHWWDJHGHUPDEUDVLRQPHGLXPRUJUHDWHUGHSWKFKHPLFDOSHHO ODVHUUHVXUIDFLQJ
ZLWKLQWKHWUHDWPHQWDUHDRU  ZLWKLQFPRIWKHVHO HFWHGWUHDWPHQWDUHD
x$FLGFRQWDLQLQJWKHUDSHXWLFSU RGXFWVHJVDOLF\OLFDFLGRUIUX LWDFLGVVXFKDVDOSKD
DQGEHWDK\GUR[\ODFLGVDQGJO\FROLFDFLGVWRSLFDOUHWLQRLGV RUOLJKWFKHPLFDOSHHOV
ZLWKLQWKHWUHDWPHQWDUHDRU  ZLWKLQFPRIWKHVHOHF WHGWUHDWPHQWDUHD
x7RSLFDOVDOYHVQRQPHGLFDWHG QRQLUULWDQWORWLRQDQGFUHDPDUH DFFHSWDEOHRUWRSLFDO
VWHURLGVZLWKLQWKHWUHDWPHQWDUHDRU  ZLWKLQFPRIWKHVHOHFWHGWUHDWPHQWDUHD
DUWLILFLDOWDQQHUVZLWKLQWKHWUHDWPHQWDUHDRU  ZLWKLQFPRIWKHVHOHFWHGWUHDWPHQW
DUHD
8VHRIWKHIROORZLQJWKHUDSLHV DQGRUPHGLFDWLRQVZLWKLQZHHN VSULRUWRWKH6FUHHQLQJ
YLVLW
x7UHDWPHQW ZLWK LPPXQRPRGXODWRUV HJ D]DWKLRSULQH F\WRWR[LF G UXJV HJ
F\FORSKRVSKDPLGHYLQEODVWLQHFKORUDPEXFLOPHWKRWUH[DWHRUL QWHUIHURQVLQWHUIHURQ
LQGXFHUV
x7UHDWPHQW ZLWK V\VWHPLF PHGLFDWLRQV WKDW VXSSUHVV WKH LPPXQH V\ VWHP HJ
F\FORVSRULQHSUHGQLVRQHPHWKRW UH[DWHDOHIDFHSWLQIOL[LPDE
8VHRIV\VWHPLFUHWLQRLGVHJ LVRWUHWLQRLQDFLWUHWLQEH[DURW HQHZLWKLQPRQWKVSULRUWR
WKH6FUHHQLQJYLVLW
$KLVWRU\RIVHQVLWLYLW\DQGRUDOOHUJ\WRDQ\RIWKHLQJUHGLHQ WVLQWKHVWXG\PHGLFDWLRQ
$VNLQGLVHDVHHJDWRSLFGHUPDWLWLVSVRULDVLVHF]HPDRUFR QGLWLRQHJVFDUULQJRSHQ
ZRXQGVWKDWLQWKHRSLQLRQRIW KH,QYHVWLJDWRUPLJKWLQWHUIH UHZLWKWKHVWXG\FRQGXFWRU
HYDOXDWLRQVRUZKLFKH[SRVHVW KHVXEMHFWWRXQDFFHSWDEOHULVN E\VWXG\SDUWLFLSDWLRQ
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
2WKHUVLJQLILFDQWXQFRQWUROOHGRUXQVWDEOHPHGLFDOGLVHDVHVRU FRQGLWLRQVWKDWLQWKH
RSLQLRQRIWKH,QYHVWLJDWRUZRXOGH[SRVHWKHVXEMHFWWRXQDFFH SWDEOHULVNE\VWXG\
SDUWLFLSDWLRQ
)HPDOHVZKRDUHSUHJQDQWRUQXUVLQJ
3DUWLFLSDWHG LQ DQ LQYHVWLJDWLRQDO GUXJ WULDO GXULQJ ZKLFK DQ L QYHVWLJDWLRQDO VWXG\
PHGLFDWLRQZDVDGPLQLVWHUHGZLWKLQGD\VRUKDOIOLYHVRIW KHLQYHVWLJDWLRQDOSURGXFW
ZKLFKHYHULVORQJHUEHIRUHGRVLQJ
 6XEMHFW:LWKGUDZDO'LVFRQWLQXDWLRQ&ULWHULD
7KH,QYHVWLJDWRUPD\ZLWKGUDZDVXEMHFWIURPVWXG\WUHDWPHQWRU ZLWKGUDZWKHVXEMHFWIURP
WKHVWXG\DWDQ\WLPHIRUVDIHW\RUDGPLQLVWUDWLYHUHDVRQV7K HVXEMHFWPD\GHFLGHWR
GLVFRQWLQXHVWXG\WUHDWPHQWRUZLWKGUDZIURPWKHVWXG\DWDQ\W LPHIRUDQ\UHDVRQ7KH
,QYHVWLJDWRUPXVWGRFXPHQWWKHUHDVRQIRUGLVFRQWLQXLQJDVXEMH FWIURPWUHDWPHQWRUIURPWKH
VWXG\LINQRZQRUZK\WKHVXEMHFW ZLWKGUHZFRQVHQWLIDSSOLFD EOH6XEMHFWGLVSRVLWLRQ
LQIRUPDWLRQZLOOEHFROOHFWHGRQWKH HOHFWURQLFFDVHUHSRUWIRU PH&5)
6XEMHFWVZKRGRQRWFRPSOHWHGD \VRIWUHDWPHQWDQGZLWKGUDZI URPVWXG\WUHDWPHQWIRU
UHDVRQVRWKHUWKDQGHDWKRUZLWKGUDZDORIFRQVHQWZLOOEHHQFR XUDJHGWRFRQWLQXHWKH
SRVWWUHDWPHQWYLVLWV$WWKHWLPHRIZLWKGUDZDOIURPWKHVWXG \WKHVXEMHFWVKRXOGFRPSOHWH
WKHHDUO\WHUPLQDWLRQDVVHVVPHQWV'D\DVVHVVPHQWV 7DEOH$VXEMHFWZKRGRHVQRW
UHWXUQIRUWKHSRVWWUHDWPHQWYLVLWVZLOOEHIROORZHGXSE\PDL OSKRQHRURWKHUPHDQVWR
JDWKHULQIRUPDWLRQVXFKDVWKH UHDVRQIRUIDLOXUHWRUHWXUQWK HSUHVHQFHRUDEVHQFHRI$(V
DQGFOLQLFDOFRXUVHVRIVLJQVD QGV\PSWRPV7KLVLQIRUPDWLRQZ LOOEHUHFRUGHGLQWKHH&5)
6XEMHFWVZKRGLVFRQWLQXHHDUO\ IURPWKHVWXG\ZLOOEHGLVFRQWLQ XHGIRURQHRIWKHVHSULPDU\
UHDVRQV
x$(V
x/RVWWRIROORZXS
x:LWKGUDZDORIFRQVHQWVXEMHFWV ZLOOEHDVNHGEXW QRWUHTXLUHG WRSURYLGHDUHDVRQ
x6WXG\WHUPLQDWHGE\6SRQVRU
x1RQFRPSOLDQFHVSHFLI\
x$.UHFXUUHQFHGXULQJWKH5HFXUU HQFH)ROORZXS3HULRGSULRUWRW KHPRQWKYLVLW
x,QYHVWLJDWRUGHFLVLRQVSHFLI\
x'HDWK
x2WKHUVSHFLI\
6XEMHFWVZKRGRQRWDFKLHYHFOHDUDQFHRI$.OHVLRQVLQWKH WUHDWPHQWDUHDDW'D\
ZLOOEHFRQVLGHUHGWRKD YHFRPSOHWHGWKHLU SDUWLFLSDWLRQLQWKH VWXG\
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 678'<75($70(176
 ,GHQWLW\RI6WXG\'UXJV
7UHDWPHQWVDGPLQLVWHUHGZLOOEH WRSLFDO.;2LQWPHQWDQG YHKLFOHRLQWPHQW
 )RUPXODWLRQ3DFNDJLQJDQG/DEHOLQJ
.;2LQWPHQWZLOOEHVXSSOLHGLQVLQJOHXVHSDFNHWVHDF KRIZKLFKFRQWDLQV
PJRIWKHRLQWPHQWHTXLYDOH QWWRPJRI.;IUHHED VH9HKLFOHRLQWPHQWZLOO
EHVXSSOLHGLQWKHVDPHVLQJOHXVHSDFNHWVHDFKRIZKLFKFRQWD LQVPJRIWKHRLQWPHQW
ZLWKRXWWKHDFWLYHGUXJ(DFKSDFNHWLVIRUXVHDVDVLQJOHGR VHDSSOLFDWLRQ&RPSOHWH
IRUPXODWLRQFRQWHQWVIRUERWK.; 2LQWPHQWDQGYHKLFOHR LQWPHQWDUHSURYLGHGLQ
WKH.;2LQWPHQW,QYHVWLJDWRU¬∂V%URFKXUH
(DFKHOLJLEOHUDQGRPL]HGVXEMHFWZLOOEHDVVLJQHGDQHQUROOPHQW QXPEHUDQGDVWXG\NLWZLWK
WKHVDPHHQUROOPHQWQXPEHU7KH VWXG\NLWZLOOFRQWDLQSDFNH WVILOOHGZLWKHLWKHU.;
2LQWPHQWRUYHKLFOHRLQWPHQW(DFKSDFNHWDQGVWXG\NLWZLO OEHODEHOHGLQDFFRUGDQFH
ZLWKQDWLRQDOUHJXODWLRQV'HWDLOHGLQIRUPDWLRQUHJDUGLQJWKH VWXG\GUXJVLQFOXGLQJODEHOLQJ
LQIRUPDWLRQZLOOEHLQWKH&OLQL FDO2SHUDWLRQV0DQXDOSURYLGHG WRWKHVLWH
7KHIROORZLQJWUHDWPHQWVZLOOEH DGPLQLVWHUHGWRVXEMHFWVLQWK LVVWXG\7DEOH
7DEOH 7UHDWPHQWVLQ.;$.
,QYHVWLJDWLRQDO
3URGXFW6WUHQJWK6L]HRI
7UHDWPHQW
$UHD1XPEHU$SSOLFDWLRQVDQG
)UHTXHQF\6WXG\'D\V
$GPLQLVWHUHG
.;2LQWPHQW  FPDSSOLFDWLRQRQFHGDLO\IRU
FRQVHFXWLYHGD\V'D\V
9HKLFOH2LQWPHQW 1$ FPDSSOLFDWLRQRQFHGDLO\IRU
FRQVHFXWLYHGD\V'D\V
1$ QRWDSSOLFDEOH
 6WRUDJH&RQGLWLRQV
6WXG\GUXJZLOOEHVWRUHGLQDFFRUGDQFHZLWKODEHOHGVWRUDJHFR QGLWLRQV
 'RVDJHDQG$GPLQLVWUDWLRQRI6WXG\'UXJV
 $GPLQLVWUDWLRQRI6WXG\'UXJV
$W%DVHOLQH'D\SUHGRVHVXEMHFWVZLOOUHFHLYHYHUEDODQGZ ULWWHQLQVWUXFWLRQVRQKRZWR
DSSO\WKHWRSLFDOPHGLFDWLRQD QGKRZWRFDUHIRUWKHWUHDWPHQW DUHD$SSHQGL[ 
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
7KHVWXG\PHGLFDWLRQLVIRUH[WHUQDOWRSLFDOXVHRQWKHWUHDWPH QWDUHD7KHWUHDWPHQWDUHD
ZLOOEHPDUNHGZLWKLQGHOLEOHPDUNHUDW%DVHOLQH'D\SUHGRVH DWWKHLQYHVWLJDWLRQDOVLWH
VHH6HFWLRQ 6XEMHFWVZLOOEHSURYLGHGZLWKD VWXG\NLWFRPSULVHGRILQG LYLGXDOSODVWLF
EDJVZLWKVLQJOHGRVHSDFNHWV FRQWDLQLQJHLWKHU.;2LQWP HQWRUYHKLFOHRLQWPHQW
DQGDGRVLQJORJ
7KHILUVWGRVHZLOOEHDGPLQLVWH UHGE\WKHVXEMHFWXQGHUWKHVX SHUYLVLRQRIVWXG\SHUVRQQHORQ
'D\DWWKHVLWH6XEMHFWVZLOOVHOIDGPLQLVWHUWKHUHPDLQLQJ VLQJOHGRVHSDFNHWVRQFHGDLO\
DWKRPHIRUWKHQH[WFRQVHFXWLYHGD\V6WXG\PHGLFDWLRQVKRX OGEHDSSOLHGHDFKGD\DW
DSSUR[LPDWHO\WKHVDPHWLPH,WLVSUHIHUDEOHWKDWVWXG\GUXJ DSSOLFDWLRQLVGRQHHDUO\LQWKH
GD\7KHWUHDWPHQWDUHDVKRXOGQRWEHWRXFKHGRUZHWIRUDSSUR [LPDWHO\KRXUVDIWHU
DSSOLFDWLRQ
6HH$SSHQGL[ IRUVXEMHFWLQVWUXFWLRQVIRUVWXG\GUXJDSSOLFDWLRQ,WLVLPS HUDWLYHWKDW
VXEMHFWVZDVKKDQGV LPPHGLDWHO\ ZLWKZDWHUDQGVRDSDIWHUDSSO\LQJWKHRLQWPHQW7KH
VXEMHFWLQVWUXFWLRQVDOVRFRQWDL QDGGLWLRQDOGHWDLOVLQFOXGLQJ SUHFDXWLRQVDVVRFLDWHGZLWK
RLQWPHQWDSSOLFDWLRQGXULQJWKH GD\VRIWUHDWPHQWDQGWKURXJK RXWWKHVWXG\
 ,QVWUXFWLRQVLQWKH(YHQWRI2FXODU([SRVXUH
6XEMHFWVZLOOEHLQVWUXFWHGWRDYRLGJHWWLQJRLQWPHQWLQWKHLU H\HV,IRLQWPHQWGRHVJHWLQWKH
H\HVWKHVXEMHFWLVWRIOXVKWKHLUH\HVZLWKZDWHULPPHGLDWHO\ DQGH[WHQVLYHO\7KHVXEMHFW
PXVWLPPHGLDWHO\FRQWDFWWKH,QYHVWLJDWRUZKRZLOOSURYLGHIXUW KHULQVWUXFWLRQVDQGZLOOUHIHU
WKHVXEMHFWWRDQRSKWKDOPRORJLVW7KHRSKWKDOPRORJLVW¬∂VDVVHV VPHQWZLOOEHLQFOXGHGLQWKH
UHSRUWRIRFXODUH[SRVXUHDVDQH YHQWRIVSHFLDOLQWHUHVWVHH 6HFWLRQ 
 &ULWHULDIRU,QWHUUXSWLRQRI7UHDWPHQW'RVH$GMXVWPHQWV
1RWDSSOLFDEOHGRVHDGMXVWPHQWLVQRWDOORZHG
 5DQGRPL]DWLRQ0HWKRGRI$VVLJQLQJ6XEMHFWVWR7UHDWPHQW
*URXSV
(QUROOPHQWZLOOEHFRQWUROOHGVRWKDWDSSUR[LPDWHO\WZRWKLUGV RIVXEMHFWVHQUROOHGZLOOEH
WUHDWHGRQWKHIDFHDQGDSSUR[LPDWHO\RQHWKLUGRIVXEMHFWVHQU ROOHGZLOOEHWUHDWHGRQWKH
VFDOS(OLJLEOHVXEMHFWVZLOOEH UDQGRPL]HGWRWUHDWPHQWLQD .;2LQWPHQWRU
YHKLFOHUDWLRLQHDFKWUH DWPHQWDUHDVXEJURXS
6XEMHFWVZLOOEHDVVLJQHGWRWUHDWPHQWVLQDGRXEOHEOLQGHGPDQ QHUEDVHGRQDFRPSXWHU
JHQHUDWHGUDQGRPL]DWLRQVFKHPH %DVHGRQWKHUDQGRPL]DWLRQVFK HPHOLVWVRIHQUROOPHQW
QXPEHUVZLOOEHLVVXHGWRHDFKVLWH RQHOLVWZLOOEHIRUVXEMH FWVZLWKWKHWUHDWPHQWDUHDRQWKH
IDFHDQGWKHRWKHUOLVWZLOOEHI RUVXEMHFWVZLWKWKHWUHDWPHQW DUHDRQWKHVFDOS6WXG\NLWV
EHDULQJFRUUHVSRQGLQJHQUROOPHQWQXPEHUVZLOOEHSURYLGHGWRWK HVLWH2QHVHWRINLWVZLOO
EHSURYLGHGIRUVXEMHFWVZLWKWKH WUHDWPHQWDUHDRQWKHIDFHDQ GWKHVHFRQGVHWRINLWVZLOOEH
SURYLGHGIRUVXEMHFWVZLWKWKHW UHDWPHQWDUHDRQWKHVFDOS
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
(QUROOPHQWQXPEHUVDQGVWXG\NLWVDUHGLVWULEXWHGVHTXHQWLDOO\ 7KHILUVWHOLJLEOHVXEMHFW
ZLWK$.OHVLRQRQWKHIDFHZLOOEHDVVLJQHGWKHILUVWHQUROOPHQ WQXPEHUIRUWUHDWPHQWRIWKH
IDFHDQGJLYHQDVWXG\NLWEHDULQ JWKHVDPHHQUROOPHQWQXPEHUR Q'D\RIWUHDWPHQW7KH
QH[WHOLJLEOHVXEMHFWZLWK$.OHVLRQVRQWKHIDFHZLOOUHFHLYH WKHQH[WHQUROOPHQWQXPEHUDQG
FRUUHVSRQGLQJVWXG\NLWLQDVHTXHQWLDORUGHU
7KHVDPHSURFHGXUHZLOORFFXUIRUVXEMHFWVZLWKWKHWUHDWPHQWD UHDRQWKHVFDOS2Q'D\
WKHILUVWHOLJLEOHVXEMHFWZLWK$.OHVLRQVRQWKHVFDOSZLOOEH DVVLJQHGWKHILUVWHQUROOPHQW
QXPEHUIRUWUHDWPHQWRQWKHVFDOSDQGJLYHQDVWXG\NLWEHDULQJ WKHVDPHHQUROOPHQWQXPEHU
7KHQH[WHOLJLEOHVXEMHFWZLWK$.OHVLRQVRQWKHVFDOSZLOOUHF HLYHWKHQH[WHQUROOPHQW
QXPEHUDQGFRUUHVSRQGLQJVWXG\N LWLQDVHTXHQWLDORUGHU
5HIHUWRWKH&OLQLFDO2SHUDWLRQV 0DQXDOIRUGHWDLOVRISURFHGXU HVRIVWXG\NLWGLVSHQVLQJDQG
GRFXPHQWDWLRQ
 %OLQGLQJ
7KH6SRQVRUFRQWUDFWUHVHDUFKR UJDQL]DWLRQV&52VLQYROYHGLQ WKHFOLQLFDOFRQGXFWRIWKH
VWXG\WKH,QYHVWLJDWRUVVWXG\VLWHSHUVRQQHODQGVWXG\VXEMHF WVZLOOEHEOLQGHGWRWKH
WUHDWPHQWWKDWLVDVVLJQHGWRHDFKVXEMHFW7KHLQWHJULW\RIW KLVFOLQLFDOVWXG\PXVWEH
PDLQWDLQHGE\REVHUYLQJ WKHWUHDWPHQWEOLQG6HH 6HFWLRQ IRUEUHDNLQJWKHEOLQG
 3ULRUDQG&RQFRPLWDQW0HGLFDWLRQV7KHUDS\
 3ULRU0HGLFDWLRQV7KHUDS\
$OO PHGLFDWLRQV SUHVFULSWLRQ DQG QRQSUHVFULSWLRQ LQFOXGLQJ YLW DPLQV DQG GLHWDU\
VXSSOHPHQWVWUHDWPHQWVDQGSU RFHGXUHVWDNHQGD\VEHIRUH' D\DUHFRQVLGHUHGSULRU
WKHUDS\DQGZLOOEHUHFRUGHGLQWKHH&5)$FRPSOHWH$.WUHDWP HQWKLVWRU\ZLOOEHUHFRUGHG
RQWKH$.7UHDWPHQW+LVWRU\H&5)VHH 6HFWLRQ 
 &RQFRPLWDQW0HGLFDWLRQV7KHUDS\
&RQFRPLWDQWPHGLFDWLRQWKHUDSLHVDUHDQ\QHZRUH[LVWLQJWKHUDS \UHFHLYHGE\WKHVXEMHFW
DIWHU VLJQLQJ WKH ,&) WKURXJK WKH ILQDO VXEMHFW FRQWDFW LQ WKH VWXG\  &RQFRPLWDQW
PHGLFDWLRQWKHUDSLHVZLOO EHUHFRUGHGLQWKHH&5)
8VHRIVXQEORFNIURP'D\RQZDUGRUDQ\WRSLFDOSURGXFWVIRU WUHDWPHQWRI/65VLQWKH
WUHDWPHQWDUHDDOORZHGE\WKH,QYHVWLJDWRUZLOOEHUHFRUGHGLQ WKH&RQFRPLWDQW0HGLFDWLRQ
H&5)XSWR'D\
'XULQJWKH5HFXUUHQFH)ROORZXS3HULRGVXQEORFNDQGQRQPHGLFD WHGWRSLFDOSURGXFWVFDQ
EHXVHGLQWKHWUHDWPHQWDUHD'XULQJWKH5HFXUUHQFH)ROORZXS 3HULRGRQO\FRQFRPLWDQW
PHGLFDWLRQVWKHUDSLHVIRUWKHWUHDWPHQWRI$(VLQWKHWUHDWPHQW DUHDDQGWKRVHWKDWPD\DIIHFW
WKHDVVHVVPHQWRI$.OHVLRQUHFX UUHQFHLQWKHWUHDWPHQWDUHDZL OOEHHQWHUHGLQWKHH&5)
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 3URKLELWHG0HGLFDWLRQ7KHUDS\
8VHRIDQ\WUHDWPHQWIRU$.OHVL RQVRWKHUWKDQVWXG\GUXJRQWK HWUHDWPHQWDUHDLVSURKLELWHG
GXULQJWKHVWXG\6XEMHFWVZLOOEHUHPLQGHGWKDW$.OHVLRQVOR FDWHGRXWVLGHWKHWUHDWPHQW
DUHDPD\EHWUHDWHGE\OHVLRQGLU HFWHGWUHDWPHQWRQO\HJFU\R WKHUDS\RUELRSV\
3URKLELWHGPHGLFDWL RQVDUHDVIROORZV
3URKLELWHGGUXJSURGXFWVDQGWUHD WPHQWVWKDWPLJKWLQIOXHQFHRU PDVNWKHHIIHFWVRIWUHDWPHQW
XQWLO'D\LQFOXGHLPPXQRPRGXO DWRUVRULPPXQRVXSSUHVVLYHWK HUDSLHVF\WRWR[LFGUXJV
LQWHUIHURQLQWHUIHURQ LQGXFHUV WRSLFDO RU V\VWHPLF VWHURLGV  )8 LQJHQRO PHEXWDWH
LPLTXLPRGGLFORIHQDFWRSLFDORU V\VWHPLFUHWLQRLGVWRSLFDOV DOLF\OLFDFLGELFKORURDFHWLF
DFLG WULFKORURDFHWLF DFLG DFLG FRQWDLQLQJ WKHUDSHXWLF SURGXFW V EHQ]R\O SHUR[LGH
FKHPRGHVWUXFWLRQPHGLFDWHGWKHU DSHXWLFWRSLFDOVDOYHVSKRWRG\ QDPLFWKHUDS\SVRUDOHQSOXV
89$RU89%WKHUDS\DUWLILFLDO WDQQHUH[FHVVL YHRUSURORQJHGH [SRVXUHWR89OLJKWVRXUFH
6XEMHFWVDUHSURKLELWHGIURPDSSO\LQJDQ\WRSLFDOSURGXFWVLQF OXGLQJEXWQRWOLPLWHGWR
ORWLRQVFUHDPVDQGRLQWPHQWVPRLVWXUL]HUVVXQVFUHHQDUWLIL FLDOWDQQHUVRUPDNHXSWRWKH
WUHDWPHQWDUHDXSXQWLOWKHHQGRI'D\9LVLWH[FHSWZKH QWKRVHPHGLFDWLRQVDUH
SUHVFULEHGE\WKH,QYHVWLJDWRUIRUWKHPDQDJHPHQWRI/65V6XE MHFWVVKRXOGDYRLGGLUHFWVXQ
RU89H[SRVXUHWRWKHWUHDWPHQWDUHDWKURXJKRXWWKHVWXG\+RZ HYHUIURP'D\RQZDUG
LI D VXEMHFW LV XQDEOH WR DYRLG GLUHFW VXQ RU 89 H[SRVXUH WR WK H WUHDWPHQW DUHD WKH
,QYHVWLJDWRUPD\DOORZWKHXVHRIVXQEORFNRQO\
6XEMHFWVKDYHXQUHVWULFWHGXVH RIQRQPHGLFDWHGWRSLFDOSURGXFWV RQDUHDVRXWVLGHRIWKH
WUHDWPHQWDUHDGXULQJWKHVWXG\
'XULQJWKH5HFXUUHQFH)ROORZXS3HULRGXVHRIWUHDWPHQWVWKDW PD\LQWHUIHUHZLWKWKH
DVVHVVPHQWRI$.UHFXUUHQFHLQWKHWUHDWPHQWDUHDDUHSURKLELWH G7KLVLQFOXGHVXVHRI$.
WUHDWPHQWDQGPHGLFDWHGWRSLFDOS URGXFWVLQWKHWUHDWPHQWDUHD DQGXVHRIV\VWHPLFWKHUDSLHV
HJLPPXQRVXSSUHVVLYHDJHQWVDQG V\VWHPLF$.WUHDWPHQWWKDWP D\LQWHUIHUHZLWKWKH
DVVHVVPHQWRI$.UHFXUUHQFH
$Q\ VXEMHFWV ZKR VWDUW V\VWHPLF R U WRSLFDO WKHUDSLHV IRU WKH WU HDWPHQW RI $. ZLOO EH
ZLWKGUDZQIURPWKHVWXG\
7KHGHFLVLRQWRDGPLQLVWHUDSURKLELWHGPHGLFDWLRQWUHDWPHQWLV GRQHZLWKWKHVDIHW\RIWKH
VWXG\VXEMHFWDVWKHSULPDU\FRQVLGHUDWLRQ
 2WKHU3URKLELWLRQVDQG5HVWULFWLRQVGXULQJ6WXG\
7KHUHDUHQRUHVWULFWLRQVGXULQJWKHVWXG\RQVPRNLQJWREDFFRX VHGLHWDOFRKROFDIIHLQH
ZDWHURURWKHUEHYHUDJHV RUSK\VLFDODFWLYLW\
$IWHU VHOIDSSOLFDWLRQ VXEMHFWV ZLOO DYRLG WRXFKLQJ RU ZHWWLQJ W K H W U H D W P H Q W D U H D I R U 
DSSUR[LPDWHO\KRXUV:KHQZDVKLQJWKHWUHDWPHQWDUHDZDVK LWJHQWO\ZLWKDPLOGQRQ
DEUDVLYHQRQPHGLFDWHGVRDSRUVKDPSRR
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
7KHWUHDWPHQWDUHDVKRXOGQRWEHRFFOXGHGZLWKEDQGDJHVEDQGD LGVWLJKWILWWLQJVFDUIVRU
FDSV7KHWUHDWPHQWDUHDVKRXOG QRWEHH[SRVHGWRH[FHVVLYHVX QOLJKWRU89OLJKW6HH
$SSHQGL[ IRUDOOSURKLELWHGDFWLYLW\
 'UXJ$FFRXQWDELOLW\DQG7UHDWPHQW&RPSOLDQFH
 'UXJ6XSSOLHVDQG$FFRXQWDELOLW\
'UXJVXSSOLHVPXVWEHNHSWLQDQDSSURSULDWHVHFXUHDUHDHJO RFNHGFDELQHWDQGVWRUHG
DFFRUGLQJWRWKHFRQGLWLRQVVS HFLILHGRQWKHGUXJODEHOV
7KH,QYHVWLJDWRUDQGVWXG\VWDIIZLOOEHUHVSRQVLEOHIRUWKHDF FRXQWDELOLW\RIDOOFOLQLFDO
VXSSOLHVHJVKLSPHQWGLVSHQVLQJLQYHQWRU\DQGUHFRUGNHHSL QJIROORZLQJWKH6SRQVRU¬∂V
LQVWUXFWLRQV,QWKLVPDWWHUWKH,QYHVWLJDWRUDQGVWXG\VWDII PXVWDGKHUHWR*RRG&OLQLFDO
3UDFWLFH*&3JXLGHOLQHVDVZH OODVORFDORUUHJLRQDOUHTXLUH PHQWV
8QGHUQRFLUFXPVWDQFHVZLOOWKH,QYHVWLJDWRUDOORZWKHVWXG\GU XJVWREHXVHGRWKHUWKDQDV
GLUHFWHGE\WKLVSURWRFRO&OLQLFDOVXSSOLHVZLOOEHGLVSHQVHG RQO\E\DQDSSURSULDWHO\
TXDOLILHGSHUVRQDQGZ LOOQRWEHGLVSHQVHGWRDQ\LQGLYLGXDOZK RLVQRWHQUROOHGLQWKHVWXG\
$QDFFXUDWHDQGWLPHO\UHFRUGRIWKHUHFHLSWRIDOOFOLQLFDOVX SSOLHVDQGGLVSHQVLQJRIVWXG\
GUXJWRWKHVXEMHFWPXVWEHPDLQWDLQHG
$OOIRUPVZLOOEHSURYLGHGE\WKH6SRQVRURULWVGHVLJQHH$ Q\FRPSDUDEOHIRUPVWKDWWKH
LQYHVWLJDWLRQDOVLWHZLVKHVWRXVHPXVWEHDSSURYHGE\WKH6SRQ VRU$FRS\RIWKHGUXJ
DFFRXQWDELOLW\UHFRUGPXVWEHSU RYLGHGWRWKH6SRQVRURULWVG HVLJQHH
7KHFOLQLFDOUHVHDUFKDVVRFLDWH&5$ZLOOUHYLHZGUXJDFFRXQWD ELOLW\GXULQJPRQLWRULQJVLWH
YLVLWV
7KH,QYHVWLJDWRURUVLWHSHUVRQQHOPXVWQRWGHVWUR\DQ\GUXJ ODEHOVRUDQ\SDUWO\XVHGRU
XQXVHGGUXJVXSSO\3RVW'D\DQGDVDSSURSULDWHGXULQJWKH VWXG\WKH,QYHVWLJDWRURUD
GHVLJQDWHGSKDUPDFLVWZLOOUHWXUQDOOXVHGDQGXQXVHGGUXJSDF NHWVVWXG\NLWVGUXJODEHOV
DQGDFRS\RIWKHFRP SOHWHGGUXJGLVSRVLWL RQIRUPWRWKHFOLQLF DOVXSSO\YHQGRU
5HIHUWRWKH&OLQLFDO2SHUDWLRQV 0DQXDOIRULQVWUXFWLRQVDQGFR QWDFWLQIRUPDWLRQ
 7UHDWPHQW&RPSOLDQFH
6XEMHFWVZLOOUHWXUQWKHXVHGRLQWPHQWSDFNHWVRUXQXVHGRLQWP HQWLIQRWDGPLQLVWHUHGEDFN
WRWKHFOLQLFDOVLWHRQ'D\9L VLWSRVWGRVHWRFKHFNFRPS OLDQFH
7KHGRVLQJORJVIRUHDFKVXEMHFWZLOOEHNHSWGXULQJWKHVWXG\ 7KH&5$VZLOOUHYLHZ
WUHDWPHQWFRPSOLD QFHGXULQJPRQLWRULQJVLWHYLVLWV
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 678'<352&('85(6$1'$66(660(176
 6FUHHQLQJ$VVHVVPHQWV
$OOVFUHHQLQJDVVHVVPHQWVZLOOEHSHUIRUPHGDIWHUWKHVXEMHFWS URYLGHVLQIRUPHGFRQVHQW
7DEOH6FUHHQLQJ9LVLWZLOORFFX UEHWZHHQ'D\DQG'D\
6XEMHFWVFUHHQLQJQXPEHUVZLOO EHDVVLJQHGDW9LVLW
7KHH&5)PXVWEHFRPSOHWHGWRLQGLFDWHZKHWKHUWKHVXEMHFWLVH OLJLEOHWRSDUWLFLSDWHLQWKH
VWXG\DQGWRSURYLGHUHDVRQVIRUV FUHHQIDLOXUHLIDSSOLFDEOH 
 ,QIRUPHG&RQVHQW
,QIRUPHGFRQVHQWZLOOEHREWDLQHGDIWHUWKHVWXG\KDVEHHQIXOO \H[SODLQHGWRHDFKVXEMHFW
DQGEHIRUHWKHFRQGXFWRIDQ\VFUHHQLQJSURFHGXUHVRUDVVHVVPHQ WV'RFXPHQWDWLRQZLOOEH
UHTXLUHGGRFXPHQWHGLQWKHFOLQLF QRWDWLRQWRFRQILUPWKDWWK H,QYHVWLJDWRUHQVXUHGWKDWWKH
LQIRUPHGFRQVHQWSURFHVVZDVGRQHFRUUHFWO\WKHVXEMHFWXQGHUV WRRGZKDWWRH[SHFWDQG
DJUHHGWRSDUWLFLSDWH
3URFHGXUHVWREHIROORZHGZKHQREWDLQLQJLQIRUPHGFRQVHQWDUHG HWDLOHGLQ6HFWLRQ 
 ,QFOXVLRQ([FOXVLRQ&ULWHULD
6XEMHFWHOLJLELOLW\ZLOOEHFRQILU PHGSHUWKHLQFOXVLRQH[FOXVL RQFULWHULDDW6FUHHQLQJ
 'HPRJUDSK\
6XEMHFWGHPRJUDSK\LQIRUPDWLRQZLOOEHFROOHFWHGDW6FUHHQLQJ 'HPRJUDSK\LQIRUPDWLRQ
LQFOXGHVDJHDWWLPHRIFRQV HQWVH[UDFHHWKQLFLW\
 0HGLFDO6XUJLFDODQG$FWLQLF.HUDWRVLV+LVWRU\
0HGLFDODQGVXUJLFDOKLVWRU\D QGFXUUHQWPHGLFDOFRQGLWLRQVZLO OEHUHFRUGHGDW6FUHHQLQJ
0HGLFDOKLVWRU\ZLOOLQFOXGH
x6LJQLILFDQWPHGLFDODQGVXUJLFDOKLVWRU\FKLOGKRRGGLVHDVHVDQ GFRPPRQFROGVDUH
QRWUHTXLUHGXQOHVVLWLV RQJRLQJDW6FUHHQLQJ
x$FRPSOHWH$.KLVWRU\IURPWKHWLPHRILQLWLDOGLDJQRVLV
x$ FRPSOHWH $. WUHDWPHQW KLVWRU\ LQFOXGLQJ DOO FRPPHUFLDO DQG LQ YHVWLJDWLRQDO
SURGXFWVDQGVXUJLFDO PRGDOLWLHVGDWLQJEDF NWRWKHLQLWLDOGLD JQRVLV
x+LVWRU\RIFDQFHUVLQFOXGLQJVNLQFDQFHUVHJ%&&6&&PHODQR PD
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 3ULRU0HGLFDWLRQV
$OO PHGLFDWLRQV SUHVFULSWLRQ DQG QRQSUHVFULSWLRQ LQFOXGLQJ YLW DPLQV DQG GLHWDU\
VXSSOHPHQWVWUHDWPHQWVDQGWKHUDSLHVWDNHQGD\VEHIRUH'D \ZLOOEHUHFRUGHGDW
6FUHHQLQJ
 )LW]SDWULFN6NLQ7\SH&ODVVLILFDWLRQ
7KH)LW]SDWULFN6NLQ7\SHLVDVNLQFODVVLILFDWLRQV\VWHPZKLFKPHDVXUHVFRPSRQHQWV
JHQHWLFGLVSRVLWLRQDQGUHDFWLRQ WRVXQH[SRVXUH6NLQW\SHV UDQJHIURPYHU\IDLU7\SH,
WRYHU\GDUN7\SH9,6XEMHFWV¬∂VNLQZLOOEHW\SHGXVLQJWKL VFODVVLILFDWLRQV\VWHPDW
6FUHHQLQJ
 ([SDQGHG'HUPDWRORJLFDO([DPLQDWLRQ
$QH[SDQGHGGHUPDWRORJLFDOH[DPLQ DWLRQWRFRYHUVXQH[SRVHGDUH DVZKHUHSKRWRGDPDJHLV
OLNHO\ZLOOEHFRQGXFWHGDW6FUHHQLQJRQO\
 7UHDWPHQW$UHD,GHQWLILFDWLRQDQG$./HVLRQ&RXQW([DPLQD WLRQ
$WWKH6FUHHQLQJYLVLWDGHUPDWRORJLVW,QYHVWLJDWRURU6XELQY HVWLJDWRUZLOOLGHQWLI\D
FRQWLJXRXVWUHDWPHQWDUHDDIIHFWHGZLWK$.RQWKHIDFHRUVFDOS IRUHDFKVXEMHFWWKDW
PHDVXUHVFPDQGFRQWDLQVWR$.OHVLRQVWKDWDUHFOLQLFDOO\W\SLFDOYLV LEOHDQG
GLVFUHWH$GHUPDWRORJLVW,QYHVWLJDWRURU6XELQYHVWLJDWRUZL OOSHUIRUPDFRXQWRI$.
OHVLRQVOHVLRQFRXQWIRUDOOVXEMHFWV
 3K\VLFDO([DPLQDWLRQV
$FRPSOHWH3(ZLOOEHSHUIRUPHGDW6FUHHQLQJDQGZLOOLQFOXGHZ HLJKWDQGDQDVVHVVPHQWRI
KHDGH\HVHDUVQRVHDQGWKURDW+((17LQWHJXPHQWDU\JDVW URLQWHVWLQDOFDUGLRYDVFXODU
UHVSLUDWRU\ PXVFXORVNHOHWDO D QG QHXURORJLFDO V\VWHPV  +HLJKW  ZLOO EH PHDVXUHG DW
6FUHHQLQJRQO\$QH[SDQGHGGHUPDWRORJLFDOH[DPLQDWLRQZLOOEH FRQGXFWHGDW6FUHHQLQJ
RQO\6HFWLRQ7KHFRPSOHW H3(ZLOOEHSDUWRIWKHEDVH OLQHDVVHVVPHQWV
 9LWDO6LJQV
9LWDOVLJQVZLOOEHUHFRUGHGDW6FUHHQLQJ9LWDOVLJQSXOVHU DWHV\VWROLFDQGGLDVWROLFEORRG
SUHVVXUHUHVSLUDWRU\UDWHD QGERG\WHPSHUDWXUHPHDVXUHPHQWV ZLOOEHWDNHQDIWHUWKHVXEMHFW
KDVEHHQVHDWHGIRUDWOHDVWPLQXWHV6HULDOYLWDOVLJQVPD\ EHREWDLQHGWRFRQILUPDFFXUDWH
UHDGLQJV
 (OHFWURFDUGLRJUDPV
(OHFWURFDUGLRJUDPWUDLQLQJHTXL SPHQWDQGDSURFHGXUDOPDQXDO ZLOOEHSURYLGHGWRWKHVLWH
E\WKHFHQWUDO(&*YHQGRU7KH(&*YHQGRUDQGWKH6SRQVRUZLOO HQVXUHWKDWWKHVWXG\VLWH
(&*RSHUDWRULVSURSHUO\WUDLQ HGSULRUWRVWDUWRIVWXG\
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
$VWDQGDUGOHDG(&*ZLOOEHREWDLQHGDW6FUHHQLQJ6XEMHFWV PXVWEHLQWKHUHFXPEHQW
SRVLWLRQIRUDSHULRGRIPLQXWHV SULRUWRWKH(&*6FUHHQLQJ (&*VPXVWEHUHYLHZHGSULRU
WRWKHVXEMHFWEHLQJUDQGRPL]HG
(&*VZLOOEHWUDQVIHUUHGHOHFWU RQLFDOO\WRWKHFHQWUDO(&*YHQG RU
 /DERUDWRU\0HDVXUHPHQWV
6DPSOHVIRUFOLQLFDOODERUDWRU\WHVWLQJKHPDWRORJ\FKHPLVWU\ XULQDO\VLVZLOOEHFROOHFWHG
DW6FUHHQLQJ&OLQLFDOODERUDWRU\WHVWLQJZLOOEHSDUWRIWKH EDVHOLQHDVVHVVPHQWV6HH
6HFWLRQ IRUIXUWKHUGHWDLOVDERXW ODERUDWRU\WHVWV
 3UHJQDQF\7HVWLQJ
,QIHPDOHVRIFKLOGEHDULQJSRWHQWLDODVHUXPSUHJQDQF\WHVWZL OOEHREWDLQHGDW6FUHHQLQJ
7HVWUHVXOWVPXVWEHUHYLHZH GEHIRUHUDQGRPL]DWLRQRIVXEMHFWV 
 %DVHOLQH$VVHVVPHQWV
$OOEDVHOLQHDVVHVVPHQWVVKRXOGEH FRPSOHWHGE\'D\9LVLW SULRUWRUDQGRPL]DWLRQ
DFFRUGLQJWRWKH6FKHGXOHRI3URFHGXUHVDQG$VVHVVPHQWV 7DEOH
 ,QFOXVLRQ([FOXVLRQ&ULWHULD
6XEMHFWHOLJLELOLW\ZLOOEHUHFR QILUPHGSHUWKHLQFOXVLRQH[FO XVLRQFULWHULDDW%DVHOLQH
 3ULRU0HGLFDWLRQV
$OO SULRU PHGLFDWLRQV SUHVFU LSWLRQ DQG QRQSUHVFULSWLRQ LQFOXGL QJ YLWDPLQV DQG GLHWDU\
VXSSOHPHQWVWUHDWPHQWVDQGWKH UDSLHVZLOOEHFRQILUPHGDW%D VHOLQH
 7UHDWPHQW$UHD,GHQWLILFDWLRQ
$W%DVHOLQH'D\SUHGRVHWKH,QYHVWLJDWRUZLOOFRQILUPWKH FPWUHDWPHQWDUHDDIIHFWHG
ZLWKWR$.OHVLRQVRQWKHIDFHRU VFDOSWKDWZDVLGHQWLILHG DW6FUHHQLQJ
$W%DVHOLQH'D\SUHGRVHWKHORFDWLRQDQGVKDSHRIWKHWUHD WPHQWDUHDDQGWKHVSHFLILF
$.OHVLRQVZLOOEHUHFRUGHGRQDQ DFHWDWHWUDQVSDUHQF\VKHHWJU LGGHGZLWKFPVTXDUHV
7KH,QYHVWLJDWRURU6XELQYHVWLJDWRUZLOOLGHQWLI\WKHWUHDWPHQW DUHDE\
3ODFLQJWKHWUDQVSDUHQF\VKHHWRYHUWKHWUHDWPHQWDUHD
:LWKDILQHWLSL QGHOLEOHPDUNHU
x0DUNDWOHDVWDQDWRPLFDOODQGPDUNVLQWKHYLFLQLW\RIWKHWUH DWPHQWDUHDRQWKH
WUDQVSDUHQF\VKHHW([DPSOHVRIODQGPDUNVFRXOGEHERQ\SURPLQ HQFHVVFDUV
PROHVVHERU[LOCATION_006]HLFNHUDWRVLVDQGYHLQV
x0DUNWKHRXWOLQHRIWKH WUHDWPHQWDUHDRQWKH WUDQVSDUHQF\VKHH W
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
x0DUNWKHORFDWLRQRIHDFKRIWKH $.OHVLRQVLQVLGHWKHWUHDWPHQ WDUHDRQWKH
WUDQVSDUHQF\VKHHW
2QWKHVXEMHFW¬∂VVNLQRXWOLQHWKHWUHDWPHQWDUHDZLWKGRWVDQG GDVKHVZLWKWKH
LQGHOLEOHPDUNHU
7KHWUDQVSDUHQF\VKHHWZLOOEHNHSWDWWKHVLWHDQGZLOOEHXVH GWRORFDWHWKHWUHDWPHQWDUHD
DQG$.OHVLRQVGXULQJWKHIROORZXSYLVLWV
 $FWLQLF.HUDWRVLV/HVLRQ&RXQW
$GHUPDWRORJLVW,QYHVWLJDWRURU 6XELQYHVWLJDWRUZLOOSHUIRUP DFRXQWRIFOLQLFDOO\YLVLEOH$.
OHVLRQVOHVLRQFRXQWIRUDOOVXEMHFWVDW%DVHOLQH'D\SUHG RVH7KHVDPH,QYHVWLJDWRURU
6XELQYHVWLJDWRUZLOOFRQGXFWWK HOHVLRQFRXQWDWDOOYLVLWVIRU DQLQGLYLGXDOVXEMHFW
)RUWKLVDVVHVVPHQWDQ$.OHVLRQVKRXOGEHFRXQWHGRQO\LILW LVFRPSOHWHO\LQVLGHWKH
WUHDWPHQWDUHD
 )RFXVHG'HUPDWRORJLFDO([DPRI7UHDWPHQW$UHD
$W%DVHOLQH'D\SUHGRVHWKHIRFXVHGGHUPDWRORJLFDOH[DPRI WUHDWPHQWDUHDZLOOLQFOXGH
HYDOXDWLRQ IRU /65V K\SR RU K\SHUSLJPHQWDWLRQ DQG VFDUULQJ VHH EHORZ  7KHVH
DVVHVVPHQWVZLOOEHXVHGD VEDVHOLQHDVVHVVPHQWV
 /RFDO6NLQ5HDFWLRQV
$W%DVHOLQH'D\SUHGRVHDIWHUWKHDVVHVVPHQWRI$(VWKH, QYHVWLJDWRURU6XELQYHVWLJDWRU
ZLOODVVHVVIRU/65VRQWKHWUHDWPHQWDUHD7KHVDPH,QYHVWLJD WRURU6XELQYHVWLJDWRUZLOO
FRQGXFWWKH/65DVVHVVPHQWDWD OOYLVLWVIRUDQLQGLYLGXDOVXEM HFW
/65VLJQVRQWKHWUHDWPHQWDUHDLQFOXGHWKHIROORZLQJHU\WKHP DIODNLQJVFDOLQJFUXVWLQJ
VZHOOLQJYHVLFXODWLRQSXVWXODWL RQDQGHURVLRQXOFHUDWLRQ7K HVHVLJQVZLOOEHDVVHVVHGXVLQJ
DSRLQWJUDGLQJVFDOH DEVHQW PLOGVOLJKWO\EDUHO\SHU FHSWLEOH PRGHUDWHGLVWLQFW
SUHVHQFHDQG VHYHUH PDUNHGLQWHQVH
$SSOLFDWLRQVLWHUHDFWLRQVQRWF ODVVLILHGDV/65VHJLWFKLQJ EXUQLQJVWLQJLQJWHQGHUQHVV
SDLQZLOOEHUHSRUWHGDV$(V
/65VZLOOEHUHSRUWHGVHSDUDWHO\IURP$(V
 3LJPHQWDWLRQDQG6FDUULQJ
$WWKHWLPHRI/65DVVHVVPHQWK\SRDQGK\SHUSLJPHQWDWLRQDQG VFDUULQJRQWKHWUHDWPHQW
DUHDZLOOEHDVVHVVHGE\WKH,QYHVWLJDWRURU6XELQYHVWLJDWRUDV EHLQJSUHVHQWRUDEVHQW
3LJPHQWDWLRQDQGVFDUULQJZLOOEHDVVHVVHGDW%DVHOLQH'D\S UHGRVHDIWHUWKHDVVHVVPHQW
RIDGYHUVHHYHQWV7KHVDPH,QYHVWLJDWRURU6XELQYHVWLJDWRUZL OODVVHVVSLJPHQWDWLRQDQG
VFDUULQJDWDOOYLVLWVI RUDQLQGLYLGXDOVXEMHFW
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 6WDQGDUGL]HG3KRWRJUDSK\
$W%DVHOLQH'D\SUHGRVHWKH,QYHVWLJDWRURUDTXDOLILHGVW DIIPHPEHUPXVWREWDLQ
VWDQGDUGL]HG SKRWRJUDSK\ RI HDFK  VXEMHFW¬∂V WUHDWPHQW DUHD EHIRU H DSSOLFDWLRQ RI VWXG\
PHGLFDWLRQ
&DUHPXVWEHWDNHQWRHQVXUHWKHVDPHOLJKWLQJEDFNJURXQGVXE MHFWSRVLWLRQLQJUHODWLYHWR
WKHFDPHUDDQGFDPHUDVHWWLQJVD UHXVHGIRUHDFKSKRWRJUDSK( TXLSPHQWVXSSOLHVDQG
GHWDLOHGLQVWUXFWLRQVIRUREWDL QLQJDQGPDQDJLQJWKHSKRWRJUDSK VZLOOEHSURYLGHGWRWKH
LQYHVWLJDWLRQDOFHQWHUSULRUW RWKHLQLWLDWLRQRIVXEMHFWHQURO OPHQW
7KHSKRWRJUDSKVDUHWRGRFXPHQWWKHDSSHDUDQFHRIWKHVXEMHFWV¬∂ WUHDWPHQWDUHDDQGWRDVVLVW
ZLWKWKHLGHQWLILFDWLRQDQGFRQI LUPDWLRQRIWKHORFDWLRQRIWKH WUHDWPHQWDUHDWKURXJKRXWWKH
VWXG\
 9LWDO6LJQV
9LWDOVLJQVZLOOEHPHDVXUHGD W%DVHOLQH'D\SUHGRVH6HH 6HFWLRQ IRUGHWDLOV
 (OHFWURFDUGLRJUDPV
$OHDG(&*ZLOOEHREWDLQHGDW %DVHOLQH'D\SUHGRVH6H H6HFWLRQ IRUGHWDLOV
 3UHJQDQF\7HVWLQJ
,QIHPDOHVRIFKLOGEHDULQJSRWHQWLDODXULQHSUHJQDQF\WHVWZL OOEHSHUIRUPHGDWWKHVLWHDW
%DVHOLQH'D\SUHGRVH7HVWUH VXOWVPXVWEHUHYLHZHGEHIRUH UDQGRPL]DWLRQRQ'D\
 5DQGRPL]DWLRQ
$IWHUVFUHHQLQJDQGEDVHOLQHDVVHVVPHQWVFRQILUPDVXEMHFW¬∂VHO LJLELOLW\WRSDUWLFLSDWHLQWKH
VWXG\KHVKHZLOOEHDVVLJQHGWKHQH[WHQUROOPHQWQXPEHUDSSUR SULDWHIRUWKHDUHDEHLQJ
WUHDWHGVHH 6HFWLRQ 
 ,QVWUXFWLRQVIRU 6HOIDGPLQLVWUDWLRQ RI 6WXG\ 7UHDWPHQW  'LVSHQVLQJ DQG
5HWXUQRI6WXG\7UHDWPHQW
$W%DVHOLQH'D\SUHGRVHVXEMHFWVZLOOUHFHLYHERWKYHUEDO DQGZULWWHQLQVWUXFWLRQV
$SSHQGL[ IRU GDLO\ VHOIDGPLQLVWUDWLRQ RI VWXG\ WUHDWPHQW  $Q\ TXHVWLRQ V ZLOO EH
DQVZHUHGE\WKHFOLQLFVWDII
5DQGRPL]HGVXEMHFWVZLOOEHDVVLJQHGDQHQUROOPHQWQXPEHUDQGD VWXG\NLWZLWKWKHVDPH
HQUROOPHQWQXPEHU7KHVWXG\NLWZLOOKDYHVLQJOHGRVHSDFNH WVIRUHDFKGD\RI
WUHDWPHQWFRQWDLQLQJHLWKHU.; 2LQWPHQWRUYHKLFOHRLQ WPHQWVHH 6HFWLRQ 
7KHVWXG\NLWZLOOLQFOXGHDGRVLQJORJZKHUHWKHVXEMHFWVZLOO UHFRUGWKHGDWHDQGWLPHRI
VWXG\GUXJVHOIDGPLQLVWUDWLRQ
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
6XEMHFWVZLOOEHLQVWUXFWHGWRSODFHWKHXVHGSDFNHWVLQFOXGLQ JWRUQSLHFHVLQWRWKHSODVWLF
EDJVLQZKLFKWKH\FDPHVHDOWKHSODVWLFEDJVSXWWKHPEDFNL QWRWKHVWXG\NLWDQGUHWXUQ
WKHVWXG\NLWFRQWDLQLQJXVHGDQGXQXVHGSDFNHWVDQGWKHGRVLQJ ORJWRWKHFOLQLFDOVLWHDIWHU
VHOIDGPLQLVWUDWLRQRQ'D\ WRFKHFNFRPSOLDQFH 6HFWLRQ 
 7UHDWPHQW3HULRGDQG5HVSRQVH$VVHVVPHQW3HULRG
 7UHDWPHQW$GPLQLVWUDWLRQ¬±'D\V
$IWHUEDVHOLQHDVVHVVPHQWVDUHF RPSOHWHGRQ'D\WKHILUVWGR VHRIVWXG\WUHDWPHQWZLOOEH
DSSOLHGE\WKHVXEMHFWXQGHUWKH VXSHUYLVLRQRIVWXG\VLWHSHUV RQQHO6XEMHFWVZLOOWKHQWDNH
KRPHWKHVWXG\NLWFRQWDLQLQJWKH UHPDLQLQJVLQJOHGRVHSDFNHWV RIVWXG\GUXJIRUGDLO\VHOI
DGPLQLVWUDWLRQRQWKHQH [WFRQVHFXWLYHGD\V
 (IILFDF\$VVHVVPHQWV
 $FWLQLF.HUDWRVLV/HVLRQ&RXQW
$GHUPDWRORJLVW,QYHVWLJDWRURU 6XELQYHVWLJDWRUZLOOSHUIRUP DFRXQWRIFOLQLFDOO\YLVLEOH$.
OHVLRQVOHVLRQFRXQWIRUDOOVX EMHFWVDWWKH5HVSRQVH$VVHVVP HQW9LVLWVRQ'D\VDQG
7DEOH7KHVDPH,QYHVWLJDWRURU6XELQYHVWLJDWRUZLOOFRQGXFWWKHO HVLRQFRXQWDWDOO
YLVLWVIRUDQLQGLYLGXDOVXEMHFW
7KH,QYHVWLJDWRURU6XELQYHVWLJDW RUPD\XVHWKHWUDQVSDUHQF\DQ GRUSKRWRJUDSKIURP%DVHOLQH
WRORFDWHWKHWUHDWPHQWDUHD$.OHVLRQFRXQWVIURPSUHYLRXVY LVLWVVKRXOGQRWEHXVHGWRDVVLVW
LQWKHDVVHVVPHQWRI$.OHVLRQFRXQWDWWKHFXUUHQWYLVLW2QO \$.OHVLRQVFRPSOHWHO\ZLWKLQ
WKHWUHDWPHQWDUHDZLOOEHFRXQWHG
 3KDUPDFRNLQHWLF3KDUPDFRG\QDPLF3KDUPDFRJHQRPLFDQG2W KHU
%LRPDUNHU$VVHVVPHQWV
1RWDSSOLFDEOH
 6DIHW\$VVHVVPHQWV
6DIHW\DVVHVVPHQWVZLOOLQFOXGHW KHPRQLWRULQJDQGUHFRUGLQJDO O$(V6$(V/65VDQG
HYHQWVRIVSHFLDOLQWHUHVW
$WHDFKVWXG\YLVLWVXEMHFWVZLOOEHDVNHGDJHQHUDOTXHVWLRQ ¬≥+RZKDYH\RXEHHQVLQFHWKH
ODVWYLVLW"¬¥$GYHUVHHYHQWVZLOOEHUHFRUGHGDWHDFKVWXG\YL VLWEHIRUHDVVHVVPHQWRI/65V
SLJPHQWDWLRQDQGVFDUULQJLQWK HWUHDWPHQWDUHD$GYHUVHHYHQ WVZLOOEHUHSRUWHGVHSDUDWHO\
IURP/65V
6DIHW\DVVHVVPHQWVZLOODOVRLQFOXGHYLWDOVLJQVWKHSHUIRUPDQ FHRI3(V(&*VODERUDWRU\
HYDOXDWLRQRIKHPDWRORJ\ELRFKH PLVWU\DQGXULQDO\VHVDVGHWD LOHGLQWKHVHFWLRQVEHORZ
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 $GYHUVH(YHQWV
$OO$(VZLOOEHDVVHVVHG SHULRGLFDOO\WKURXJK'D\ 7DEOH
$Q$(LVDQ\XQWRZDUGPHGLFDORFFXUUHQFHLQDSDWLHQWRUFOLQLF DOLQYHVWLJDWLRQVXEMHFW
DGPLQLVWHUHG DQ LQYHVWLJDWLRQD O SURGXFW  $Q $( GRHV QRW QHFHVV DULO\ KDYH D FDXVDO
UHODWLRQVKLSZLWKWKHPHGLFLQDOS URGXFW)RUWKLVVWXG\WKHV WXG\GUXJVDUH.;
2LQWPHQWDQGYHKLFOHRLQWPHQW
7KHFULWHULDIRULGHQWLI\LQJ$(VLQWKLVVWXG\DUH
x$Q\ XQIDYRUDEOH DQG XQLQWHQGHG VL JQ LQFOXGLQJ DQ DEQRUPDO ODER UDWRU\ ILQGLQJ
V\PSWRPRUGLVHDVHWHPSRUDOO\DVVRFLDWHGZLWKWKHXVHRIDQLQ YHVWLJDWLRQDOSURGXFW
ZKHWKHURUQRWFRQVLGHUHGUHODW HGWRWKHLQYHVWLJDWLRQDOSURGXF W
x$Q\QHZGLVHDVHRUH[DFHUEDWLRQRIDQH[LVWLQJGLVHDVH
x$Q\GHWHULRUDWLRQLQQRQSURWRFRO UHTXLUHGPHDVXUHPHQWVRIDOD ERUDWRU\YDOXHRURWKHU
FOLQLFDOWHVWHJ(&*RU[UD\WKDWUHVXOWVLQV\PSWRPVDFK DQJHLQWUHDWPHQWRU
GLVFRQWLQXDWLRQRIVWXG\GUXJ
x5HFXUUHQFHRIDQLQWHUPLWWHQWPHGLFDOFRQGLWLRQHJKHDGDFKH QRWSUHVHQWSUHWUHDWPHQW
%DVHOLQH
$OO$(VUHJDUGOHVVRIUHODWLRQVKLSWRVWXG\GUXJRUSURFHGXUH VKRXOGEHFROOHFWHGEHJLQQLQJ
IURPWKHWLPHWKHVXEMHFWVLJQVWKHVWXG\,&)WKURXJKWKHILQDO VXEMHFWFRQWDFWLQWKHVWXG\
6XEMHFWVZKRKDYHXQUHVROYHG/65VK\SRRUK\SHUSLJPHQWDWLRQ VFDUULQJLQWKHWUHDWPHQW
DUHDRUWUHDWPHQWUHODWHG$(VDW'D\ZLOOUHWXUQIRUDGGLWL RQDOIROORZXSHYHU\WR
GD\VXQWLOUHVROXWLRQUHWXUQHGW REDVHOLQHRUGHHPHGVWDELOL] HGE\WKH,QYHVWLJDWRUV
6XEMHFWVZKRIDLOVFUHHQLQJSULPDULO\GXHWR$(VPXVWKDYHWK H$(VUHFRUGHGLQWKH$(
H&5)DQGVFUHHQIDLOXUH UHSRUWHGRQWKHH&5)
6XEMHFWVZLWKRQVHWRIDVWXG\WUHDWPHQWUHODWHG$(VZLOOEHIR OORZHGXQWLOUHVROXWLRQXQGHU
PHGLFDOFDUHRUGHHPHGVWDELOL]HGE\WKH,QYHVWLJDWRU$OO6$ (VPXVWEHIROORZHGWR
UHVROXWLRQRULIUHVROXWLRQLVXQOLNHO\WRVWDELOL]DWLRQ
$OO$(VREVHUYHGGXULQJWKHVWXG \ZLOOEHUHSRU WHGRQWKHH&5) 
/DERUDWRU\$GYHUVH(YHQWV
$WUHDWPHQWHPHUJHQWDEQRUPDOOD ERUDWRU\WHVWUHVXOWVKRXOGEH FRQVLGHUHGDVD7($(LIWKH
LGHQWLILHGODERUDWRU\DEQRUPDOLW\OHDGVWRDQ\W\SHRILQWHUYHQ WLRQZKHWKHUSUHVFULEHGLQWKH
SURWRFRORUQRW
$QDEQRUPDOODERUDWRU\UHVXOWV KRXOGEHFRQVLGHUHGE\WKH,QYHV WLJDWRUWREHDQ$(LILW
x5HVXOWVLQWKHZLWKGUDZDORIVWXG\GUXJ
x5HVXOWVLQDQLQWHUYHQWLRQEDVH GRQPHGLFDOHYDOXDWLRQHJSR WDVVLXPVXSSOHPHQWIRU
K\SRNDOHPLD
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
x5HVXOWVLQDQ\RXWRIUDQJHODERUDWRU\YDOXHWKDWLQWKH,QYHVW LJDWRU¬∂VMXGJPHQWIXOILOOV
WKHGHILQLWLRQVRIDQ$(ZLWKU HJDUGWRWKHVXEMHFW¬∂VPHGLFDOS URILOH
$EQRUPDOODERUDWRU\YDOXHVVKRXOG QRWEHOLVWHGDVVHSDUDWH$(V LIWKH\DUHFRQVLGHUHGWREH
SDUWRIWKHFOLQLFDOV\QGURPHWKDWLVEHLQJUHSRUWHGDVDQ$( ,WLVWKHUHVSRQVLELOLW\RIWKH
,QYHVWLJDWRUWRUHYLHZDOOODERUDWRU\ILQGLQJVLQDOOVXEMHFWV DQGGHWHUPLQHLIWKH\FRQVWLWXWH
DQ$(0HGLFDODQGVFLHQWLILFMXGJPHQWVKRXOGEHH[HUFLVHGLQ GHFLGLQJZKHWKHUDQLVRODWHG
ODERUDWRU\ DEQRUPDOLW\ VKRXOG EH FODVVLILHG DV DQ $(  $Q\ ODER UDWRU\ DEQRUPDOLW\
FRQVLGHUHGWRFRQVWLWXWHDQ$( VKRXOGEHUHSRUWHGRQWKH$GYHUV H(YHQWH&5)
(OHFWURFDUGLRJUDP&KDQJHV
$Q\FKDQJHVIURPWKHEDVHOLQH(&*ZLOOEHHYDOXDWHGIRUFOLQLFD OVLJQLILFDQFH(&*
FKDQJHVWKDWDUHGHWHUPLQHGWREHFOLQLFDOO\VLJQLILFDQWUHJDU GOHVVRIUHODWLRQVKLSZLOOEH
UHSRUWHGDVDQ$(
)RUV\PSWRPDWLF(&*D EQRUPDOLWLHVPHHWLQJFU LWHULDDV6$(VWKH VWXG\VLWHPXVWVXEPLWDQ
6$(UHSRUWLQFOXGLQJWKH(&*UHS RUWWRWKH6SRQVRURUGHVLJQHH XVLQJWKH6$(UHSRUWLQJ
SURFHGXUHV 6HFWLRQ 
 $ 66(66,1* 6(9(5,7<2) $'9(56((9(176
(YHU\HIIRUWPXVWEHPDGHE\WKH,QYHVWLJDWRUWRFDWHJRUL]HHDF K$(DFFRUGLQJWRLWV
VHYHULW\
$GYHUVHHYHQWVZLOOEHJUDGHGRQDSRLQWVFDOHPLOGPRGHUDW HVHYHUHDQGUHSRUWHGLQ
GHWDLOLQGLFDWHGRQWKHH&5)7KH GHILQLWLRQVDUHDVIROORZV
0LOG 'LVFRPI[INVESTIGATOR_13318]QRWLFHGEXW QRGLVUXSWLRQRIQRUPDOGDLO\DFWL YLW\
0RGHUDWH 'LVFRPI[INVESTIGATOR_13318]VXIILFLHQW WRUHGXFHRUDIIHFWQRUPDOGDLO\ DFWLYLW\
6HYHUH ,QFDSDFLWDWLQJZLWKLQD ELOLW\WRZRUNRUWRSHUIRUPQR UPDOGDLO\DFWLYLW\
7KH FULWHULD IRU DVVHVVLQJ VHYHU LW\ DUH GLIIHUHQW WKDQ WKRVH XV HG IRU VHULRXVQHVV VHH
6HFWLRQ IRUWKHGHILQLWLRQRIDQ6$(
 $ 66(66,1* 5(/$7,216+,372 678'<75($70(17 
(YHU\HIIRUWPXVWEHPDGHE\WKH,QYHVWLJDWRUWRFDWHJRUL]HHDF K$(DFFRUGLQJWRLWV
UHODWLRQVKLSWRWKHVWXG\WUHDWPHQW
,WHPVWREHFRQVLGHUHGZKHQDVVH VVLQJWKHUHODWLRQVKLSRIDQ$( WRWKHVWXG\WUHDWPHQWDUH
x7HPSRUDOUHODWLRQVKLSRIWKHRQV HWRIWKHHYHQWWRWKHLQLWLDWL RQRIWKHVWXG\WUHDWPHQW 
x7KHFRXUVHRIWKHHYHQWHVSHFLDOO\WKHHIIHFWRIGLVFRQWLQXDWL RQRIVWXG\WUHDWPHQWRU
UHLQWURGXFWLRQRIVWXG\WU HDWPHQWDVDSSOLFDEOH 
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
x:KHWKHUWKHHYHQWLVNQRZQWREHDVVRFLDWHGZLWKWKHVWXG\WUHD WPHQWRUZLWKRWKHU
VLPLODUWUHDWPHQWV 
x7KHSUHVHQFHRIULVNIDFWRUVLQWKHVWXG\VXEMHFWNQRZQWRLQFU HDVHWKHRFFXUUHQFHRIWKH
HYHQW
x7KHSUHVHQFHRIQRQWUHDWPHQWUHOD WHGIDFWRUVWKDWDUHNQRZQWR EHDVVRFLDWHGZLWKWKH
RFFXUUHQFHRIWKHHYHQW 
&ODVVLILFDWLRQRI&DXVDOLW\
7KHUHODWLRQVKLSRIHDFK$(WRWKHVWXG\GUXJZLOOEHUHFRUGHG RQWKHH&5)XVLQJWKH
IROORZLQJFULWHULD
'HILQLWHO\5HODWHG $FOLQLFDOHYHQWLQFOXGLQJOD ERUDWRU\WHVWDEQRUPDOLW\RFFX UULQJLQD
SODXVLEOH WLPH UHODWLRQVKLS WR G UXJ DGPLQLVWUDWLRQ DQG ZKLFK F DQQRW EH H[SODLQHG E\
FRQFXUUHQWRUXQGHUO\LQJGLVHDVH RURWKHUGUXJVRUFRQGLWLRQV
3UREDEO\5HODWHG $FOLQLFDOHYHQWLQFOXGLQJO DERUDWRU\WHVWDEQRUPDOLW\ZLWK DUHDVRQDEOH
WLPHVHTXHQFHWRDGPLQLVWUDWLRQRIWKHGUXJXQOLNHO\WREHDWW ULEXWHGWRFRQFXUUHQWRU
XQGHUO\LQJGLVHDVHRURWKHUGUXJVRUFRQGLWLRQV
3RVVLEO\5HODWHG $FOLQLFDOHYHQWLQFOXGLQJODERUDWRU\WHVWDEQRUPDOLW\ZLWK DUHDVRQDEOH
WLPHVHTXHQFHWRDGPLQLVWUDWLRQRIWKHGUXJEXWZKLFKFRXOGDO VREHH[SODLQHGE\FRQFXUUHQW
RUXQGHUO\LQJGLVHDVHRURWKHUGUXJVRUFRQGLWLRQV
1RW5HODWHG 7KH$(LVFOHDUO\QRWUHODWH GWRLQYHVWLJDWLRQDOSURGXFWDQG LVFOHDUO\UHODWHGWR
XQGHUO\LQJGLVHDVHHQYLURQPHQWD ORUWR[LFIDFWRUVRURWKHU GUXJWKHUDS\
 6HULRXV$GYHUVH(YHQWV
$OO6$(VZLOOEHDVVHVVH GGXULQJWKH7UHDWPHQWDQG5HVSRQVH$VV HVVPHQW3HULRGVRQ
'D\VDQG 7DEOH
$6$(LVDQ\XQWRZDUGPHGLFDOR FFXUUHQFHWKDWDWDQ\GRVH
x5HVXOWVLQGHDWK
x,VOLIHWKUHDWHQLQJLHWKHVXEMHFWZDVDWLPPHGLDWHULVNRIG HDWKIURPWKH$(DVLW
RFFXUUHGWKLVGRHVQRWLQFOXGHDQHYHQWWKDWKDGLWRFFXUUHG LQDPRUHVHYHUHIRUPRU
ZDVDOORZHGWRFRQWLQXH PLJKWKDYHFDXVHGGHDWK
x5HTXLUHVLQSDWLHQWKRV SLWDOL]DWLRQRUSURORQJ DWLRQRIH[LVWLQJ KRVSLWDOL]DWLRQ
x5HVXOWVLQSHUVLVWHQWRUVLJQLILFDQWGLVDELOLW\LQFDSDFLW\
x,VDFRQJHQLWDODQRPDO\ELUWKGHIHFWLQWKHFKLOGRIDVXEMHFW ZKRZDVH[SRVHGWRWKH
VWXG\GUXJ
2WKHULPSRUWDQWPHGLFDOHYHQWVWKDWPD\QRWEHLPPHGLDWHO\OLIH WKUHDWHQLQJRUUHVXOWLQ
GHDWKRUKRVSLWDOL]DWLRQEXWZKHQEDVHGRQDSSURSULDWHPHGLFDO MXGJPHQWPD\MHRSDUGL]H
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
WKHVXEMHFWRUPD\UHTXLUHLQWHUYHQWLRQWRSUHYHQWRQHRIWKHR XWFRPHVLQWKHGHILQLWLRQRI
6$(OLVWHGDERYHVKRXOGDOVREHFRQVLGHUHG6$(V0HGLFDODQGV FLHQWLILFMXGJPHQWVKRXOG
EHH[HUFLVHGLQGHFLGLQJZKHWKHU H[SHGLWHGUHSRUWLQJLVDSSURSU LDWHLQVXFKVLWXDWLRQV
$OO6$(VPXVWEHIROORZHGWRU HVROXWLRQRULIUHVROXWLRQLVXQ OLNHO\WRVWDELOL]DWLRQ
 (YHQWVRI6SHFLDO,QWHUHVW
$OOHYHQWVRIVSHFLDOLQWHUHVWZLOOEHDVVHVVHGGXULQJWKH7UHD WPHQWDQG5HVSRQVH$VVHVVPHQW
3HULRGVRQ'D\VDQG 7DEOH
,QDGGLWLRQWRWKH$(VDQG6$(VGHVFULEHGDERYHHYHQWVRIVSHF LDOLQWHUHVWDUHWREH
FDSWXUHGDQGUHSRUWHGLQWKHDSSU RSULDWHH&5)DQG(YHQWVRI6SH FLDO,QWHUHVW)RUPVVHH
6HFWLRQ (YHQWVRIVSHFLDOLQWHUHVWZLOOEHFRQVLGHUHGDV6$(VLIWKH\P HHWWKHFULWHULD
IRUDQ6$( 6HFWLRQ 
(YHQWVRIVSHFLDOLQWHUHVWGXULQ JWKH7UHDWPHQWDQG5HVSRQVH$V VHVVPHQW3HULRGV'D\VWR
DUHDVIROORZV
x2YHUGRVHRIVWXG\PHGLFDWLRQ 
x3UHJQDQF\ 
x2FXODUH[SRVXUHVWRVWXG\PHGLFDWLRQ
x6NLQFDQFHUVLQFOXGLQJ%&&6&&DQGPHODQRPDORFDWLRQDQGW UHDWPHQWZLOOEH
UHSRUWHG
 &RQFRPLWDQW0HGLFDWLRQV
&RQFRPLWDQWPHGLFDWLRQVZLOOEHDVVHVVHGGXULQJWKH7UHDWPHQWD QG5HVSRQVH$VVHVVPHQW
3HULRGV RQ 'D\V      DQG   7DEOH $Q\ PHGLFDWLRQ LQFOXGLQJ
QRQSUHVFULSWLRQPHGLFDWLRQVRUWKH UDS\DGPLQLVWHUHGWRWKHVXE MHFWGXULQJWKHFRXUVHRIWKH
VWXG\ VWDUWLQJ DW WKH GDWH RI LQIRUPHG FRQVHQW ZLOO EH UHFRUG HG RQ WKH &RQFRPLWDQW
0HGLFDWLRQH&5)XSWR'D\7KH,QYHVWLJDWRUZLOOUHFRUGDQ\ $(RQWKH$GYHUVH(YHQW
H&5)IRUZKLFKWKHFRQFRPLWDQWPHGLFDWLRQWKHUDS\ZDVDGPLQLVWH UHG
8VHRIVXQEORFNIURP'D\RQZDUGRUDQ\WRSLFDOSURGXFWVIRU WKHWUHDWPHQWRI/65VLQ
WKH WUHDWPHQW DUHD DOORZHG E\ WKH ,QYHVWLJDWRU ZLOO EH UHFRUGHG  LQ WKH &RQFRPLWDQW
0HGLFDWLRQH&5)XSWR'D\
 )RFXVHG'HUPDWRORJLFDO([DPRI7UHDWPHQW$UHDDQG6WDQG DUG3KRWRJUDSK\
7KH IRFXVHG GHUPDWRORJLFDO H[DP RI WKH WUHDWPHQW DUHD LQFOXGHV HYDOXDWLRQ RI /65V
SLJPHQWDWLRQDQGVFDUULQJVHH 6HFWLRQ DQG6HFWLRQ UHVSHFWLYHO\
6WDQGDUGL]HGSKRWRJUDSK\ZLOOEH SHUIRUPHGDWWKH5HVSRQVH$VVH VVPHQW9LVLWV'D\V
DQG 7DEOH6HH6HFWLRQ IRUGHWDLOV
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 / 2&$/6.,15($&7,216 
$IWHUWKHDVVHVVPHQWRI$(VDW WKH5HVSRQVH$VVHVVPHQW9LVLWV 'D\VDQG
7DEOHWKH,QYHVWLJDWRURU6XELQYHVWLJDWRUZLOODVVHVVIRU/65VLQ WKHWUHDWPHQWDUHD6HH
6HFWLRQ IRUGHWDLOV7KHVDPH,QYHVWLJDWRURU6XELQYHVWLJDWRUZLOOFRQ GXFWWKH/65
DVVHVVPHQWDWDOOYLVLWVI RUDQLQGLYLGXDOVXEMHFW
$OODSSOLFDWLRQVLWHUHDFWLRQVDQG/65VZLOOEHIROORZHGWRUHV ROXWLRQRULIUHVROXWLRQLV
XQOLNHO\WRVWDELOL]DWLRQ
7UHDWPHQW IRU DQ\ /65 ZLOO EH UHFRUGHG RQ WKH &RQFRPLWDQW 0HGLF DWLRQV H&5)
,QWHUUXSWLRQGLVFRQWLQXDWLRQRIVWX G\WUHDWPHQWIRUDQ/65ZLOO EHUHFRUGHGRQWKHH&5)
 3 ,*0(17$7,21$1' 6&$55,1* 
+\SRDQGK\SHUSLJPHQWDWLRQDQG VFDUULQJLQWKHWUHDWPHQWDUHD ZLOOEHDVVHVVHGDWWKH
5HVSRQVH$VVHVVPHQW9LVLWV'D\VDQG 7DEOH6HH6HFWLRQ IRU
GHWDLOV7KHVDPH,QYHVWLJDWRURU6XELQYHVWLJDWRUZLOODVVHVV SLJPHQWDWLRQDQGVFDUULQJDWDOO
YLVLWVIRUDQLQGLYLGXDOVXEMHFW
 3K\VLFDO([DPLQDWLRQV
$FRPSOHWH3(ZLOOEHSHUIRUPHGRQ'D\ 7DEOHDQGZLOOLQFOXGHZHLJKWDQGDQ
DVVHVVPHQWRIKHDGH\HVHDUVQRVHDQGWKURDW+((17LQWHJ XPHQWDU\JDVWURLQWHVWLQDO
FDUGLRYDVFXODU UHVSLUDWRU\ PXVFX ORVNHOHWDO DQG QHXURORJLFDO V\VWHPV  +HLJKW ZLOO EH
PHDVXUHGDW6FUHHQLQJRQO\
'RFXPHQWDWLRQ RI WKH 3( ZLOO EH LQFOXGHG LQ WKH VRXUFH GRFXPHQW DWLRQ DW WKH VLWHV
&KDQJHVIURPVFUHHQLQJ3(WRILQGLQJVDWWKHODVWYLVLWWKDWPH HWWKHGHILQLWLRQRIDQ$(ZLOO
EHUHFRUGHGRQWKH$GYHUVH(YHQWH&5)
 9LWDO6LJQV
9LWDOVLJQVZLOODOVREHUHFRUG HGDWWKH5HVSRQVH$VVHVVPHQW9L VLWVRQ'D\VDQG
7DEOH9LWDOVLJQSXOVHUDWHV\ VWROLFDQGGLDVWROLFEORRGSUHVVX UHUHVSLUDWRU\UDWHDQG
ERG\WHPSHUDWXUHPHDVXUHPHQWVZLOOEHWDNHQDIWHUWKHVXEMHFW KDVEHHQVHDWHGIRUDWOHDVW
PLQXWHV6HULDOYLWDOVLJQV PD\EHREWDLQHGWRFRQILUPDFFXU DWHUHDGLQJV
&OLQLFDOO\VLJQLILFDQWDEQRUPDOYLWDOVLJQVDVDVVHVVHGE\WKH ,QYHVWLJDWRUZLOOEHUHSRUWHGDV
DGYHUVHHYHQWV
 (OHFWURFDUGLRJUDPV
(OHFWURFDUGLRJUDPVZLOOEHREWDL QHGDWWKH5HVSRQVH$VVHVVPHQW 9LVLWVRQ'D\VDQG
7DEOH6HH6HFWLRQ IRUGHWDLOV
$Q\(&*DEQRUPDOLW\WKDWWKH,QYHVWLJDWRUFRQVLGHUVDVDQ$(VK RXOGEHUHFRUGHGDVVXFKRQ
WKH$GYHUVH(YHQWH&5)
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 /DERUDWRU\0HDVXUHPHQWV
%ORRG ZLOO EH FROOHFWHG IRU FOLQLFDO ODERUDWRU\ WHVWV DW 5HVSRQ VH $VVHVVPHQW 9LVLWV RQ
'D\VDQG 7DEOH&ROOHFWLRQRIEORRGDQGXULQH LQFOXGLQJVDPSOHVIRUSUHJQD QF\
WHVWLQJZKHUHDSSOLFDEOHZ LOOEHFRQGXFWHGDWWKHFOLQLFVLWH $SSUR[LPDWHO\P/RIEORRG
ZLOOEHFROOHFWHGIRUFOLQLFDOODERUDWRU\WHVWLQJLQFOXGLQJSU HJQDQF\WHVWLQJZKHQUHTXLUHG
IRUDWRWDORIP/RIEORRGSH UVXEMHFWGXULQJWKHVWXG\$O OVDPSOHVZLOOEHVHQWWRD
FHQWUDOODERUDWRU\IRUWHVWLQJ
0LFURVFRSLFXULQDO\VLVZLOOEHFRQGXFWHGRQO\ZKHQFOLQLFDOO\L QGLFDWHGEDVHGRQGLSVWLFN
UHVXOWV ODERUDWRU\ SURWRFRO RU D V GHWHUPLQHG E\ WKH ,QYHVWLJD WRU  :KHQ FRQGXFWHG
PLFURVFRSLFXULQDO\VLVUHVXOWV ZLOOEHUHFRUGHGRQWKHH&5)
7KHFOLQLFDOODERUDWRU\WHVWV WREHPHDVXUHGGXULQJWKHVWXG\D UHSURYLGHGLQ7DEOH 
7DEOH &OLQLFDO/DERUDWRU\7HVWV
&DWHJRU\ 3DUDPHWHUV
+HPDWRORJ\ UHGEORRGFHOOV5%&KHPRJORELQKHPDWRFULWSODWHOHWVDQGZ KLWH
EORRGFHOOV:%&ZLWKGLIIHUHQWLDOQHXWURSKLOVO\PSKRF\WHVPRQRF\WHVHRVLQRSKLOVEDVRSKLOV
&KHPLVWU\ 
 (OHFWURO\WHV FKORULGHSRWDVVLXPVRGLXPELFDUERQDWH+&2 
 /LYHUIXQFWLRQWHVWV DODQLQHDPLQRWUDQVIHUDVH$/7DONDOLQH SKRVSKDWDVH$/3DVSDUWDWH
DPLQRWUDQVIHUDVH$67GLUHFWELOLUXELQWRWDOELOLUXELQ
 5HQDOIXQFWLRQWHVWV EORRGXUHDEORRGXUHDQLWURJHQFUHDWLQLQ H
 2WKHU $OEXPLQFDOFLXPFKROHVWHUROJOXFRVHODFWDWHGHK\GURJ HQDVH/'+
SKRVSKRUXVWRWDOSURWHLQWULJO\FHULGHVXULFDFLG
8ULQDO\VLVGLSVWLFN K\GURJHQLRQFRQFHQWUDWLRQS+VSHFLILFJUDYLW\SURWHLQJOX FRVH
NHWRQHVOHXNRF\WHHVWHUDVHQLWULWHELOLUXELQXURELOLQRJHQ EORRG
3UHJQDQF\7HVWLQJ VHUXPSUHJQDQF\WHVWRUXULQHSUHJQDQF\WHVWVHH 7DEOH

$ODERUDWRU\DEQRUPDOLW\PD\PHHWWKHFULWHULDWRTXDOLI\DVDQ $(DVGHVFULEHGLQWKLV
SURWRFROVHH 6HFWLRQ ,QWKHVHLQVWDQFHVWKH$(FRUUHVSRQGLQJWRWKHODERUDWRU\
DEQRUPDOLW\ZLOOEHUHFRUGH GRQWKH$GYHUVH(YHQWH&5)
)RUODERUDWRU\DEQRUPDOLWLHVPHHWLQJWKHFULWHULDRI6$(VVHH 6HFWLRQ WKHVLWHPXVW
UHSRUWWKH6$(LQFOXGLQJWKHO DERUDWRU\UHSRUWDVUHJLRQDOO\ UHTXLUHGWRWKH6SRQVRUXVLQJ
WKH6$(IRUPVHH 6HFWLRQ 
 3UHJQDQF\7HVWLQJ
6HUXPSUHJQDQF\WHVWVZLOOEHREWDLQHGDWWKH5HV SRQVH$VVHVVPHQW9LV LWVRQ'D\VDQG
7DEOH$OOVDPSOHVZLOOEHVHQWWRD FHQWUDOODERUDWRU\IRUWHVWLQ J
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 $GGLWLRQDO)ROORZXS$VVHVVPHQWV
$OO VXEMHFWV ZKR KDYH XQUHVROYHG /65V K\SR RU K\SHUSLJPHQWDW LRQ VFDUULQJ LQ WKH
WUHDWPHQWDUHDRUWUHDWPHQWUHODWHG$(VDW'D\ZLOOUHWXUQ IRUDGGLWLRQDOIROORZXSHYHU\
WRGD\VXQWLOUHVROXWLRQUHWXUQHGWREDVHOLQHRUGHHPHG VWDELOL]HGE\WKH,QYHVWLJDWRUV
 5HFXUUHQFH)ROORZXS3HULRG$VVHVVPHQWV
 5HFXUUHQFH$VVHVVPHQWV
$GHUPDWRORJLVW,QYHVWLJDWRURU 6XELQYHVWLJDWRUZLOOSHUIRUP DFRXQWRIFOLQLFDOO\YLVLEOH$.
OHVLRQVOHVLRQFRXQWIRUVXEMHFWVZKRDFKLHYHFOHDUDQFH RI$.OHVLRQVLQWKHWUHDWPHQW
DUHDDW'D\GXULQJWKH5HFXUUHQFH)ROORZXS3HULRGDWWKH DQGPRQWKYLVLWV
7DEOH7KH,QYHVWLJDWRURU6XELQYHVWLJDWRUSHUIRUPLQJWKHOHVLRQF RXQWVKRXOGEHWKH
VDPH,QYHVWLJDWRURU6XELQYHVWLJ DWRUZKRHYDOXDWHGWKHVXEMHFW SUHYLRXVO\GXULQJWKHVWXG\
$Q$.OHVLRQVKRXOGEHFRXQWHGRQO\LILWLVFRPSOHWHO\LQVLGH WKHWUHDWPHQWDUHD$OO$.
OHVLRQVLQWKHWUHDWPHQWDUHD PXVWEHFRXQWHGDQGUHFRUGHGLQW KHH&5)DVDQ$.UHFXUUHQFH
:KHQ$.OHVLRQVDUHLGHQWLILHGLQWKHWUHDWPHQWDUHDWKHWUDQV SDUHQF\ZKLFKZDVXVHGWR
PDSWKH$.OHVLRQVDW%DVHOLQHV KRXOGEHXVHGWRGHWHUPLQHLIW KHOHVLRQVLVQHZLHRQH
ZKLFKZDVQRWLGHQWLILHGLQWKHWDUJHWWUHDWPHQWDUHDDW%DVHOL QHDQGHPHUJHQWGXULQJWKH
5HFXUUHQFH)ROORZXS3HULRGRUUHFXUUHGLHRQHZKLFKLVDWW KHVDPH$.OHVLRQORFDWLRQ
LGHQWLILHGDW%DVHOLQHDQ GUHVROYHGDW'D\
)RU VXEMHFWV ZKR KDYH FRPSOHWH UHVSRQVH DW 'D\  DQG QR UHFXUU HQFH PRQWKV
SRVW'D\LVWKH)LQDO9LVLW6XEMHFWVZKRKDYH$.UHFXUUHQF HLQWKHWUHDWPHQWDUHDZLOO
KDYHWKHLU)LQDO9LVLWDWWKHYLV LWZKHQWKH$.UHFXUUHQFHLVL GHQWLILHG6XEMHFWVZKRGHYHORS
$. OHVLRQV LQ WKH WUHDWPHQW DUHD GXULQJ WKH 5HFXUUHQFH )ROORZX S 3HULRG ZLOO EH
GLVFRQWLQXHGDWWKHWLPHRIUHFXUUHQFH
 6DIHW\$VVHVVPHQWV
'XULQJWKH5HFXUUHQFH)ROORZXS3HULRGVDIHW\DVVHVVPHQWVZLOO LQFOXGHWKHPRQLWRULQJDQG
UHFRUGLQJRI$(VDQG6$(VZLWKLQWKHWUHDWPHQWDUHDDWWKH DQGPRQWKYLVLWV
7DEOH6HH6HFWLRQ IRUIXUWKHULQIRUPDWLRQRQWKHDVVHVVPHQWVRI$(V
&RQFRPLWDQW PHGLFDWLRQVWKHUDSLHV JLYHQ IRU $(V ZLWKLQ WKH WUHD WPHQW DUHD DQG DQ\
FRQFRPLWDQW PHGLFDWLRQVWKHUDSLHV JLYHQ WKDW PD\ DIIHFW DVVHVVP HQW RI $. OHVLRQV
UHFXUUHQFHLQWKHWUHDWPHQWDUHDZLOOEHDVVHVVHGGXULQJWKH5H FXUUHQFH)ROORZXS3HULRGDW
WKHDQGPRQWKYLVLWV 7DEOHDQGZLOOEHUHFRUGHGRQWKH&RQFRPLWDQW
0HGLFDWLRQH&5)7KH,QYHVWLJDWRUZLOOUHFRUGDQ\$(ZLWKLQWK HWUHDWPHQWDUHDRQWKH
$GYHUVH(YHQWH&5)IRUZKLFKWKHFRQFRPLWDQWPHGLFDWLRQWKHUDS\ ZDVDGPLQLVWHUHG
(YHQWVRIVSHFLDOLQWHUHVWGXULQJWKH5HFXUUHQFH)ROORZXS3HUL RGLQFOXGHVNLQFDQFHUV
LQFOXGLQJ%&&6&&PHODQRPDZLWKLQWKHWUHDWPHQWDUHDDQGSU HJQDQF\,QIRUPDWLRQRQ
VNLQFDQFHUVZLOOEHFROOHFWHGGXULQJWKH5HFXUUHQFH)ROORZXS 3HULRGDWWKHDQG
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
PRQWKYLVLWVDQGUHSRUWHGDVD QHYHQWRIVSHFLDOLQWHUHVWDQ GDVDQ$(LQWKH$GYHUVH
(YHQWH&5)VHH 6HFWLRQ 
 $SSURSULDWHQHVVRI0HDVXUHPHQWV
$OOFOLQLFDODVVHVVPHQWVDUHVWD QGDUGPHDVXUHPHQWVFRPPRQO\XVH GLQVWXGLHVRIDGXOWVZLWK
$.
7KHVDIHW\DVVHVVPHQWVWREHSHUIRUPHGLQWKLVVWXG\LQFOXGLQJ KHPDWRORJ\DQDO\VHVEORRG
FKHPLVWU\WHVWVXULQDO\VLVYLWD OVLJQV3(V(&*VDQGDVVHVV PHQWRI$(VDUHVWDQGDUG
HYDOXDWLRQVWRHQVXUHVXEMHFWVDIHW\7KHWHVWVXVHGWRHYDOXD WH$.OHVLRQVLQFOXGLQJ$.
OHVLRQFRXQWLQJ/65JUDGLQJDSS OLFDWLRQVLWH$(VDQGHYDOXDW LRQRISLJPHQWDWLRQDQG
VFDUULQJLQWKHWUHDWPH QWDUHDDUHVWDQGDUG
 (;3(',7('5(3257,1*
6HULRXV DGYHUVH HYHQWV DQG HYHQWV  RI VSHFLDO LQWHUHVW RYHUGRVH  RI VWXG\ PHGLFDWLRQ
SUHJQDQF\RFXODUH[SRVXUHWRVWXG\PHGLFDWLRQDQGVNLQFDQFHU V>LQFOXGLQJ%&&6&&DQG
PHODQRPD@DUHWREHUHSRUWHGWRWKH6SRQVRUZLWKLQEXVLQHVV GD\RIWKH,QYHVWLJDWRU
EHFRPLQJDZDUHRIWKHHYHQW6SHFLILFIRUPVIRUUHSRUWLQJHDFK W\SHRIHYHQWZLOOEH
SURYLGHGWRWKHVLWHV
7KH 6SRQVRU RU LWV GHVLJQHH PXVW LQIRUP ,QYHVWLJDWRUV DQG UHJ XODWRU\ DXWKRULWLHV RI
UHSRUWDEOHHYHQWVLQFRPSOLDQFH ZLWKDSSOLFDEOHUHJXODWRU\UHT XLUHPHQWVRQDQH[SHGLWHG
EDVLVLHZLWKLQVSHFLILFWLPHIUDPHV)RUWKLVUHDVRQLWLV LPSHUDWLYHWKDWVLWHVSURYLGH
FRPSOHWH6$(DQGHYHQWVRIVSHFL DOLQWHUHVWLQIRUPDWLRQLQWKH PDQQHUGHVFULEHGEHORZ
,QGHWHUPLQLQJZKDW6$(VPHHWFULWHULDIRUH[SHGLWHGUHSRUWLQJ WKHFXUUHQWYHUVLRQRIWKH
.;2LQWPHQW,QYHVWLJDWRU¬∂V% URFKXUHZLOOEHXVHGDVWKHUH IHUHQFHVDIHW\LQIRUPDWLRQ
IRU.;2LQWPHQW
 5HSRUWLQJRI6HULRXV$GYHUVH(YHQWV
$OO6$(VUHJDUGOHVVRIWKHLUUHODWLRQVKLSWRVWXG\WUHDWPHQW PXVWEHUHSRUWHGRQD
FRPSOHWHG6$(IRUPE\HOHFWURQLFWUDQVPLVVLRQDVVRRQDVSRVVLE OHEXWQRODWHUWKDQ
EXVLQHVVGD\IURPWKHGDWHWKH ,QYHVWLJDWRUEHFRPHVDZDUHRI WKHHYHQW
'HWDLOHGFRQWDFWLQIRUPDWLRQDQG6$(UHSRUWLQJUHTXLUHPHQWVZLO OEHSURYLGHGLQWKH
,QYHVWLJDWRU)LOH 
'XULQJ6FUHHQLQJ7UHDWPHQWDQG5HVSRQVH$VVHVVPHQW3HULRGVDO O6$(VPXVWEHUHSRUWHG
EHJLQQLQJIURPWKHWLPHWKHVXEMHFWVLJQVWKHVWXG\,&)XSWR GD\VIROORZLQJWKHODVW
FRQWDFWRU'D\ZKLFKHYHULVV KRUWHU$OO6$(VZLOOEHUHSR UWHGUHJDUGOHVVRIFDXVDOLW\
'XULQJWKH5HFXUUHQFH)ROORZXS3HULRGRQO\6$(VZLWKLQWKHWU HDWPHQWDUHDZLOOEH
UHSRUWHG6$(VZLWKLQWKHWUHDWPHQWDUHDZLOOEHUHSRUWHGUHJD UGOHVVRIFDXVDOLW\2QFH
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
UHFXUUHQFHRI$.OHVLRQVRFFXUVLQWKHWUHDWPHQWDUHDDQGWKH VXEMHFWLVGLVFRQWLQXHGIURP
WKH5HFXUUHQFH)ROORZXS3HUL RG6$(VZLOOQRORQJHUEHFROOHFW HG
$Q\6$(HYHQWMXGJHGE\WKH,QYHVWLJDWRUWREHUHODWHGGHILQLW HO\SUREDEO\RUSRVVLEO\
UHODWHGWRVWXG\WUHDWPHQWVKRXO GEHUHSRUWHGWRWKH6SRQVRUU HJDUGOHVVRIWKHOHQJWKRIWLPH
WKDWKDVSDVVHGVLQFHVWXG\FRPSOHWLRQ
'HDWKVDQGOLIHWKUHDWHQLQJHYHQWVVKRXOGEHUHSRUWHGLPPHGLDWH O\E\WHOHSKRQH7KH
LQLWLDOUHSRUWPXVWEHVXEPLWWHGZLWKLQEXVLQHVVGD\E\HOHFW URQLFDOO\WUDQVPLWWLQJWKH
FRPSOHWHG6$(IRUP 
,WLVYHU\LPSRUWDQWWKDWWKH6$(5HSRUW)RUPEHILOOHGRXWDV FRPSOHWHO\DVSRVVLEOHDWWKH
WLPHRIWKHLQLWLDOUHSRUW7KLVLQFOXGHVWKH,QYHVWLJDWRU¬∂VD VVHVVPHQWRIFDXVDOLW\$OO
VXSSRUWLQJGRFXPHQWVVKRXOGEHVHQ WGHLGHQWLILHGDQGVKRXOGFR QWDLQWKHVXEMHFW¬∂VDVVLJQHG
HQUROOPHQWQXPEHU2QO\VXSSRUWLQJGRFXPHQWVGLUHFWO\UHODWHG WRWKHHYHQWVKRXOGEHVHQW
$Q\IROORZXSLQIRUPDWLRQUHFHLYH GRQ6$(VVKRXOGEHIRUZDUGHG DVVRRQDVSRVVLEOH,IWKH
IROORZXSLQIRUPDWLRQFKDQJHVWKH,QYHVWLJDWRU¬∂VDVVHVVPHQWRI FDXVDOLW\WKLVVKRXOGDOVREH
QRWHGRQWKHIROORZXS6$(IRUP
3UHOLPLQDU\6$(UHSRUWVVKRXOGEHIROORZHGDVVRRQDVSRVVLEOH E\GHWDLOHGGHVFULSWLRQV
LQFOXGLQJUHGDFWHGFRSLHVRIKRVS LWDOFDVHUHSRUWVDXWRSV\UHS RUWVDQGRWKHUGRFXPHQWV
UHTXHVWHGE\WKH6SRQVRU
 5HSRUWLQJRI(YHQWVRI6SHFLDO,QWHUHVW
 3UHJQDQF\
$Q\SUHJQDQF\ZKHWKHURFFXUULQJLQDVXEMHFWRULQWKHIHPDOH SDUWQHURIDPDOHVXEMHFW
PXVWEHUHSRUWHG3UHJQDQFLHVL QIHPDOHVXEMHFWVIRUZKLFKWKH HVWLPDWHGGDWHRIFRQFHSWLRQ
ZDVSULRUWR'D\PXVWEHUHSRU WHGSUHJQDQFLHVLQIHPDOHSDU WQHUVRIPDOHVXEMHFWVIRU
ZKLFKWKHHVWLPDWHGGDWHRIFRQFHSWLRQZDVZLWKLQGD\VRIWK HODVWVWXG\WUHDWPHQWPXVW
EHUHSRUWHG
7KH3UHJQDQF\5HSRUW)RUPPXVWEHXVHGIRUUHSRUWLQJ3UHJQDQF LHVPXVWEHUHSRUWHGE\
HOHFWURQLFWUDQVPLVVLRQDVVRRQDV SRVVLEOHEXWQRODWHUWKDQ EXVLQHVVGD\IURPWKHGDWHWKH
,QYHVWLJDWRUEHFRPHVDZDUHRIWKHSUHJQDQF\7KHFRQWDFWLQIRU PDWLRQIRUWKHUHSRUWLQJRI
SUHJQDQFLHVLVSURYLGHGL QWKH,QYHVWLJDWRU)LOH
,IDQDGYHUVHRXWFRPHRIDSUHJQDQF\LVVXVSHFWHGWREHUHODWHG WRVWXG\GUXJH[SRVXUHWKLV
VKRXOGEHUHSRUWHGUHJD UGOHVVRIWKHOHQJW KRIWLPHWKDWKDVSD VVHGVLQFHWKHH[SRVXUHWRVWXG\
WUHDWPHQW
$FRQJHQLWDODQRPDO\GHDWKGXU LQJSHULQDWDOSHULRGDQLQGXFHG DERUWLRQRUDVSRQWDQHRXV
DERUWLRQDUHFRQVLGHUHGWREH6$( VDQGVKRXOGEHUHSRUWHGLQWK HVDPHWLPHIUDPHDQGLQWKH
VDPHIRUPDWDVDOO RWKHU6$(VVHH 6HFWLRQ 
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
$OOSUHJQDQFLHVPXVWEHIROORZHGWRRXWFRPH7KHRXWFRPHRIWK HSUHJQDQF\PXVWEH
UHSRUWHGDVVRRQDVSRVVLEOHEXWQRODWHUWKDQEXVLQHVVGD\I URPWKHGDWHWKH,QYHVWLJDWRU
EHFRPHVDZDUHRIWKHRXWFRPH
$IHPDOHVXEMHFWZKREHFRPHVSUHJ QDQWGXULQJWKH7UHDWPHQW3HUL RGPXVWEHZLWKGUDZQ
IURPVWXG\WUHDWPHQWEXWPD\FRQWLQXHDOOVWXG\DVVHVVPHQWVDQ GEHIROORZHGIRUVWXG\
RXWFRPH0DOHVXEMHFWVZKRVHIHPDOHSDUWQHUVEHFRPHSUHJQDQWG XULQJWKH7UHDWPHQW
3HULRGPD\FRQWLQXHZLWKVWXG\W UHDWPHQWDQGDOO DVVHVVPHQWV
$SUHJQDQWIHPDOHVXEMHFWVKRXOG EHUHTXHVWHGWRSURYLGHRXWFRP HLQIRUPDWLRQRQDQ\
SUHJQDQF\ RFFXUULQJ GXULQJ WKH 7 UHDWPHQW 3HULRG RU WKH 5HFXUUHQ FH )ROORZXS 3HULRG
ZKHWKHURUQRWWKHVXEMHFWHOHFW VWRFRQWLQXHZLWKVWXG\DVVHVV PHQWV0DOHVXEMHFWVZKRVH
IHPDOHSDUWQHUVEHFRPHSUHJQDQWZLWKLQGD\VRIWKHODVWVWXG \WUHDWPHQWVKRXOGEH
UHTXHVWHGWRSURYLGHRXWFRPHL QIRUPDWLRQRQWKHSUHJQDQF\
 6WXG\'UXJ2YHUGRVH
6WXG\GUXJRYHUGRVHLVGHILQHGDVWKHDFFLGHQWDORULQWHQWLRQDO XVHRIWKHGUXJLQDQDPRXQW
KLJKHUWKDQWKHGRVHEHLQJVWXGL HGRUIRUDGXUDWLRQORQJHUWKD QVSHFLILHGLQWKHSURWRFRO
7KH2YHUGRVH5HSRUW)RUPPXVWEHXVHGIRUUHSRUWLQJ 7KHRYHUGRVHPXVWEHUHSRUWHGE\
HOHFWURQLFWUDQVPLVVLRQDVVRRQDV SRVVLEOHEXWQRODWHUWKDQ EXVLQHVVGD\IURPWKHGDWHWKH
,QYHVWLJDWRUEHFRPHVDZDUHRIW KHHYHQW7KHFRQWDFWLQIRUPDWL RQIRUWKHUHSRUWLQJRI
RYHUGRVHLVSURYLGHGLQW KH,QYHVWLJDWRU)LOH 
$Q\VWXG\GUXJRYHUGRVHGXULQJWKHVWXG\PXVWEHQRWHGRQWKHH &5)
$OO$(VDVVRFLDWHGZLWKRYHUGRVHVKRXOGEHFDSWXUHGRQWKH2YHU GRVH5HSRUW)RUPDQGWKH
$GYHUVH(YHQWH&5) ,IWKHRYHUGRVHLVDVVRFLDWHGZLWKDQ6$(DQ6$(5HSRUW)RUP
VKRXOGEHFRPSOHWHGD QGVHQWDORQJZLWKWKH2YHUGRVH)RUP
 2FXODU([SRVXUH
2FXODUH[SRVXUHWRVWXG\PHGL FDWLRQZLOOEHUHSRU WHGDVDQHYHQ WRIVSHFLDOLQWHUHVW
7KH2FXODU([SRVXUH5HSRUW)RUP PXVWEHXVHGIRUUHSRUWLQJ 7KHRFXODUH[SRVXUHPXVWEH
UHSRUWHGE\HOHFWURQLFWUDQVPL VVLRQDVVRRQDVSRVVLEOHEXWQR ODWHUWKDQEXVLQHVVGD\IURP
WKHGDWHWKH,QYHVWLJDWRUEHFRPHVDZDUHRIWKHHYHQW7KHUHVX OWVRIDQRSKWKDOPRORJLVW¬∂V
DVVHVVPHQWPXVWEHSURYLGHGDVD IROORZXSRQWKH2FXODU([SRVX UH5HSRUW)RUP7KH
FRQWDFWLQIRUPDWLRQ IRUWKHUHSRUWLQJRI RFXODUH[SRVXUH LVSURYLGHGLQWKH,QYHVWLJDWRU)LOH 
2FXODUH[SRVXUHWRVWXG\PHGLFDWLRQPXVWEHFDSWXUHGRQWKHDSS URSULDWHH&5),IWKH
RFXODUH[SRVXUHLVDVVRFLDWHGZLWKDQ$(WKH$(PXVWEHFDSWXU HGRQWKH2FXODU([SRVXUH
5HSRUW)RUPDQGWKH$ GYHUVH(YHQWH&5) ,IWKHRFXODUH[SRVXUH LVDVVRFLDWHGZLWKDQ6$(
DQ6$(5HSRUW)RUPVKRXOGEHFRPSOHWHGDQGVHQWDORQJZLWK 2FXODU([SRVXUH5HSRUW
)RUP
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 6NLQ&DQFHU
'XULQJWKH7UHDWPHQWDQG5HVSRQV H$VVHVVPHQW3HULRGV'D\VWR DOOVNLQFDQFHUV
LQFOXGLQJ%&&6&&DQGPHODQRPDZLOOEHUHSRUWHGDVHYHQWVR IVSHFLDOLQWHUHVW7KH
ORFDWLRQDQGWUHDWPHQWZLOOEHUHSRUWHG'XULQJWKH5HFXUUHQFH )ROORZXS3HULRGVNLQ
FDQFHUVLQFOXGLQJ%&&6&&DQGPHODQRPDZLWKLQWKHWUHDWPHQW DUHDZLOOEHUHSRUWHGDV
HYHQWVRIVSHFLDOLQWHUHVW7KH WUHDWPHQWRIWKHVNLQFDQFHUZ LOOEHUHSRUWHG
7KH6NLQ&DQFHU5HSRUW)RUP PXVWEHXVHGIRUUHSRUWLQJ 7KHVNLQFDQFHUPXVWEHUHSRUWHG
E\HOHFWURQLFWUDQVPLVVLRQDVVRRQDVSRVVLEOHEXWQRODWHUWKD QEXVLQHVVGD\IURPWKHGDWH
WKH,QYHVWLJDWRUEHFRPHVDZDUHRIWKHHYHQW7KHFRQWDFWLQIRU PDWLRQIRUWKHUHSRUWLQJRI
VNLQFDQFHUV LVSURYLGHGLQWKH,QYHVWLJDWRU)LOH 
7KHVNLQFDQFHUPXVWEHFDSWXUHGRQWKH$GYHUVH(YHQWH&5)$Q \RWKHU$(VDVVRFLDWHG
ZLWKWKHVNLQFDQFHUPXVWEHFDSWXUHGRQWKH6NLQ&DQFHU5HSRUW )RUPDQGWKH$GYHUVH
(YHQWH&5) ,IWKHVNLQFDQFHU LVDVVRFLDWHGZLWKDQ6$(DQ6$(5HSRUW)RUPVKRXOGEH
FRPSOHWHGDQGVHQWDORQJZLWK 6NLQ&DQFHU5HSRUW) RUP
 %UHDNLQJWKH%OLQG
7KH 3KDUPDFRYLJLODQFH GHSDUWPHQW ZLOO PDLQWDLQ D VHFXUH FRS\ RI  WKH VHW RI VHDOHG
HQYHORSHVHDFKFRQWDLQLQJWKHV XEMHFW¬∂VWUHDWPHQWDOORFDWLRQI RUWKLVVWXG\7KH,QYHVWLJDWRU
PD\UHTXHVWWRXQEOLQGWKHWUHDWPHQWDVVLJQPHQWRIDQ\VXEMHFW ZKHQWKLVLVQHHGHGIRU
SURSHUPHGLFDOPDQDJHPHQWRIDPHGLFDOHPHUJHQF\RU6$($JUHH PHQWRIWKH6SRQVRU¬∂V
0HGLFDO 0RQLWRU RU GHVLJQHH V KRXOG EH VRXJKW SULRU WR XQEOLQGLQ J  ,QVWUXFWLRQV IRU
UHTXHVWLQJXQEOLQGLQJRIDVXEM HFWZLOOEHSURYLGHGLQWKH&OLQ LFDO2SHUDWLRQV0DQXDO
7KH3KDUPDFRYLJLODQFHGHSDUWPH QWPD\XQEOLQGLQGLYLGXDOFDVHVZ KHQUHTXLUHGIRUVDIHW\
UHSRUWLQJ7KHWUHDWPHQWDVVLJQPHQWZLOOEHLQFOXGHGRQWKH0H G:DWFKRU&,206IRUPIRU
VXVSHFWHG XQH[SHFWHG VHULRXV DGYHUVH UHDFWLRQ 686$5 UHSRUWV S URYLGHG WR KHDOWK
DXWKRULWLHV 
 67$7,67,&$/0(7+2'6
 6WDWLVWLFDODQG$QDO\WLFDO3ODQV
$OOVWDWLVWLFDODQDO\VHVZLOOEH SHUIRUPHGE\WKH6SRQVRURUGH VLJQHHDIWHUWKHGDWDEDVHLV
ORFNHG DQG UHOHDVHG IRU XQEOLQGLQJ  'DWDEDVH ORFN UDQGRPL]DWL RQ FRGH UHOHDVH DQG
VXEVHTXHQWGDWDDQDO\VHV ZLOOEHSHUIRUPHGLQVWHSV
)RUWKHILUVWVWHSDIWHUDOO GRVHGVXEMHFWVKDYHFRPSOHWHGWKH 'D\9LVLWRUGLVFRQWLQXHGE\
WKH'D\9LVLWDQGDIWHUDOO/65VK\SRRUK\SHUSLJPHQWDW LRQVFDUULQJRUWUHDWPHQW
UHODWHG$(VZKLFKRFFXUEHIRUHRURQWKH'D\9LVLWKDYHUHVR OYHGUHWXUQHGWREDVHOLQHRU
EHHQGHHPHGVWDELOL]HGE\WKH,QYHVWLJDWRUVWKHGDWDFROOHFWHG EHIRUHWKH5HFXUUHQFH)ROORZ
XS3HULRGZLOOEHORFNHGDQGWK HUDQGRPL]DWLRQFRGHZLOOEHUHO HDVHGWRWKH6SRQVRURQO\
7KHHQGSRLQWDQDO\VHVH[FHSWIRUWKHUHFXUUHQFHUDWHDQG$(VL QWKHWUHDWPHQWDUHDDIWHU'D\
ZLOOEHSHUIRUPHG
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
)RUWKHVHFRQGVWHSDIWHUWKHHQWLUHVWXG\KDVEHHQFRPSOHWHG WKHGDWDFROOHFWHGGXULQJWKH
5HFXUUHQFH)ROORZXS3HULRGZLOO EHORFNHGDQGWKHUDQGRPL]DWLR QFRGHZLOOEHUHOHDVHGWR
WKHVWXG\VLWHVDVZHOO7KHQWKHUHFXUUHQFHUDWHDQG$(VLQ WKHWUHDWPHQWDUHDDIWHU'D\
ZLOOEHDQDO\]HG
6WDWLVWLFDODQDO\VHVZLOOEHSHUIRUPHGXVLQJ6$6VRIWZDUHRURW KHUYDOLGDWHGVWDWLVWLFDO
VRIWZDUHDVUHTXLUHG7KHVWDWLVWLFDODQDO\VHVRIWKHVWXG\GD WDDUHGHVFULEHGLQWKLVVHFWLRQ
)XUWKHUGHWDLOVRIWKHVWDWLVWL FDODQDO\VHVZLOOEHLQFOXGHGLQ DVHSDUDWHVWDWLVWLFDODQDO\VLVSODQ
6$3ZKLFKZLOOEHZULWWHQD QGVLJQHGRIISULRUWRXQEOLQGLQJ RI'D\GDWD
,IQRWVSHFLILHGWKHEDVHOLQHYDOXHRIHDFKDVVHVVPHQWZLOOEH GHILQHGDVWKHODWHVWQRQ
PLVVLQJYDOXHDVVHVVHGEHIRUHWK HILUVWGRVHRIVWXG\WUHDWPHQW 
 6WXG\(QGSRLQWV
 3ULPDU\(QGSRLQW
&RPSOHWHFOHDUDQFHUDWHRI $.OHVLRQVGHILQHGDVWKHSU RSRUWLRQRIVXEMHFWVDW
'D\ZLWKQRFOLQLFDOO\YLVLEOH $.OHVLRQVLQWKHWUHDWPHQWD UHD
 6HFRQGDU\(QGSRLQWV
6HFRQGDU\HQGSRLQWVDUHDVIROORZV
x(YDOXDWLRQRI/65VSLJPHQWDWLRQ DQGVFDUULQJLQWKHWUHDWPHQW DUHD$(V6$(V
HYHQWVRIVSHFLDOLQWHUHVWFOLQLFDOODERUDWRU\GDWDDQGRWKHU VDIHW\DVVHVVPHQWVYLWDO
VLJQV3(V(&*V
x3DUWLDOFOHDUDQFHUDWHRI$.OHVL RQVGHILQHGDVWKHSURSRUWLRQ RIVXEMHFWVDW'D\
ZLWKD¬ïUHGXFWLRQLQWKHQXPEHURI$.OHVLRQVLGHQWLILHGDW %DVHOLQH'D\
SUHGRVHLQWKHWUHDWPHQWDUHD
x5HGXFWLRQLQ$.OHVLRQFRXQWVGXULQJ'D\VWR
x5HFXUUHQFHUDWHRI$.OHVLRQVL QVXEMHFWVZKRDFKLHYHGFRPSOHWH FOHDUDQFHDW'D\
x$(VZLWKLQWKHWUHDWPHQWDU HDDIWHU'D\DQGXSWRPRQWKV SRVW'D\
 'HILQLWLRQVRI$QDO\VLV6HWV
,QWHQW7R7UHDW,773RSXODWLRQ DOOUDQGRPL]HGVXEMHFWV7KLVLVWKHSULPDU\HIILFDF\
SRSXODWLRQ
3HU3URWRFRO33(YDOXDEOH3RSXODWLRQ DOOUDQGRPL]HGVXEMHFWVZKRKDYHUHFHLYHGDW
OHDVW RI WKH GRVHV FRQIRUPHG WR WKH SURWRFRO DV WR HQWU\ F ULWHULD GLG QRW UHFHLYH
FRQFRPLWDQWPHGLFDWLRQVWKDWFD QDIIHFWHIILFDF\DQGUHWXUQHG IRUWKHILQDOYLVLWRQ'D\
6DIHW\3RSXODWLRQ DOOUDQGRPL]HGVXEMHFWVZKRKDYHUHFHLYHGDWOHDVWRQHGRVH RIVWXG\
WUHDWPHQW
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
5HFXUUHQFH )ROORZXS 3RSXODWLRQ DOO VXEMHFWV ZKR DFKLHYHG FRPSOHWH FOHDUDQFH DW
'D\UHJDUGOHVVRIZKLFKW UHDWPHQWWKH\UHFHLYHG
 6XEMHFW'LVSRVLWLRQ
$OOVXEMHFWVZLOOEHWDEXODWHGDVWRVWXG\GLVFRQWLQXDWLRQDQG WKHUHDVRQVIRUGLVFRQWLQXDWLRQ
DVGHVFULEHGLQ 6HFWLRQ 
'LVFRQWLQXDWLRQVWKURXJK'D\DQGGXULQJWKH5HFXUUHQFH)ROOR ZXS3HULRGZLOOEH
DQDO\]HGVHSDUDWHO\
 'HPRJUDSKLFDQG2WKHU%DVHOLQH&KDUDFWHULVWLFV
'HPRJUDSKLFDQGEDVHOLQHFKDUDFWHULVWLFVZLOOEHVX[COMPANY_003]UL]HG) RUFRQWLQXRXVGHPRJUDSKLF
YDULDEOHV UHVXOWV ZLOO EH SUHVHQWHG DV Q PHDQ VWDQGDUG GHYLD WLRQ 6' PHGLDQ DQG
PLQLPXPDQGPD[LPXPYDOXHV)RUFDWHJRULFDOQRPLQDORURUGLQD OYDULDEOHVWKHQXPEHU
DQGSHUFHQWDJHRIVXEMHFWVZLOOEH VX[COMPANY_003]UL]HGIRUHDFKFDWHJRU\ 
 3ULRUDQG&RQFRPLWDQW7KHUDS\
$OOLQYHVWLJDWRUWHUPVIRUPHGLFDWLRQVUHFRUGHGLQWKHH&5)ZLO OEHFRGHGXVLQJWKH:+2
'UXJ'LFWLRQDU\
3ULRUPHGLFDWLRQVZLOOEHGHILQHGDVPHGLFDWLRQVWKHUDSLHVWDNH QGD\VEHIRUH'D\
&RQFRPLWDQWPHGLFDWLRQVWKHUDSLHVZLOOEHGHILQHGDVPHGLFDWLRQ VWKHUDSLHVWKDWVWDUWHG
EHIRUHWKHILUVWGRVHRIVWXG\GUXJDQGZHUHFRQWLQXLQJDWWKH WLPHRIWKHILUVWGRVHRIVWXG\
GUXJRUVWDUWHGRQRUDIWHUWKH GDWHRIWKHILUVWGRVHRIV WXG\GUXJ
3ULRUDQGFRQFRPLWDQWPHGLFDWLRQVZLOOEHIXUWKHUFRGHGWRWKH DSSURSULDWH$QDWRPLFDO
7KHUDSHXWLF&KHPLFDO $7& FRGH LQGLFDWLQJ WKHUDSHXWLF FODVVLIL FDWLRQ$VX[COMPANY_003]U\RI
FRQFRPLWDQWPHGLFDWLRQVE\GUXJDQGGUXJFODVVZLOOEHLQFOXGHG LQWKHFOLQLFDOVWXG\UHSRUW
IRUWKLVSURWRFRO
$OOSULRUDQGFRQFRPLWDQWPHGLFD WLRQVWKHUDSLHVZLOOEHSUHVHQW HGLQVXEMHFWGDWDOLVWLQJV
 (IILFDF\$QDO\VHV
 3ULPDU\(IILFDF\(QGSRLQW$QDO\VLV
7RDFKLHYHVWDWLVWLFDOVLJQLILFDQFHLQWKHVWXG\DVDZKROHZLW KFRQFRUGDQFHLQERWKIDFHDQG
VFDOSWKH'D\FRPSOHWHFOHDUDQFHUDWHZLOOEHDQDO\]HGXVLQ JD&RFKUDQ0DQWHO+DHQV]HO
&0+PRGHOFRQWUROOLQJIRUWUHDWPHQWDQGWUHDWPHQWORFDWLRQI DFHDQGVFDOSSRVVLEOH
WUHDWPHQWORFDWLRQ LQWHUDFWLRQ ZLOO EH DGGUHVVHG E\ DQDO\]LQJ W KH WUHDWPHQW ORFDWLRQV
LQGHSHQGHQWO\WRVKRZFRQFRUGDQFH 7KH3HDUVRQ&KL6TXDUHXVH GWRSRZHUWKHVWXG\ZLOO
EHXVHGWRGHPRQVWUDWHEDVLF DJUHHPHQWZLWKWKH&0+
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
3ULRUWRXQEOLQGLQJWKHGDWDWKH QXPEHURIVXEMHFWVHQUROOHGS HUVLWHZLOOEHUHYLHZHGDQGDQ
LQYHVWLJDWRUVLWHDQDO\VLVRIKRZORZHQUROOPHQWVLWHVPLJKWEH FRPELQHGDQGWKHLPSDFWRI
KLJKHQUROOPHQWVLWHVZLOOEHIXOO\GLVFXVVHG
([SORUDWRU\DQDO\VHVPD\EHFRQGXFWHGWRLGHQWLI\RXWOLHUVWXG\ VLWHV7KHRXWOLHUVLWHVZLOO
EHGLVFXVVHGDQGDQH[SORUDWRU\DQDO\VLVH[FOXGLQJWKHRXWOLHU VLWHVPD\EHFDUULHGRXWWR
HVWLPDWHWKHLPSDFWRIVLWHE\WU HDWPHQWLQWHUDFWLRQV7KLVSU RFHVVZLOOEHGRFXPHQWHG
7KHSULPDU\HIILFDF\DQDO\VLVZLOOEHSHUIRUPHGZLWKWKH,77SR SXODWLRQDQGZLOOEH
UHSHDWHGZLWKWKH33(YDOXDEO HSRSXODWLRQWRVXSSRU WWKHSULPDU \HIILFDF\DQDO\VLVUHVXOWV
 6HFRQGDU\(IILFDF\(QGSRLQW$QDO\VHV
3DUWLDOFOHDUDQFHUDWHZLOOEHDQDO\]HGLQWKHVDPHZD\DVWKH SULPDU\HIILFDF\HQGSRLQW
FRPSOHWHFOHDUDQFHUDWH
7KHQXPEHURI$.OHVLRQVDQGWKHFKDQJHIURPEDVHOLQHDWHDFKV FKHGXOHGYLVLWZLOOEH
VX[COMPANY_003]UL]HGXVLQJGHVFULSWLYHVWDWLVWLFVLHPHDQ6'PHGLDQ PLQLPXPDQGPD[LPXPE\
WUHDWPHQWJURXSDQGWKHQ FRQWUDVWHGIRUHDF KWUHDWPHQWJURXS
5HFXUUHQFHUDWHZLOODOVREHGHWH UPLQHGDWHDFKVFKHGXOHGYLVLW DIWHU'D\
 0LVVLQJ'DWD+DQGOLQJDQG6HQVLWLYLW\$QDO\VLV
)RUDOOHIILFDF\DQDO\VHVDOOPLVVLQJGDWDFDXVHGE\VXEMHFWH DUO\GLVFRQWLQXDWLRQZLOOEH
LPSXWHGZLWKDODVWREVHUYDWLRQFDUULHGIRUZDUG/2&)PHWKRG )RUVXEMHFWVZLWKRXWDQ\
SRVWEDVHOLQH OHVLRQ DVVHVVPHQWV WKH EDVHOLQH YDOXHV ZLOO EH U H J D U G H G D V W K H ' D \   
HYDOXDWLRQUHVXOWV
$ VHQVLWLYLW\ DQDO\VLV ZLWK WKH DVVXPSWLRQ WKDW DOO HDUO\WHUPL QDWHG VXEMHFWV DUH QRW
UHVSRQGHUVIRUFRPSOHW HFOHDUDQFHRUSDUWLDOFOHDUDQFHDW'D\ LQWKH,77SRSXODWLRQZLOO
EHXVHGWRH[DPLQHWKHUREXVWQ HVVRIWKHGUXJHIILFDF\
 6XEJURXS$QDO\VLV
7R LQGLFDWH FRQFRUGDQFH ZLWK WKH RYHUDOO UHVXOWV FRPSOHWH FOHD UDQFH UDWH ZLOO DOVR EH
WDEXODWHGDQGGLVSOD\HGJUDSKLFDOO\LQVXFKVXEJURXSVDVWUHDWP HQWDUHDIDFHRUVFDOS
JHQGHUDJHRU¬ï\HDUVVWXG\VLWHEDVHOLQHOHVLRQFRX QWRUVNLQW\SH
)LW]SDWULFN,,,RU,,,,999,2XWOLHUVZLOOEHFOLQLFDOO \H[SODLQHGLQWKHFOLQLFDOVWXG\
UHSRUW
 6DIHW\$QDO\VHV
$OOVXEMHFWVLQWKH6DIHW\$QDO \VLV6HWZLOOEHLQFOXGHGLQWKH VDIHW\DQDO\VHV
6DIHW\GDWDZLOOEHVX[COMPANY_003]UL]HGE\WUHDWPHQWJURXSXVLQJGHVFULS WLYHVWDWLVWLFVHJQPHDQ
6'PHGLDQPLQLPXPPD[LPXPIRUFRQWLQXRXVYDULDEOHVQ>@IR UFDWHJRULFDOYDULDEOHV
6DIHW\YDULDEOHVLQFOXGHHYDOXD WLRQRI/65VSLJPHQWDWLRQDQGV FDUULQJLQWKHWUHDWPHQWDUHD
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
$(V6$(VHYHQWVRIVSHFLDOLQWHUHVWFOLQLFDOODERUDWRU\GDWD DQGRWKHUVDIHW\DVVHVVPHQWV
YLWDOVLJQV3(V(&*V
6DIHW\GDWDFROOHFWHGWKURXJK'D\DQGGXULQJWKH5HFXUUHQFH )ROORZXS3HULRGZLOOEH
DQDO\]HGVHSDUDWHO\
 ([WHQWRI([SRVXUH
7KHDFWXDOQXPEHURIGRVHVIRUH DFKVXEMHFWZLOOEHVX[COMPANY_003]UL]HG E\WUHDWPHQWJURXS
 $GYHUVH(YHQWV
)RU$(VYHUEDWLPWHUPVRQWKHH&5)ZLOOEHPDSSHGWRSUHIHUUHG WHUPV37VDQGV\VWHP
RUJDQFODVVHV62&VXVLQJWKH0 HGLFDO'LFWLRQDU\IRU5HJXODWRU \$FWLYLWLHV0HG'5$
YHUVLRQRUKLJKHU
$OO$(VWUHDWPHQWHPHUJHQWRURWKHUZLVHZLOOEHSUHVHQWHGLQ VXEMHFWGDWDOLVWLQJV2QO\
WKRVH$(VWKDWDUHWUHDWPHQWH PHUJHQWZLOOEHLQFOXGHGLQVX[COMPANY_003] U\WDEOHV
7UHDWPHQWHPHUJHQW$(VDUHGHILQHGDV
xHLWKHUWKRVH$(VZLWKDQRQVH WDIWHUWKHILUVWGRVHRU
xWKRVHSUHH[LVWLQJ$(VWKDWZ RUVHQDIWHUWKHILUVWGRVH
7($(VZLOOEHVX[COMPANY_003]UL]HGE\WUHD WPHQWJURXS7KHLQFLGHQFHRI 7($(VZLOOEHUHSRUWHGDV
WKHQXPEHUSHUFHQWDJHRIVXEMHFWVZLWK7($(VE\0HG'5$62&DQ G37DQGWUHDWPHQW
JURXS$VXEMHFWZLOOEHFRXQWHGRQO\RQFHZLWKLQDQ62&DQG3 7HYHQLIWKHVXEMHFW
H[SHULHQFHGPRUHWKDQ7($(ZLWKLQDVSHFLILF62&DQG377KH QXPEHUSHUFHQWDJHRI
VXEMHFWVZLWK7($(VZLOODOVREHVX[COMPANY_003]UL]HGE\PD[LPXPVHYHULW\ E\KLJKHVWPLOG
PRGHUDWHRUVHYHUHUDWLQJDQGE\UHODWLRQVKLSWRVWXG\WUHDWPH QW7UHDWPHQWUHODWHG7($(V
LQFOXGHWKRVHHYHQWVFRQVLGHUHG E\WKH,QYHVWLJDWRUWREHUHODW HGGHILQLWHO\SUREDEO\RU
SRVVLEO\UHODWHGW RVWXG\WUHDWPHQW
%\VXEMHFWOLVWLQJVRIDOO6$(VDQGHYHQWVRIVSHFLDOLQWHUHVW ZLOOEHSURYLGHG,IDQ\GHDWKV
RFFXULQWKHVWXG\DE\VXEMHFWOLVWLQJRIDOO$(VOHDGLQJWR GHDWKZLOOEHSURYLGHG
$VXEMHFWGDWDOLVWLQJRIDOO$(VOHDGLQJWRGLVFRQWLQXDWLRQIU RPWKHVWXG\ZLOOEHSURYLGHG
)RUVXEMHFWVZKRKDYHWUHDWPHQWUHODWHG$(VDW'D\DOOVDIH W\HQGSRLQWVREVHUYHGGXULQJ
DQ\DGGLWLRQDOIROORZXSDVVHVVPHQWVZLOOEHOLVWHG
'XULQJWKH5HFXUUHQFH)ROORZXS3HULRG7($(VLQWKHWUHDWPHQW DUHDZLOOEHVX[COMPANY_003]UL]HG
VHSDUDWHO\
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 /DERUDWRU\9DOXHV
/DERUDWRU\SDUDPHWHUVZLOOEHVX[COMPANY_003]UL]HGXVLQJGHVFULSWLYHVWDW LVWLFVDWEDVHOLQHDQGDWHDFK
VXEVHTXHQWWLPHSRLQWE \WUHDWPHQWJURXS&KD QJHVIURPEDVHOLQH ZLOODOVREHVX[COMPANY_003]UL]HG
E\WUHDWPHQWJURXS
,QDGGLWLRQVKLIWWDEOHVLHOR ZQRUPDOKLJKDWEDVHOLQHYHUV XVORZQRUPDOKLJKDWIROORZXS
LQDE\FRQWLQJHQF\WDEOHZLOOEHSURYLGHGWRDVVHVVFKDQJ HVLQODERUDWRU\YDOXHVIURP
EDVHOLQHWR'D\DQGEDVHOLQHW R'D\LQHDFKWUHDWPHQWJURX S
$OOODERUDWRU\GDWDZLOO EHOLVWHGE\VXEMHFW
 3UHJQDQF\7HVWV
5HVXOWVRISUHJQDQF\WHVWVZLOO EHOLVWHGIRUDOOVXEMHFWVDV DSSOLFDEOH
 9LWDO6LJQV
9LWDOVLJQYDOXHVZLOOEHOLVWHGE\VXEMHFW
 (OHFWURFDUGLRJUDPV
$OO(&*GDWDZLOOEHOLVWHGIRUHDFKVXEMHFW$E\VXEMHFWOLV WLQJRIFOLQLFDOO\VLJQLILFDQW
(&*DEQRUPDOLW\GD WDZLOOEHSURYLGHG
 3K\VLFDO([DPLQDWLRQV
3K\VLFDOH[DPLQDWLRQILQGLQJVZ LOOEHOLVWHGIRUHDFKVXEMHFW
 /RFDO6NLQ5HDFWLRQVDQG3LJPHQWDWLRQDQG6FDUULQJ
/65K\SHURUK\SRSLJPHQWDWL RQDQGVFDUULQJDVVHVVPHQWUHVXOW VREWDLQHGWKURXJK'D\
ZLOOEHGLVSOD\HGDQGVX[COMPANY_003]UL]H GE\YLVLWDQGWUHDWPHQWJURXS ,QDGGLWLRQDFRPSRVLWH
VFRUHZKLFKLVGHILQHGDVWKHV XPRILQGLYLGXDO/65VFRUHVI URPWKHVDPHYLVLWZLOOEH
DQDO\]HGLQWKHVDPHZD\
$OO/65K\SHURUK\SRSLJPHQWDWLRQDQGVFDUULQJDVVHVVPHQWU HVXOWVGXULQJDQ\DGGLWLRQDO
IROORZXSVDIWHU'D\ZLOOEHSU HVHQWHGLQWKHE\VXEMHFWOLV WLQJV
 'HWHUPLQDWLRQRI6DPSOH6L]H
7KHVDPSOHVL]HZDVHVWLPDWHGEDVHGRQWKHSULPDU\HIILFDF\HQG SRLQWIRUWKHFRPSDULVRQRI
.;2LQWPHQWDQGYHKLFOHFRQWURO%\XVLQJD3HDUVRQ&K LVTXDUHPHWKRGD
VDPSOHVL]HRIVFDOSWUHDWHGVXEMHFWVDQGIDFHWUHDWHG VXEMHFWVERWKRIZKLFKDUH
ZLWKDWUHDWPHQWDOORFDWLRQUDWLRZLOOJLYHDJUHDWHUWKDQ SRZHUWRGHWHFWD
GLIIHUHQFH  IRU DFWLYH WUHD WPHQW DQG  IRU YHKLFOH FRQWUR O ZLWK D WZRWDLOHG
VLJQLILFDQWOHYHO
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 ,QWHULP$QDO\VLV
1RLQWHULPDQDO\VLVLVSODQQHGIRUWKLVVWXG\
 2WKHU6WDWLVWLFDO$QDO\WLFDO,VVXHV
1RWDSSOLFDEOH
 3URFHGXUHIRU5HYLVLQJWKH3ODQQHG$QDO\VLV
,IWKHSUHVSHFLILHGSODQVIRUDQDO\VLVQHHGWREHUHYLVHGDIWHU WKHVWXG\VWDUWVWKH6SRQVRUZLOO
GHWHUPLQHKRZWKHUHYLVLRQLPSDFWVWKHVWXG\DQGKRZWKHUHYLVL RQVKRXOGEHLPSOHPHQWHG
7KHGHWDLOVRIWKHUHYLVLRQZLOO EHGRFXPHQWHGDQ GGHVFULEHGLQ WKHFOLQLFDOVWXG\UHSRUW
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 352&('85(6$1',[ZIP_CODE]&7,216
7KH,QYHVWLJDWRUZLOOFRQGXFWWKHVWXG\LQVWULFWDFFRUGDQFHZL WKWKHSURWRFROUHIHUWR
,&+(6HFWLRQ
 $FFHVVWR6RXUFH'DWD'RFXPHQWV
7KH6SRQVRU¬∂V&5$ZLOOPDLQWDLQFRQWDFWZLWKWKH,QYHVWLJDWRUD QGGHVLJQDWHGVWDIIE\
WHOHSKRQHOHWWHURUHP DLOEHWZHHQVWXG\YLVLWV0RQLWRULQJY LVLWVWRHDFKVLWHZLOOEH
FRQGXFWHGE\WKHDVVLJQHG&5$DV GHVFULEHGLQWKHPRQLWRULQJSO DQ7KH,QYHVWLJDWRUZLOO
DOORZ WKH &5$ WR LQVSHFW WKH FOLQLFDO ODERUDWRU\ DQG SKDUPDF\  IDFLOLWLHV WR DVVXUH
FRPSOLDQFH ZLWK *&3 DQG ORFDO UHJXODWRU\ UHTXLUHPHQWV  7KH H&5 )V DQG VXEMHFW¬∂V
FRUUHVSRQGLQJRULJLQDOPHGLFDOUHFR UGVVRXUFHGRFXPHQWVDUHW REHIXOO\DYDLODEOHIRU
UHYLHZE\WKH6SRQVRU¬∂VUHSUHVHQW DWLYHVDWUHJXODULQWHUYDOV 7KHVHUHYLHZVYHULI\DGKHUHQFH
WRVWXG\SURWRFRODQGGDWDDFFXUDF\LQDFFRUGDQFHZLWKORFDOUH JXODWLRQV$OOUHFRUGVDWWKH
VLWHDUHVXEMHFWWRLQVSHFWLRQE\WKHORFDODXGLWLQJDJHQF\DQG ,QVWLWXWLRQDO5HYLHZ%RDUG
,5%UHYLHZ
,QDFFRUGDQFHZLWK,&+(6HFWLRQVRXUFHGRFXPHQWVLQFOX GHEXWDUHQRWOLPLWHGWR
WKHIROORZLQJ
x&OLQLFRIILFHRUKRVSLWDOFKDUWV
x&RSLHVRUWUDQVFULEHGKHDOWKFDU HSURYLGHUQRWHVZKLFKKDYHEHH QFHUWLILHGIRUDFFXUDF\
DIWHUSURGXFWLRQ
x5HFRUGHGGDWDIURPDXWRPDWHGLQVWUXPHQWVVXFKDV[UD\VDQGRW KHULPDJLQJUHSRUWV
HJ VRQRJUDPV &7 VFDQV PDJQHWLF UHVRQDQFH LPDJHV UDGLRDFWLY H LPDJHV (&*V
[LOCATION_006]\WKPVWULSV((*VSRO\VRPQR JUDSKVSXOPRQDU\IXQFWLRQWHVWV UHJDUGOHVVRIKRZ
WKHVHLPDJHVDUHVWRUHGLQFOXGL QJPLFURILFKHDQGSKRWRJUDSKLF QHJDWLYHV
x0HGLFDOKLVWRU\RURWKHUTXHVWLRQQD LUHVFRPSOHWHGE\VXEMHFWV
x5HFRUGVRIWHOHSKRQHFRQWDFWV
x'LDULHVRUHYDOXDWLRQFKHFNOLVWV
x'UXJ GLVWULEXWLRQ DQG DFFRXQWDELOLW \ ORJV PDLQWDLQHG LQ SKDUPDF LHV RU E\ UHVHDUFK
SHUVRQQHO
x/DERUDWRU\UHVXOWVDQGRWKHUODERUDWRU\WHVWRXWSXWVHJXULQH SUHJQDQF\WHVWUHVXOW
GRFXPHQWDWLRQDQGXULQHGLSVWLFNV
x&RUUHVSRQGHQFHUHJDUGLQJDVWXG\ VXEMHFW¬∂VWUHDWPHQWEHWZHHQSK \VLFLDQVRUPHPRUDQGD
VHQWWRWKH,5%
,QDGGLWLRQWRWKHURXWLQHPRQLWR ULQJSURFHGXUHVTXDOLILHGSHU VRQQHOGHVLJQDWHGE\WKH
6SRQVRUPD\FRQGXFWDXGLWVRIF OLQLFDOUHVHDUFKDFWLYLWLHVLQD FFRUGDQFHZLWKWKH6SRQVRU¬∂V
VWDQGDUGRSHUDWLQJSURFHGXUHV62 3VWRHYDOXDWHFRPSOLDQFHZLW KWKHSULQFLSOHVRI,&+
*&3DQGDOODSSOLFDEOHORFDOUHJ XODWLRQV,IDJRYHUQPHQWUHJX ODWRU\DXWKRULW\UHTXHVWVDQ
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
LQVSHFWLRQGXULQJWKHVWXG\RUDIWHULWVFRPSOHWLRQWKH,QYHVW LJDWRUPXVWLQIRUPWKH6SRQVRU
LPPHGLDWHO\
 4XDOLW\&RQWURODQG4XDOLW\$VVXUDQFH
7KLVVWXG\ZLOOEHRUJDQL]HGSHUIRUPHGDQGUHSRUWHGLQFRPSOL DQFHZLWKWKHSURWRFRO
623VZRUNLQJSUDFWLFHGRFXPHQWV DQGDSSOLFDEOHUHJXODWLRQVDQ GJXLGHOLQHV6LWHDXGLWV
ZLOOEHPDGHSHULRGLFDOO\E\WKH 6SRQVRU¬∂VRUWKH&52¬∂VTXDOLIL HGFRPSOLDQFHDXGLWLQJWHDP
ZKLFKLVDQLQGHSHQGHQW IXQFWLRQIURPWKHVWXG\WHDPUHVSRQVLEO HIRUFRQGXFWRIWKHVWXG\
 'DWD&ROOHFWLRQ
'DWDUHTXLUHGE\WKHSURWRFROZLOOEHGRFXPHQWHGLQWKHSDUWLFL SDQWVRXUFHGRFXPHQWDWLRQ
DQGHQWHUHGLQWRDYDOLGDWHGHOHFW URQLFGDWDFDSWXUH('&V\VW HP
5HVSRQVLEOHVLWHSHUVRQQHOZLOOHQ WHUWKHLQIRUPDWLRQUHTXLUHG E\WKHSURWRFRORQWRWKH
H&5)VLQDFFRUGDQFHZLWKWKHH&5)&RPSOHWLRQ*XLGHOLQHVWKDWDU HSURYLGHG$&5$ZLOO
YLVLWHDFKVLWHDVGRFXPHQWHGLQWKHPRQLWRULQJSODQWRYHULI\ WKHGDWDRQH&5)VIRU
FRPSOHWHQHVVDQGDFFXUDF\DJD LQVWWKHVRXUFHGRFXPHQWV
7KH,QYHVWLJDWRUKDVXOWLPDWHUHVSRQVLELOLW\IRUWKHFROOHFWLRQ DQGUHSRUWLQJRIDOOFOLQLFDO
VDIHW\DQGODERUDWRU\GD WDHQWHUHGRQWKHH&5)
'DWDWKDWDUHSURYLGHGE\DQH[WHUQDOYHQGRUZLOOEHWUDQVIHUUH GDQGYDOLGDWHGDFFRUGLQJWR
WKHSURFHGXUHVVSHFLILHGLQ WKH'DWD0DQDJHPHQW3ODQ
$OOGDWDGHULYHGIURPWKHVWXG\ZLOOEHWKHSURSHUW\RIWKH6SR QVRUDQGVKRXOGQRWEHPDGH
DYDLODEOHLQDQ\IRUPWRWKLUG SDUWLHVZLWKRXWZ ULWWHQSHUPLVVL RQIURPWKH6SRQVRUH[FHSWIRU
DXWKRUL]HGUHSUHVHQWDWLYHVRIW KH6SRQVRURUDSSURSULDWHUHJXOD WRU\DXWKRULWLHV
 &OLQLFDO'DWD0DQDJHPHQW
7KHUHZLOOEHD'DWD0DQDJHPHQW 3ODQWRGHWDLODOOUHOHYDQWGDW DPDQDJHPHQWDFWLYLWLHVIURP
H&5)GHVLJQWRGD WDEDVHORFN
4XDOLW\FRQWUROIRUDOOUHOHYDQWGDWDPDQDJHPHQWDFWLYLWLHVDQG GDWDYDOLGDWLRQSURFHGXUHV
ZLOOEHDSSOLHGWRHQVXUHWKHYD OLGLW\DQGDFFXUDF\RIWKHFOLQ LFDOGDWD
 (7+,&6
7KLVVWXG\ZLOOEHFRQGXFWHGLQDFF RUGDQFHZLWK623VRIWKH6SR QVRURUGHVLJQHHZKLFK
DUHGHVLJQHGWRHQVXUHDGKHUHQF HWR*&3JXLGHOLQHVDVUHTXLUHG E\WKHIROORZLQJ
x3ULQFLSOHVRIWKH:RUOG0HGLFDO $VVRFLDWLRQ'HFODUDWLRQRI+HOV LQNL
x,&+(*&3JXLGHOLQHV
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
x7LWOHRIWKH86&RGHRI)HGHUDO 5HJXODWLRQV86&)5UHJD UGLQJFOLQLFDOVWXGLHV
LQFOXGLQJ3DUWDQG3DUWFRQFHU QLQJLQIRUPHGVXEMHFWFRQVH QWDQG,5%UHJXODWLRQV
DQGDSSOLFDEOHVHFWLRQV RI86&)53DUW
 ,QVWLWXWLRQDO5HYLHZ%RDUGV
7KHSURWRFRODQ\SURWRFRODPHQGPHQWVDQG,&)ZLOOEHUHYLHZHG DQGDSSURYHGE\DQ,5%
FRQVWLWXWHGDQGIXQFWLRQLQJLQDFFRUGDQFHZLWK,&+(*&36H FWLRQDQGDQ\ORFDO
UHJXODWLRQV$Q\SURWRFRODPHQGPHQWDQGRUUHYLVLRQWRWKH,&) ZLOOUHFHLYHDSSURSULDWH
DSSURYDOSULRUWRLPS OHPHQWDWLRQ9HULIL FDWLRQRIXQFRQGLWLRQD ODSSURYDORIWKHSURWRFROZLOO
EHWUDQVPLWWHGWRWKH6SRQVRUSULRU WRWKHVKLSPHQWRIGUXJVXS SOLHVWRWKHLQYHVWLJDWLRQDO
VLWH7KH,QYHVWLJDWRUVRUWKH 6SRQVRUZLOOVXEPLWGHSHQGLQJ RQORFDOUHJXODWLRQVSHULRGLF
UHSRUWVDQGLQIRUPWKH ,5%RIDQ\ UHSRUWDEOH$(VSHU ,&+ JXLGHO LQHVDQGORFDO ,5%
VWDQGDUGVRISUDFWLFH
$VLJQHGOHWWHURIVWXG\DSSURYDOIURPWKH,5%FKDLUPDQPXVWEH VHQWWRWKH3ULQFLSDO
,QYHVWLJDWRUZLWKDFRS\WRWKH6SRQVRUEHIRUHVWXG\VWDUWDQG WKHUHOHDVHRIDQ\VWXG\GUXJWR
WKHVLWHE\WKH6SRQVRURULWVGHVLJQHH,&+(6HFWLRQ ,IWKH,5%GHFLGHVWRVXVSHQG
RUWHUPLQDWHWKHVWXG\WKH,QYHVWLJDWRUZLOOLPPHGLDWHO\VHQG WKHQRWLFHRIVWXG\VXVSHQVLRQ
RUWHUPLQDWLRQE\WKH,5%WRWKH6SRQVRU
6WXG\SURJUHVVLVWREHUHSRUWH GWR,5%DQQXDOO\RUDVUHTXLUH GE\WKH,QYHVWLJDWRURU
6SRQVRUGHSHQGLQJRQORFDOUHJXODWRU\REOLJDWLRQV,IWKH,QY HVWLJDWRULVUHTXLUHGWRUHSRUW
WRWKH,5%KHVKHZLOOIRUZDUGDFRS\WRWKH6SRQVRUDWWKHWL PHRIHDFKSHULRGLFUHSRUW7KH
,QYHVWLJDWRUVRUWKH6SRQVRUZLOOVXEPLWGHSHQGLQJRQORFDO UHJXODWLRQVSHULRGLFUHSRUWV
DQGLQIRUPWKH,5%RIDQ\UHSRUWDEOH$(VSHU,&+JXLGHOLQHVDQG ORFDO,5%VWDQGDUGVRI
SUDFWLFH8SRQFRPSOHWLRQRIWKH VWXG\WKH,QYHVWLJDWRUZLOO SURYLGHWKH,5%ZLWKDEULHI
UHSRUWRIWKHRXWFRPHRIWKHVWXG\LIUHTXLUHG
$WWKHHQGRIWKHVWXG\WKH6 SRQVRUVKRXOGQRWLI\WKH,5%ZLWK LQGD\V
,QWKHFDVHRIHDUO\WHUPLQDWLRQWHPSRUDU\KDOWRIWKHVWXG\W KH,QYHVWLJDWRUVKRXOGQRWLI\WKH
,5%ZLWKLQFDOHQGDUGD\VDQGDGHWDLOHGZULWWHQH[SODQDWLRQ RIWKHUHDVRQVIRUWKH
WHUPLQDWLRQKDOWVKRXOGEHJLYHQ
 6XEMHFW,QIRUPDWLRQDQG,QIRUPHG&RQVHQW
$VSDUWRIDGPLQLVWHULQJWKHLQI RUPHGFRQVHQWGRFXPHQWWKH,QY HVWLJDWRURUGHVLJQHHPXVW
H[SODLQWRHDFKVXEMHFWWKHQDWXUHRIWKHVWXG\LWVSXUSRVHW KHSURFHGXUHVLQYROYHGWKH
H[SHFWHG GXUDWLRQ WKH SRWHQWLDO ULVNV DQG EHQHILWV LQYROYHG D Q\ SRWHQWLDO GLVFRPI[INVESTIGATOR_13318]
SRWHQWLDODOWHUQDWLYHSURFHGXUHV RUFRXUVHVRIWUHDWPHQWDY DLODEOHWRWKHVXEMHFWDQGWKH
H[WHQWRIPDLQWDLQLQJFRQILGHQWLDOLW\RIWKHVXEMHFW¬∂VUHFRUGV (DFKVXEMHFWPXVWEHLQIRUPHG
WKDWSDUWLFLSDWLRQLQWKHVWXG\LVYROXQWDU\WKDWKHVKHPD\Z LWKGUDZIURPWKHVWXG\DWDQ\
WLPHDQGWKDWZLWKGUDZDORIFRQVHQWZLOOQRWDIIHFWKLVKHUVX EVHTXHQWPHGLFDOWUHDWPHQWRU
UHODWLRQVKLSZLWKWKHW UHDWLQJSK\VLFLDQ
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
7KHLQIRUPHGFRQVHQWVKRXOGEHJLYHQE\PHDQVRIDVWDQGDUGZUL WWHQVWDWHPHQWZULWWHQLQ
QRQWHFKQLFDOODQJXDJH7KHVXEMHF WVKRXOGXQGHUVWDQGWKHVWDWH PHQWEHIRUHVLJQLQJDQG
GDWLQJLWDQGZLOOEHJLYHQDFRS\RIWKHVLJQHGGRFXPHQW$W WKH6FUHHQLQJ9LVLWDIWHUWKH
,&)DQGDQ\RWKHUZULWWHQLQIRUPDWLRQWREHSURYLGHGLVUHDGDQ GH[SODLQHGWKHVXEMHFWZLOO
EHDVNHGWRVLJQWKH,&)EHIRUHDQ\VWXG\VSHFLILFSURFHGXUHVD UHSHUIRUPHG1RVXEMHFWFDQ
HQWHUWKHVWXG\EHIRUHKLVKHU LQIRUPHGFRQVHQWKDVEHHQREWDLQ HG
$Q DSSURYHG ,&) PXVW EH SUHSDUHG LQ DFFRUGDQFH ZLWK ,&+ ( DQG  DOO DSSOLFDEOH
UHJXODWLRQV(DFKVXEMHFWPXVWVLJQDQDSSURYHG,&)EHIRUHVWX G\SDUWLFLSDWLRQ7KHIRUP
PXVWEHVLJQHGDQGGDWHGE\WKH DSSURSULDWHSDUWLHV7KHRULJL QDOVLJQHG,&)IRUHDFK
VXEMHFWZLOOEHYHULILHGE\WKH 6SRQVRUDQGNHSWRQILOHDFFRUG LQJWRORFDOSURFHGXUHVDWWKH
VLWH
7KHVXEMHFWVKRXOGEHLQIRUPHGLQ DWLPHO\PDQQHULIQHZLQIRUP DWLRQEHFRPHVDYDLODEOH
WKDWPD\EHUHOHYDQWWRWKHVXEMHFW¬∂VZLOOLQJQHVVWRFRQWLQXHS DUWLFLSDWLRQLQWKHVWXG\7KH
FRPPXQLFDWLRQRIWKLVLQIR UPDWLRQVKRXOGEHGRFXPHQWHG
 'DWD+DQGOLQJDQG5HFRUGNHHSLQJ
 5HFRUGLQJRI'DWD
$QH&5)PXVWEHFRPSOHWHGIRUHDFKVXEMHFWE\TXDOLILHGDQGDXW KRUL]HGSHUVRQQHO$Q\
FRUUHFWLRQ WR HQWULHV PDGH RQ WKH H&5) PXVW KDYH D UHVSHFWLYH D XGLW WUDLO ZKHUH WKH
FRUUHFWLRQLVGDWHGWKHLQGLYLGXD OPDNLQJWKHFRUUHFWLRQLVLG HQWLILHGWKHUHDVRQIRUWKH
FKDQJHLVVWDWHGDQGWKHRULJLQDOGDWDDUHQRWREVFXUHG2QO\ GDWDUHTXLUHGE\WKHSURWRFRO
IRUWKHSXUSRVHVRIWKHVWXG\VKRXOGEHFROOHFWHG
 ,GHQWLILFDWLRQRI6RXUFH'DWD
$OOGDWDWREHUHFRUGH GRQWKHH&5)PXVWUHIOHFWWKHFRUUHVSRQG LQJVRXUFHGRFXPHQWV 
 5HWHQWLRQRI5HFRUGV
7KH FLUFXPVWDQFHV RI FRPSOHWLRQ RU WHUPLQDWLRQ RI WKH VWXG\ QRW ZLWKVWDQGLQJ WKH
,QYHVWLJDWRULVUHVSRQVLEOHIRUUHWDLQLQJDOOVWXG\GRFXPHQWV LQFOXGLQJEXWQRWOLPLWHGWRWKH
SURWRFROFRSLHVRIH&5)VWKH, QYHVWLJDWRU
V%URFKXUHDQGUHJ XODWRU\DJHQF\UHJLVWUDWLRQ
GRFXPHQWV,&)VDQG,5%FRUUHVSRQGHQFH,QDGGLWLRQWKH6SRQ VRUZLOOVHQGDOLVWRI
WUHDWPHQWFRGHVE\VWXG\VXEMHFWW RWKH,QYHVWLJDWRUDIWHUWKH FOLQLFDOGDWDEDVHIRUWKLVVWXG\
KDVEHHQORFNHG7KHVLWHVV KRXOGSODQWRUHWDLQVWXG\GRFXPHQ WVDVGLUHFWHGE\WKH6SRQVRU
IRUDWOHDVW\HDUVDIWHUWKHODVWDSSURYDORIDPDUNHWLQJDSS OLFDWLRQLQDQ,&+UHJLRQDQG
XQWLOWKHUHDUHQRSHQGLQJRUFRQWHPSODWHGPDUNHWLQJDSSOLFDWLR QVLQDQ,&+UHJLRQRUDW
OHDVW\HDUVKDYHHODSVHGVLQFH WKHIRUPDOGLVFRQWLQXDWLRQRI FOLQLFDOGHYHORSPHQWRIWKH
LQYHVWLJDWLRQDOSURGXFW
,W LV UHTXHVWHG WKDW DW WKH FRPSO HWLRQ RI WKH UH TXLUHG UHWHQWLR Q SHULRG RU VKRXOG WKH
,QYHVWLJDWRUUHWLUHRUUHORFDWHWKH,QYHVWLJDWRUFRQWDFWWKH6 SRQVRUDOORZLQJWKH6SRQVRUWKH
RSWLRQRISHUPDQHQWO\UHWDLQLQJWKHVWXG\UHFRUGV
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 3XEOLFDWLRQ3ROLF\
7KHGHWDLOHGREOLJDWLRQVUHJDUGLQJWKHSXEOLFDWLRQRIDQ\GDWD PDWHULDOUHVXOWVRURWKHU
LQIRUPDWLRQJHQHUDWHGRUFUHDWHGLQUHODWLRQWRWKHVWXG\VKDOO EHVHWRXWLQWKHDJUHHPHQW
EHWZHHQHDFK,QYHVWLJDWRUDQGWKH 6SRQVRURU&52DVDSSURSULDW H
 2WKHU$GPLQLVWUDWLYH3ROLFLHV
 &KDQJHVWRWKH3URWRFRO
7KHUHDUHWREHQRFKDQJHVWRWKHSURWRFROZLWKRXWZULWWHQDSSU RYDOIURPWKH6SRQVRU
3URWRFROVZLOOEHIROORZHGDVZULWWHQ 
$Q\FKDQJHWRWKHSURWRFROUHTXLUHVDZULWWHQSURWRFRODPHQGPHQ WRUDGPLQLVWUDWLYHFKDQJH
WKDWPXVWEHDSSURYHGE\WKH6 SRQVRUEHIRUHLPSOHPHQWDWLRQ$P HQGPHQWVVSHFLILFDOO\
DIIHFWLQJWKHVDIHW\RIVXEMHFWVWKHVFRSHRIWKHLQYHVWLJDWLR QRUWKHVFLHQWLILFTXDOLW\RIWKH
VWXG\UHTXLUHVXEPLVVLRQWRKHD OWKRUUHJXODWRU\DXWKRULWLHVDV ZHOODVDGGLWLRQDODSSURYDOE\
WKHDSSOLFDEOH,5%V7KHVHUHTXL UHPHQWVVKRXOGLQQRZD\SUHYH QWDQ\LPPHGLDWHDFWLRQ
IURPEHLQJWDNHQE\WKH,QYHVWLJDWRURUE\WKH6SRQVRULQWKH LQWHUHVWRISUHVHUYLQJWKH
VDIHW\RIDOOVXEMHFWVLQFOXGHGLQWKHVWXG\,IDQLPPHGLDWH FKDQJHWRWKHSURWRFROLVIHOWE\
WKH,QYHVWLJDWRUWREHQHFHVVDU\IRUVDIHW\UHDVRQVWKH6SRQVR U¬∂V0HGLFDO0RQLWRUDQGWKH
,5%IRUWKHVLWHVPXVWEHQRWLILHGLPPHGLDWHO\7KH6SRQVRU PXVWQRWLI\WKHKHDOWKRU
UHJXODWRU\ DXWKRULW\ DV UHTXLUHG SHU ORFDO UHJXODWLRQV  $ SURW RFRO FKDQJH LQWHQGHG WR
HOLPLQDWHDQLPPHGLDWHKD]DUGPD\EHLPSOHPHQWHGLPPHGLDWHO\S URYLGHGWKHKHDOWKRU
UHJXODWRU\DXWKRULW\DQG,5%VDUHLPPHGLDWHO\QRWLILHGDQGDSSU RSULDWHGRFXPHQWDWLRQRIWKH
XUJHQWSURWRFROFKDQJHDUHV XEPLWWHGSHUORFDOUHJXODWLRQV
3URWRFRODPHQGPHQWVWKDWDIIHFWRQO\DGPLQLVWUDWLYHDVSHFWVRI WKHVWXG\PD\QRWUHTXLUH
VXEPLVVLRQWRKHDOWKRUUHJXODWRU\DXWKRULW\RUWKH,5%EXWWK HKHDOWKRUUHJXODWRU\DXWKRULW\
DQG,5%VKRXOGEHNHSWLQIRUPHGRIVXFKFK DQJHVDVUHTXLUHGE\ORFDOUH JXODWLRQV
 'LVFORVXUHDQG&RQILGHQWLDOLW\
7KHFRQWHQWVRIWKLVSURWRFRODQGDQ\DPHQGPHQWVDQGUHVXOWVRE WDLQHGGXULQJWKHVWXG\
VKRXOGEHNHSWFRQILGHQWLDOE\WKH,QYHVWLJDWRUWKH,QYHVWLJDW RU¬∂VVWDIIDQGWKH,5%DQGZLOO
QRWEHGLVFORVHGLQZKROHRULQSDUWWRRWKHUVRUXVHGIRUDQ\ SXUSRVHRWKHUWKDQUHYLHZLQJRU
SHUIRUPLQJWKHVWXG\ZLWKRXWWKH ZULWWHQFRQVHQWRIWKH6SRQVR U1RGDWDFROOHFWHGDVSDUW
RIWKLVVWXG\ZLOOEHXVHGLQD Q\ZULWWHQZRUNLQFOXGLQJSXEOL FDWLRQVZLWKRXWWKHZULWWHQ
FRQVHQWRIWKH6SRQVRU7KHVH REOLJDWLRQVRIFRQILGHQWLDOLW\D QGQRQXVHVKDOOLQQRZD\
GLPLQLVKVXFKREOLJDWLRQVDVVHWIRUWKLQHLWKHUWKH&RQILGHQWL DOLW\$JUHHPHQWRU&OLQLFDO
7ULDO$JUHHPHQWH[HFXWHGEHWZHH QWKH6SRQVRU&52DQGWKHLQVWLW XWLRQ,QYHVWLJDWRU
$OOSHUVRQVDVVLVWLQJLQWKHSHUIRUPDQFHRIWKLVVWXG\PXVWEH ERXQGE\WKHREOLJDWLRQVRI
FRQILGHQWLDOLW\DQGQRQXVHVHWI RUWKLQHLWKHUWKH&RQILGHQWLD OLW\$JUHHPHQWRU&OLQLFDO7ULDO
$JUHHPHQWH[HFXWHGEHWZHHQWKHLQVWLWXWLRQ,QYHVWLJDWRUDQGWKH 6SRQVRU&52
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 'LVFRQWLQXDWLRQRI6WXG\
7KH6SRQVRUUHVHUYHVWKHULJKWWRGLVFRQWLQXHWKHVWXG\IRUPHG LFDOUHDVRQVRUDQ\RWKHU
UHDVRQDWDQ\WLPH,IDVWXG\LVSUHPDWXUHO\WHUPLQDWHGRUVX VSHQGHGWKH6SRQVRUZLOO
SURPSWO\LQIRUPWKH,QYHVWLJDWRUVLQVWLWXWLRQVDQGUHJXODWRU\D XWKRULWLHVRIWKHWHUPLQDWLRQRU
VXVSHQVLRQDQGWKHUHDVRQVIRUWKHWHUPLQDWLRQRUVXVSHQVLRQ 7KH,5%ZLOODOVREH
LQIRUPHGSURPSWO\DQGSURYLGHG WKHUHDVRQVIRUWKHWHUPLQDWLR QRUVXVSHQVLRQE\WKH
6SRQVRU RU E\ WKH ,QYHVWLJDWRULQVWLWXWLRQ DV VSHFLILHG E\ WKH  DSSOLFDEOH UHJXODWRU\
UHTXLUHPHQWV
7KH,QYHVWLJDWRUUHVHUYHVWKHULJKWWRGLVFRQWLQXHWKHVWXG\VK RXOGKLVKHUMXGJPHQWVR
GLFWDWH,IWKH,QYHVWLJDWRUWHUPLQDWHVRUVXVSHQGVDVWXG\ZL WKRXWSULRUDJUHHPHQWRIWKH
6SRQVRU WKH ,QYHVWLJDWRU VKRXOG LQIRUP WKH LQVWLWXWLRQ ZKHUH D SSOLFDEOH DQG WKH
,QYHVWLJDWRULQVWLWXWLRQVKRXOGSURPSWO\LQIRUPWKH6SRQVRUDQG WKH,5%DQGSURYLGHWKHP
ZLWKDGHWDLOHGZULWWHQH[SODQDWLRQRIWKHWHUPLQDWLRQRUVXVSH QVLRQ6WXG\UHFRUGVPXVWEH
UHWDLQHGDVQRWHGDERYH
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 5()(5(1&(/,67
0DUNV55HQQLH*6HOZRRG760 DOLJQDQWWUDQVIRUPDWLRQRIVRO DUNHUDWRVHVWR
VTXDPRXVFHOOFDUFLQRPD/DQFHW
&ULVFLRQH9':HLQVWRFN0$1D\ORU0)HWDO$FWLQLFNHUDWRVHV QDWXUDOKLVWRU\
DQG ULVN RI PDOLJQDQW WUDQVIRUPD WLRQ LQ WKH 9HWHUDQV $IIDLUV 7R SLFDO 7UHWLQRLQ
&KHPRSUHYHQWLRQ7ULDO&DQFHU
*ORJDX5*7KH ULVNRISURJUH VVLRQWRLQYDVLYHGLVHDVH-$P$F DG 'HUPDWRO
3W
6DODVFKH6-(SLGHPLRORJ\RIDF WLQLFNHUDWRVHVDQGVTXDPRXVFHO OFDUFLQRPD-$P
$FDG'HUPDWRO3W
*XLGHOLQHV IRU WKH 0DQDJHPHQW RI $FWLQLF .HUDWRVHV   (XURSHDQ
'HUPDWRORJ\)RUXP$YDLODEOHIURPKWWSZZZHXURGHUPRUJ>$ FFHVVHG-XO\
@
'UDNH/$&HLOOH\5,&RUQHOLVRQ5/HWDO*XLGHOLQHVRIFDUH IRUDFWLQLFNHUDWRVHV
&RPPLWWHHRQ*XLGHOLQHVRI&DUH- $P$FDG'HUPDWRO 
,&+(*XLGDQFHIRU,QGXVWU\(*RRG&OLQLFDO3UDFWLFH&RQVROLG DWHG*XLGDQFH
86'HSDUWPHQWRI+HDOWKDQG+XPDQ6HUYLFHV)RRGDQG'UXJ$GPLQ LVWUDWLRQ$SULO

)LW]SDWULFN7%7KHYDOLGLW\D QGSUDFWLFDOLW\RIVXQUHDFWLYHV NLQW\SHV,WKURXJK,9
$UFK'HUPDWRO
'UDIW *XLGDQFH RQ LQJHQRO PHEXWDWH -DQXDU\ 
KWWSZZZIGDJRYGRZQORDGV'UXJV *XLGDQFH&RPSOLDQFH5HJXODWRU\ ,QIRUPDWLRQ*
XLGDQFHV8&0SGI

&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
 $33(1',&(6
 
&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
$33(1',;,[ZIP_CODE]&7,216)2568%-(&76¬∂6(/)
$'0,1,675$7,212)678'<75($70(17
7KHVWXG\NLWFRQWDLQV
xSDFNHWVILOOHGZLWKVWXG\GUXJLQVLGHLQGLYLGXDOSODVWLFEDJ V
x$GRVLQJORJ
6WRUDJH
6WRUHWKHVWXG\NLWDWURRPWHPSHUDWXUHDQGLQDVHFXUHSODFH RXWRIGLUHFWVXQOLJKWDQGDZD\
IURPIRRGSURGXFWVFKLOGUHQDQGSHWV
3DWLHQW,QVWUXFWLRQV
$SSOLFDWLRQRIVWXG\GUXJLVSUHIHUDEO\GRQHHDUO\LQWKHGD\D QGDWDSSUR[LPDWHO\WKHVDPH
WLPHHYHU\GD\IRUDWRWDORI GD\V7KHILUVWGRVHZLOOEHV HOIDGPLQLVWHUHGLQWKHFOLQLF
)ROORZWKHVHVWHSVWRDSSO\VWXG\GUXJ
x7DNHWKHGRVLQJORJLQWKHVWX G\NLWDQGUHFRUGWKHGDWHDQGWL PHRIGRVLQJ
x2SHQWKHSODVWLFEDJDQGUHP RYHDVLQJOHGRVHSDFNHW
x7HDUWKHSDFNHWRSHQDORQJWKHSHUIRUDWLRQV
x6TXHH]HDVPDOODPRXQWRIRLQWPH QWIURPWKHSDFNHWRQ\RXUILQJ HUWLSDQGDSSO\LW
HYHQO\RYHUWKHHQWLUHWUHDWPHQWDUHD1RWH(DFKSDFNHWFRQWD LQVPRUHWKDQWKH
DPRXQWQHHGHGIRUWUHDWPHQWDSSOLFDWLRQ
x3ODFHWKHXVHGSDFNHWLQFOXGLQJWRUQSLHFHVLQWRWKHSODVWLF EDJLQZKLFKLWFDPH
VHDOWKHSODVWLFEDJDQGSXWLWEDFNLQWRWKHVWXG\NLW
x:DVKKDQGV LPPHGLDWHO\ ZLWKZDWHUDQGVRDS
x3ODFHWKHGRVLQJORJEDFNLQWRWKHVWXG\NLWDQGVWRUHDZD\WKH VWXG\NLWDVLQVWUXFWHG
DERYHLQDVHFXUHSODFH
x5HSHDWWKHDERYHVWHSVIRUHDFKG D\RIWUHDWPHQWDWDERXWWKHV DPHWLPHHDFKGD\
x2Q'D\DSSO\WUHDWPHQW EHIRUHUHWXUQLQJWRFOLQLF%ULQJWKHVWXG\NLWFRQWDLQLQJ
DOOXVHGDQGXQXVHGSDFNHWVD QGWKHGRVLQJORJZLWK\RX

&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
3UHFDXWLRQVRQ7UHDWPHQW'D\V'D\V
x6XEMHFWV ZKR ZHDU FRQWDFW OHQVH V VKRXOG SXW RQ WKHLU FRQWDFW OH QVHV %()25(
DSSO\LQJVWXG\GUXJ
x$YRLGWRXFKLQJRUZHWWLQJWKHWUHDWPHQWDUHDIRUDSSUR[LPDWHO\ KRXUV,I\RX
WRXFKWKHWUHDWPHQWDUHDZDVK\RXUKDQGVLPPHGLDWHO\
x$YRLGDFWLYLWLHVWKDWPLJKWFDXVHH[FHVVLYHVZHDWLQJVRWKDWW KHRLQWPHQWZLOOQRWJHW
LQ\RXUH\HV
x,IRLQWPHQWGRHVJHWLQWR\RXUH\HVIOXVK\RXUH\HVZLWKZDWHU LPPHGLDWHO\DQG
H[WHQVLYHO\<RXPXVWLPPHGLDWHO\FRQWDFWWKHVWXG\GRFWRUZKR ZLOOJLYH\RX
IXUWKHULQVWUXFWLRQV<RXZLOOEHUHIHUUHGWRDQH\HGRFWRUVR \RXUH\HVFDQEH
H[DPLQHG
x,IDQ\VHYHUHORFDOVNLQUHDFWLRQRFFXUVRUSHUVLVWVOHW\RXU VWXG\GRFWRUNQRZ
LPPHGLDWHO\
x'RQRWDSSO\VWXG\GUXJPRUHWKDQRQFHHDFKGD\
x'RQRWDOORZRWKHUSHRSOHRUSHWVWRFRPHLQWRFRQWDFWZLWKWKH WUHDWPHQWDUHD,IWKH
WUHDWPHQWDUHDLVWRXFKHGWKHDUHDRIFRQWDFWRQWKHRWKHUSHU VRQRUSHWVKRXOGEH
ZDVKHGLPPHGLDWHO\
x'RQRWFRYHUWKHWUHDWPHQWDUHD ZLWKEDQGDJHVEDQGDLGVWLJKW ILWWLQJVFDUIVRUFDSV
3UHFDXWLRQV7KURXJKRXWWKH6WXG\
x:KHQZDVKLQJWKHWUHDWPHQWDUHDZDVKLWJHQWO\ZLWKDPLOGQR QDEUDVLYHQRQ
PHGLFDWHGVRDSRUVKDPSRR
x'RQRWH[SRVHWKHWUHDWPHQWDUHDWRH[FHVVLYHVXQOLJKWRUXOWU DYLROHWOLJKWLQFOXGLQJ
WDQQLQJEHGV:KHQRXWGRRUVZHDU SURWHFWLYHORRVHFORWKLQJRY HUWKHWUHDWPHQWDUHD
x'RQRWXVHPRLVWXUL]HUVVXQVFU HHQDUWLILFLDOWDQQHUVPDNHXS RURWKHURYHUWKH
FRXQWHUWRSLFDOSURGXFWV WRWKHVWXG\WUHDWPHQWDUHDXQWLO'D\ ,I\RXDUHXQVXUHRI
ZKDWWRXVHDVN\RXUVWXG\GRFWRU$IWHUGD\VLI\RXDUH XQDEOHWRDYRLG
H[FHVVLYHVXQOLJKWRUXOWUDYLROHWOLJKWWRWKHWUHDWPHQWDUHD WKHVWXG\GRFWRUPD\
DOORZ\RXWRXVHVXQEORFN
x'RQRWXVHPHGLFDWLRQVQRWDSSU RYHGE\\RXUVWXG\GRFWRU
x$IWHU'D\VXQEORFNDQGQRQPH GLFDWHGWRSLFDOSURGXFWVFDQE HXVHGLQWKH
WUHDWPHQWDUHD

&OLQLFDO6WXG\3URWRFRO .;$.


$WKHQH[,QF
),1$/YB-XQ&RQILGHQWLDO 3DJHRI
,19(67,*$7256,*1$785(3$*(
6WXG\3URWRFRO1XPEHU .;$.
6WXG\3URWRFRO7LWOH $3KDVH'RXEOH%OLQG9HKLFOH&RQWUROOHG5DQGRPL]HG3DUDOO HO
*URXS0XOWLFHQWHU(IILFDF\DQG6DIHW\6WXG\RI.;2LQWPH QW
LQ$GXOW6XEMHFWVZLWK$FWLQLF.HUDWRVLVRQWKH)DFHRU6FDO S
,QYHVWLJDWLRQDO3URGXFW
1DPH.;2LQWPHQW
,1'1XPEHU 
8711XPEHU 8 

,KDYHUHDGWKLVSURWRFRODQGDJUHHWRFRQGXFWWKLVVWXG\LQDF FRUGDQFHZLWKDOOVWLSXODWLRQVRI
WKHSURWRFRODQGLQDFFRUGDQFH ZLWK,QWHUQDWLRQDO&RXQFLOIRU+ DUPRQLVDWLRQRI7HFKQLFDO
5HTXLUHPHQWVIRU5HJLVWUDWLRQRI3KDUPDFHXWLFDOVIRU+XPDQ8VH ,&+DQGDOODSSOLFDEOH
ORFDO*RRG&OLQLFDO3UDFW LFH*&3JXLGHOLQHVLQFOXGLQJWKH'H FODUDWLRQRI+HOVLQNL

1DPHRILQVWLWXWLRQ!
0HGLFDO,QVWLWXWLRQ

1DPHGHJUHHV!    
,QYHVWLJDWRU  6LJQDWXUH  'DWH
